{"aopId":193,"aopName":"Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis","targetName":"dual oxidase 1","targetId":"ENSG00000137857","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":1156,"keyEventName":"Inhibition, Dual oxidase"},{"keyEventId":426,"keyEventName":"Decreased, Thyroxine (T4) in serum"}],"reference":"https://aopwiki.org/aops/193"}
{"aopId":154,"aopName":"Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response","targetName":"NFAT activation molecule 1","targetId":"ENSG00000235568","adverseOutcome":"Impairment, T-cell dependent antibody response","adverseOutcomeId":984,"keyEvents":[{"keyEventId":979,"keyEventName":"Interference, nuclear localization of NFAT"},{"keyEventId":1202,"keyEventName":"Suppression, IL-2 and IL-4 production"},{"keyEventId":980,"keyEventName":"Inhibition, Calcineurin Activity"},{"keyEventId":984,"keyEventName":"Impairment, T-cell dependent antibody response"},{"keyEventId":981,"keyEventName":"Reduction, NFAT/AP-1 complex formation"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/154"}
{"aopId":77,"aopName":"Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1","targetName":"calmodulin","adverseOutcome":"Death/Failure, Colony","adverseOutcomeId":563,"keyEvents":[{"keyEventId":560,"keyEventName":"Abnormal, Foraging activity and behavior"},{"keyEventId":563,"keyEventName":"Death/Failure, Colony"},{"keyEventId":177,"keyEventName":"N/A, Mitochondrial dysfunction 1"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":559,"keyEventName":"Activation, Nicotinic acetylcholine receptor"},{"keyEventId":1243,"keyEventName":"Altered, Ca2+-calmodulin activated signal transduction"},{"keyEventId":1107,"keyEventName":"Weakened, Colony"}],"reference":"https://aopwiki.org/aops/77"}
{"aopId":87,"aopName":"Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure ","targetName":"calmodulin","adverseOutcome":"Death/Failure, Colony","adverseOutcomeId":563,"keyEvents":[{"keyEventId":560,"keyEventName":"Abnormal, Foraging activity and behavior"},{"keyEventId":1108,"keyEventName":"Abnormal, Role change within caste"},{"keyEventId":563,"keyEventName":"Death/Failure, Colony"},{"keyEventId":177,"keyEventName":"N/A, Mitochondrial dysfunction 1"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":559,"keyEventName":"Activation, Nicotinic acetylcholine receptor"},{"keyEventId":1243,"keyEventName":"Altered, Ca2+-calmodulin activated signal transduction"},{"keyEventId":1107,"keyEventName":"Weakened, Colony"}],"reference":"https://aopwiki.org/aops/87"}
{"aopId":88,"aopName":"Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste","targetName":"calmodulin","adverseOutcome":"Death/Failure, Colony","adverseOutcomeId":563,"keyEvents":[{"keyEventId":560,"keyEventName":"Abnormal, Foraging activity and behavior"},{"keyEventId":563,"keyEventName":"Death/Failure, Colony"},{"keyEventId":663,"keyEventName":"Desensitization, Nicotinic acetylcholine receptor"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":559,"keyEventName":"Activation, Nicotinic acetylcholine receptor"},{"keyEventId":1243,"keyEventName":"Altered, Ca2+-calmodulin activated signal transduction"},{"keyEventId":1107,"keyEventName":"Weakened, Colony"}],"reference":"https://aopwiki.org/aops/88"}
{"aopId":89,"aopName":"Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure","targetName":"calmodulin","adverseOutcome":"Death/Failure, Colony","adverseOutcomeId":563,"keyEvents":[{"keyEventId":560,"keyEventName":"Abnormal, Foraging activity and behavior"},{"keyEventId":1108,"keyEventName":"Abnormal, Role change within caste"},{"keyEventId":563,"keyEventName":"Death/Failure, Colony"},{"keyEventId":663,"keyEventName":"Desensitization, Nicotinic acetylcholine receptor"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":559,"keyEventName":"Activation, Nicotinic acetylcholine receptor"},{"keyEventId":1243,"keyEventName":"Altered, Ca2+-calmodulin activated signal transduction"},{"keyEventId":1107,"keyEventName":"Weakened, Colony"}],"reference":"https://aopwiki.org/aops/89"}
{"aopId":155,"aopName":"Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation","targetName":"type II iodothyronine deiodinase","targetId":"ENSG00000211448","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1002,"keyEventName":"Inhibition, Deiodinase 2"},{"keyEventId":1004,"keyEventName":"Reduced, Posterior swim bladder inflation"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/155"}
{"aopId":155,"aopName":"Deiodinase 2 inhibition leading to increased mortality via reduced posterior swim bladder inflation","targetName":"type II iodothyronine deiodinase","targetId":"ENSG00000211448","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1002,"keyEventName":"Inhibition, Deiodinase 2"},{"keyEventId":1004,"keyEventName":"Reduced, Posterior swim bladder inflation"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/155"}
{"aopId":190,"aopName":"Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis","targetName":"type II iodothyronine deiodinase","targetId":"ENSG00000211448","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":1002,"keyEventName":"Inhibition, Deiodinase 2"},{"keyEventId":1116,"keyEventName":"Decreased, Triiodothyronine (T3) in tissues"},{"keyEventId":1829,"keyEventName":"Altered, Thyroid hormone-dependent gene expression"},{"keyEventId":1828,"keyEventName":"Increased, Thyroxine (T4) in serum"},{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":1023,"keyEventName":"Increased, Thyroid-stimulating hormone (TSH)"}],"reference":"https://aopwiki.org/aops/190"}
{"aopId":156,"aopName":"Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation","targetName":"type II iodothyronine deiodinase","targetId":"ENSG00000211448","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1002,"keyEventName":"Inhibition, Deiodinase 2"},{"keyEventId":1007,"keyEventName":"Reduced, Anterior swim bladder inflation"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/156"}
{"aopId":156,"aopName":"Deiodinase 2 inhibition leading to increased mortality via reduced anterior swim bladder inflation","targetName":"type II iodothyronine deiodinase","targetId":"ENSG00000211448","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1002,"keyEventName":"Inhibition, Deiodinase 2"},{"keyEventId":1007,"keyEventName":"Reduced, Anterior swim bladder inflation"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/156"}
{"aopId":31,"aopName":"Oxidation of iron in hemoglobin leading to hematotoxicity","targetName":"glucose-6-phosphate 1-dehydrogenase","targetId":"ENSG00000160211","adverseOutcome":"N/A, Cyanosis occurs","adverseOutcomeId":321,"keyEvents":[{"keyEventId":321,"keyEventName":"N/A, Cyanosis occurs"},{"keyEventId":246,"keyEventName":"Increase, RBC congestion in liver"},{"keyEventId":213,"keyEventName":"N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)"},{"keyEventId":173,"keyEventName":"N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"},{"keyEventId":118,"keyEventName":"Formation, Formation of hemoglobin adducts"},{"keyEventId":161,"keyEventName":"Increase, Liver and splenic hemosiderosis"},{"keyEventId":131,"keyEventName":"Down Regulation, Gulcose-6-phosphate dehydrogenase"},{"keyEventId":250,"keyEventName":"Damaging, Red blood cells; hemolysis"},{"keyEventId":21,"keyEventName":"Altered regulation, Alpha hemoglobin"},{"keyEventId":211,"keyEventName":"Propagation, Oxidative stress"}],"status":"Under Development","reference":"https://aopwiki.org/aops/31"}
{"aopId":71,"aopName":"Modulation of Adult Leydig Cell Function Subsequent to Glucocorticoid Activation","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcomeId":520,"keyEvents":[{"keyEventId":652,"keyEventName":"Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells"},{"keyEventId":525,"keyEventName":"Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells"},{"keyEventId":651,"keyEventName":"Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells"},{"keyEventId":650,"keyEventName":"Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid"},{"keyEventId":520,"keyEventName":"Decreased sperm quantity or quality in the adult, Decreased fertility "}],"reference":"https://aopwiki.org/aops/71"}
{"aopId":71,"aopName":"Modulation of Adult Leydig Cell Function Subsequent to Glucocorticoid Activation","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"Decreased sperm quantity or quality in the adult, Decreased fertility ","adverseOutcomeId":520,"keyEvents":[{"keyEventId":652,"keyEventName":"Direct effects of Corticosterone on steroidogenesis, Decreased testosterone by adult Leydig cells"},{"keyEventId":525,"keyEventName":"Apoptosis of adult Leydig cells, Decreased testosterone by adult Leydig cells"},{"keyEventId":651,"keyEventName":"Glucocorticoid Receptor mediated alterations in steriodogenic enzymes, Decreased testosterone by adult Leydig cells"},{"keyEventId":650,"keyEventName":"Stimulation of adult Leydig cells via the Adrenal Corticosterone, Increased Glucocorticoid"},{"keyEventId":520,"keyEventName":"Decreased sperm quantity or quality in the adult, Decreased fertility "}],"reference":"https://aopwiki.org/aops/71"}
{"aopId":214,"aopName":"Network of SSRIs (selective serotonin reuptake inhibitors)","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"Increased, depression","adverseOutcomeId":1346,"keyEvents":[{"keyEventId":1326,"keyEventName":"Increased, 5-HT3 (5-hydroxytryptamine)"},{"keyEventId":1319,"keyEventName":"Decreased, extracellular chloride (Cl-)"},{"keyEventId":1321,"keyEventName":"Increased, intracellular sodium (Na+)"},{"keyEventId":1345,"keyEventName":"Increased, agitation"},{"keyEventId":1328,"keyEventName":"Inactivated, 5-HTR (serotonin receptors)"},{"keyEventId":1337,"keyEventName":"Activate, PLC (Phospholipase C)"},{"keyEventId":1329,"keyEventName":"Reduce expression, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1323,"keyEventName":"Decreased, intracellular serotonin"},{"keyEventId":1334,"keyEventName":"Increase, cortisone"},{"keyEventId":1341,"keyEventName":"Increase, myosin light chain phosphorylation"},{"keyEventId":1322,"keyEventName":"Increased, intracellular chloride (Cl-)"},{"keyEventId":1342,"keyEventName":"Increase, vascular smooth muscle contraction"},{"keyEventId":1325,"keyEventName":"Decreased, synaptic release"},{"keyEventId":1316,"keyEventName":"Inhibit, serotonin transporter activity"},{"keyEventId":1320,"keyEventName":"Increased, extracellular serotonin"},{"keyEventId":1339,"keyEventName":"Increase, intracellular calcium"},{"keyEventId":1335,"keyEventName":"Reduced, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1318,"keyEventName":"Decreased, extracellular sodium (Na+) "},{"keyEventId":1338,"keyEventName":"Increase, inositol triphosphate"},{"keyEventId":1346,"keyEventName":"Increased, depression"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":1343,"keyEventName":"Increase, hypertension"},{"keyEventId":1344,"keyEventName":"Increased, seizure"},{"keyEventId":1324,"keyEventName":"Decreased, packaged serotonin"},{"keyEventId":1330,"keyEventName":"Decreased, neuroplasticity"},{"keyEventId":1336,"keyEventName":"Activation, 5-HT2A (Serotonin 2A)"},{"keyEventId":1317,"keyEventName":"Decreased, serotonin transporter activity"},{"keyEventId":1347,"keyEventName":"Decreased, extracellular serotonin"},{"keyEventId":1340,"keyEventName":"Activate, calmodulin"}],"reference":"https://aopwiki.org/aops/214"}
{"aopId":214,"aopName":"Network of SSRIs (selective serotonin reuptake inhibitors)","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"Increased, agitation","adverseOutcomeId":1345,"keyEvents":[{"keyEventId":1326,"keyEventName":"Increased, 5-HT3 (5-hydroxytryptamine)"},{"keyEventId":1319,"keyEventName":"Decreased, extracellular chloride (Cl-)"},{"keyEventId":1321,"keyEventName":"Increased, intracellular sodium (Na+)"},{"keyEventId":1345,"keyEventName":"Increased, agitation"},{"keyEventId":1328,"keyEventName":"Inactivated, 5-HTR (serotonin receptors)"},{"keyEventId":1337,"keyEventName":"Activate, PLC (Phospholipase C)"},{"keyEventId":1329,"keyEventName":"Reduce expression, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1323,"keyEventName":"Decreased, intracellular serotonin"},{"keyEventId":1334,"keyEventName":"Increase, cortisone"},{"keyEventId":1341,"keyEventName":"Increase, myosin light chain phosphorylation"},{"keyEventId":1322,"keyEventName":"Increased, intracellular chloride (Cl-)"},{"keyEventId":1342,"keyEventName":"Increase, vascular smooth muscle contraction"},{"keyEventId":1325,"keyEventName":"Decreased, synaptic release"},{"keyEventId":1316,"keyEventName":"Inhibit, serotonin transporter activity"},{"keyEventId":1320,"keyEventName":"Increased, extracellular serotonin"},{"keyEventId":1339,"keyEventName":"Increase, intracellular calcium"},{"keyEventId":1335,"keyEventName":"Reduced, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1318,"keyEventName":"Decreased, extracellular sodium (Na+) "},{"keyEventId":1338,"keyEventName":"Increase, inositol triphosphate"},{"keyEventId":1346,"keyEventName":"Increased, depression"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":1343,"keyEventName":"Increase, hypertension"},{"keyEventId":1344,"keyEventName":"Increased, seizure"},{"keyEventId":1324,"keyEventName":"Decreased, packaged serotonin"},{"keyEventId":1330,"keyEventName":"Decreased, neuroplasticity"},{"keyEventId":1336,"keyEventName":"Activation, 5-HT2A (Serotonin 2A)"},{"keyEventId":1317,"keyEventName":"Decreased, serotonin transporter activity"},{"keyEventId":1347,"keyEventName":"Decreased, extracellular serotonin"},{"keyEventId":1340,"keyEventName":"Activate, calmodulin"}],"reference":"https://aopwiki.org/aops/214"}
{"aopId":214,"aopName":"Network of SSRIs (selective serotonin reuptake inhibitors)","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"Increase, hypertension","adverseOutcomeId":1343,"keyEvents":[{"keyEventId":1326,"keyEventName":"Increased, 5-HT3 (5-hydroxytryptamine)"},{"keyEventId":1319,"keyEventName":"Decreased, extracellular chloride (Cl-)"},{"keyEventId":1321,"keyEventName":"Increased, intracellular sodium (Na+)"},{"keyEventId":1345,"keyEventName":"Increased, agitation"},{"keyEventId":1328,"keyEventName":"Inactivated, 5-HTR (serotonin receptors)"},{"keyEventId":1337,"keyEventName":"Activate, PLC (Phospholipase C)"},{"keyEventId":1329,"keyEventName":"Reduce expression, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1323,"keyEventName":"Decreased, intracellular serotonin"},{"keyEventId":1334,"keyEventName":"Increase, cortisone"},{"keyEventId":1341,"keyEventName":"Increase, myosin light chain phosphorylation"},{"keyEventId":1322,"keyEventName":"Increased, intracellular chloride (Cl-)"},{"keyEventId":1342,"keyEventName":"Increase, vascular smooth muscle contraction"},{"keyEventId":1325,"keyEventName":"Decreased, synaptic release"},{"keyEventId":1316,"keyEventName":"Inhibit, serotonin transporter activity"},{"keyEventId":1320,"keyEventName":"Increased, extracellular serotonin"},{"keyEventId":1339,"keyEventName":"Increase, intracellular calcium"},{"keyEventId":1335,"keyEventName":"Reduced, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1318,"keyEventName":"Decreased, extracellular sodium (Na+) "},{"keyEventId":1338,"keyEventName":"Increase, inositol triphosphate"},{"keyEventId":1346,"keyEventName":"Increased, depression"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":1343,"keyEventName":"Increase, hypertension"},{"keyEventId":1344,"keyEventName":"Increased, seizure"},{"keyEventId":1324,"keyEventName":"Decreased, packaged serotonin"},{"keyEventId":1330,"keyEventName":"Decreased, neuroplasticity"},{"keyEventId":1336,"keyEventName":"Activation, 5-HT2A (Serotonin 2A)"},{"keyEventId":1317,"keyEventName":"Decreased, serotonin transporter activity"},{"keyEventId":1347,"keyEventName":"Decreased, extracellular serotonin"},{"keyEventId":1340,"keyEventName":"Activate, calmodulin"}],"reference":"https://aopwiki.org/aops/214"}
{"aopId":214,"aopName":"Network of SSRIs (selective serotonin reuptake inhibitors)","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcomeId":1344,"keyEvents":[{"keyEventId":1326,"keyEventName":"Increased, 5-HT3 (5-hydroxytryptamine)"},{"keyEventId":1319,"keyEventName":"Decreased, extracellular chloride (Cl-)"},{"keyEventId":1321,"keyEventName":"Increased, intracellular sodium (Na+)"},{"keyEventId":1345,"keyEventName":"Increased, agitation"},{"keyEventId":1328,"keyEventName":"Inactivated, 5-HTR (serotonin receptors)"},{"keyEventId":1337,"keyEventName":"Activate, PLC (Phospholipase C)"},{"keyEventId":1329,"keyEventName":"Reduce expression, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1323,"keyEventName":"Decreased, intracellular serotonin"},{"keyEventId":1334,"keyEventName":"Increase, cortisone"},{"keyEventId":1341,"keyEventName":"Increase, myosin light chain phosphorylation"},{"keyEventId":1322,"keyEventName":"Increased, intracellular chloride (Cl-)"},{"keyEventId":1342,"keyEventName":"Increase, vascular smooth muscle contraction"},{"keyEventId":1325,"keyEventName":"Decreased, synaptic release"},{"keyEventId":1316,"keyEventName":"Inhibit, serotonin transporter activity"},{"keyEventId":1320,"keyEventName":"Increased, extracellular serotonin"},{"keyEventId":1339,"keyEventName":"Increase, intracellular calcium"},{"keyEventId":1335,"keyEventName":"Reduced, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1318,"keyEventName":"Decreased, extracellular sodium (Na+) "},{"keyEventId":1338,"keyEventName":"Increase, inositol triphosphate"},{"keyEventId":1346,"keyEventName":"Increased, depression"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":1343,"keyEventName":"Increase, hypertension"},{"keyEventId":1344,"keyEventName":"Increased, seizure"},{"keyEventId":1324,"keyEventName":"Decreased, packaged serotonin"},{"keyEventId":1330,"keyEventName":"Decreased, neuroplasticity"},{"keyEventId":1336,"keyEventName":"Activation, 5-HT2A (Serotonin 2A)"},{"keyEventId":1317,"keyEventName":"Decreased, serotonin transporter activity"},{"keyEventId":1347,"keyEventName":"Decreased, extracellular serotonin"},{"keyEventId":1340,"keyEventName":"Activate, calmodulin"}],"reference":"https://aopwiki.org/aops/214"}
{"aopId":214,"aopName":"Network of SSRIs (selective serotonin reuptake inhibitors)","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"Increased, seizure","adverseOutcomeId":1344,"keyEvents":[{"keyEventId":1326,"keyEventName":"Increased, 5-HT3 (5-hydroxytryptamine)"},{"keyEventId":1319,"keyEventName":"Decreased, extracellular chloride (Cl-)"},{"keyEventId":1321,"keyEventName":"Increased, intracellular sodium (Na+)"},{"keyEventId":1345,"keyEventName":"Increased, agitation"},{"keyEventId":1328,"keyEventName":"Inactivated, 5-HTR (serotonin receptors)"},{"keyEventId":1337,"keyEventName":"Activate, PLC (Phospholipase C)"},{"keyEventId":1329,"keyEventName":"Reduce expression, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1323,"keyEventName":"Decreased, intracellular serotonin"},{"keyEventId":1334,"keyEventName":"Increase, cortisone"},{"keyEventId":1341,"keyEventName":"Increase, myosin light chain phosphorylation"},{"keyEventId":1322,"keyEventName":"Increased, intracellular chloride (Cl-)"},{"keyEventId":1342,"keyEventName":"Increase, vascular smooth muscle contraction"},{"keyEventId":1325,"keyEventName":"Decreased, synaptic release"},{"keyEventId":1316,"keyEventName":"Inhibit, serotonin transporter activity"},{"keyEventId":1320,"keyEventName":"Increased, extracellular serotonin"},{"keyEventId":1339,"keyEventName":"Increase, intracellular calcium"},{"keyEventId":1335,"keyEventName":"Reduced, BDNF (Brain-derived neurotrophic factor)"},{"keyEventId":1318,"keyEventName":"Decreased, extracellular sodium (Na+) "},{"keyEventId":1338,"keyEventName":"Increase, inositol triphosphate"},{"keyEventId":1346,"keyEventName":"Increased, depression"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":1343,"keyEventName":"Increase, hypertension"},{"keyEventId":1344,"keyEventName":"Increased, seizure"},{"keyEventId":1324,"keyEventName":"Decreased, packaged serotonin"},{"keyEventId":1330,"keyEventName":"Decreased, neuroplasticity"},{"keyEventId":1336,"keyEventName":"Activation, 5-HT2A (Serotonin 2A)"},{"keyEventId":1317,"keyEventName":"Decreased, serotonin transporter activity"},{"keyEventId":1347,"keyEventName":"Decreased, extracellular serotonin"},{"keyEventId":1340,"keyEventName":"Activate, calmodulin"}],"reference":"https://aopwiki.org/aops/214"}
{"aopId":318,"aopName":"Glucocorticoid Receptor activation leading to hepatic steatosis","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcomeId":459,"keyEvents":[{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":860,"keyEventName":"Decreased, Mitochondrial Fatty Acid Beta Oxidation"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":1834,"keyEventName":"Decrease, Acyl-CoA dehydrogenases"}],"reference":"https://aopwiki.org/aops/318"}
{"aopId":318,"aopName":"Glucocorticoid Receptor activation leading to hepatic steatosis","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":860,"keyEventName":"Decreased, Mitochondrial Fatty Acid Beta Oxidation"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":1834,"keyEventName":"Decrease, Acyl-CoA dehydrogenases"}],"reference":"https://aopwiki.org/aops/318"}
{"aopId":334,"aopName":"Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":1761,"keyEventName":"Inhibition, Fin regeneration"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1759,"keyEventName":"Increase, Cripto-1 expression"},{"keyEventId":1760,"keyEventName":"Inhibition, Activin signaling"}],"reference":"https://aopwiki.org/aops/334"}
{"aopId":66,"aopName":"Modulation of Adult Leydig Cell Function Subsequent Glucocorticoid Activation in the Fetal Testis","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"Decreased sperm quantity / quality in the adult, Decreased fertility ","adverseOutcomeId":505,"keyEvents":[{"keyEventId":656,"keyEventName":"Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells"},{"keyEventId":653,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased corticosterone"},{"keyEventId":655,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"},{"keyEventId":657,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells"},{"keyEventId":654,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists"},{"keyEventId":505,"keyEventName":"Decreased sperm quantity / quality in the adult, Decreased fertility "}],"reference":"https://aopwiki.org/aops/66"}
{"aopId":14,"aopName":"Glucocorticoid Receptor Activation Leading to Increased Disease Susceptibility","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"Increased, Disease susceptibility","adverseOutcomeId":323,"keyEvents":[{"keyEventId":152,"keyEventName":"Suppression, Inflammatory cytokines"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":168,"keyEventName":"Decreased, Lymphocytes"},{"keyEventId":145,"keyEventName":"Induction, IKB inhibitory protein"},{"keyEventId":323,"keyEventName":"Increased, Disease susceptibility"},{"keyEventId":403,"keyEventName":"Suppression, Immune system"},{"keyEventId":202,"keyEventName":"Inhibition, Nuclear factor kappa B (NF-kB)"}],"reference":"https://aopwiki.org/aops/14"}
{"aopId":64,"aopName":"Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":496,"keyEventName":"Increased apoptosis, decreased number of adult Leydig Cells "},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":494,"keyEventName":"Glucocorticoid Receptor Agonist, Activation"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":495,"keyEventName":"Repressed expression of steroidogenic enzymes "},{"keyEventId":520,"keyEventName":"Decreased sperm quantity or quality in the adult, Decreased fertility "}],"reference":"https://aopwiki.org/aops/64"}
{"aopId":64,"aopName":"Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility","targetName":"glucocorticoid receptor","targetId":"ENSG00000113580","adverseOutcome":"impaired, Fertility","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":496,"keyEventName":"Increased apoptosis, decreased number of adult Leydig Cells "},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":494,"keyEventName":"Glucocorticoid Receptor Agonist, Activation"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":495,"keyEventName":"Repressed expression of steroidogenic enzymes "},{"keyEventId":520,"keyEventName":"Decreased sperm quantity or quality in the adult, Decreased fertility "}],"reference":"https://aopwiki.org/aops/64"}
{"aopId":57,"aopName":"AhR activation leading to hepatic steatosis","targetName":"cytochrome P450 1A1","targetId":"ENSG00000140465","adverseOutcome":"Accumulation, Liver lipid","adverseOutcomeId":455,"keyEvents":[{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":467,"keyEventName":"Increased, LDL uptake"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":466,"keyEventName":"Up Regulation, LDLR (low density lipoprotein receptor)"},{"keyEventId":80,"keyEventName":"Up Regulation, CYP1A1"},{"keyEventId":455,"keyEventName":"Accumulation, Liver lipid"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":450,"keyEventName":"Suppression, VLDL secretion"},{"keyEventId":216,"keyEventName":"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/57"}
{"aopId":36,"aopName":"Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis","targetName":"peroxisome proliferator-activated receptor delta","targetId":"ENSG00000112033","adverseOutcomeId":459,"keyEvents":[{"keyEventId":233,"keyEventName":"Decreased, PPAR-gamma activation"},{"keyEventId":232,"keyEventName":"Decreased, PPAR-beta activation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":8,"keyEventName":"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"},{"keyEventId":140,"keyEventName":"Decreased, HSD17B10 expression"},{"keyEventId":231,"keyEventName":"Decreased, PPAR-alpha activation"}],"reference":"https://aopwiki.org/aops/36"}
{"aopId":36,"aopName":"Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis","targetName":"peroxisome proliferator-activated receptor delta","targetId":"ENSG00000112033","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":233,"keyEventName":"Decreased, PPAR-gamma activation"},{"keyEventId":232,"keyEventName":"Decreased, PPAR-beta activation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":8,"keyEventName":"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"},{"keyEventId":140,"keyEventName":"Decreased, HSD17B10 expression"},{"keyEventId":231,"keyEventName":"Decreased, PPAR-alpha activation"}],"reference":"https://aopwiki.org/aops/36"}
{"aopId":114,"aopName":"HPPD inhibition leading to corneal papillomas and carcinomas (in rat)","targetName":"4-hydroxyphenylpyruvate dioxygenase (rat)","adverseOutcome":"Increase, Papillomas/carcinomas (squamous cells)","adverseOutcomeId":779,"keyEvents":[{"keyEventId":775,"keyEventName":"Increased, Plasma tyrosine"},{"keyEventId":766,"keyEventName":"Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme"},{"keyEventId":776,"keyEventName":"Increase, Cytotoxicity (corneal cells)"},{"keyEventId":777,"keyEventName":"Increase, Inflammation (corneal cells)"},{"keyEventId":778,"keyEventName":"Increase, Regenerative cell proliferation (corneal cells)"},{"keyEventId":779,"keyEventName":"Increase, Papillomas/carcinomas (squamous cells)"}],"reference":"https://aopwiki.org/aops/114"}
{"aopId":46,"aopName":"AFB1: Mutagenic Mode-of-Action leading to Hepatocellular Carcinoma (HCC)","targetName":"cellular tumor antigen p53","targetId":"ENSG00000141510","adverseOutcome":"Tumorigenesis, Hepatocellular carcinoma","adverseOutcomeId":378,"keyEvents":[{"keyEventId":378,"keyEventName":"Tumorigenesis, Hepatocellular carcinoma"},{"keyEventId":409,"keyEventName":"Metabolism of AFB1, Production of Reactive Electrophiles"},{"keyEventId":376,"keyEventName":"Increased, Induced Mutations in Critical Genes"},{"keyEventId":491,"keyEventName":"Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)"},{"keyEventId":493,"keyEventName":"Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts"},{"keyEventId":373,"keyEventName":"Formation, Pro-mutagenic DNA Adducts"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/46"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"nuclear receptor subfamily 0 group B member 2","targetId":"ENSG00000131910","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"nuclear receptor subfamily 0 group B member 2","targetId":"ENSG00000131910","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":29,"aopName":"Estrogen receptor agonism leading to reproductive dysfunction","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Altered, Reproductive behaviour","adverseOutcomeId":363,"keyEvents":[{"keyEventId":111,"keyEventName":"Agonism, Estrogen receptor"},{"keyEventId":252,"keyEventName":"Increase, Renal pathology due to VTG deposition"},{"keyEventId":364,"keyEventName":"Impaired development of, Reproductive organs"},{"keyEventId":363,"keyEventName":"Altered, Reproductive behaviour"},{"keyEventId":339,"keyEventName":"Altered, Larval development"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":307,"keyEventName":"Increase, Vitellogenin synthesis in liver"},{"keyEventId":220,"keyEventName":"Increase, Plasma vitellogenin concentrations"}],"reference":"https://aopwiki.org/aops/29"}
{"aopId":29,"aopName":"Estrogen receptor agonism leading to reproductive dysfunction","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":111,"keyEventName":"Agonism, Estrogen receptor"},{"keyEventId":252,"keyEventName":"Increase, Renal pathology due to VTG deposition"},{"keyEventId":364,"keyEventName":"Impaired development of, Reproductive organs"},{"keyEventId":363,"keyEventName":"Altered, Reproductive behaviour"},{"keyEventId":339,"keyEventName":"Altered, Larval development"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":307,"keyEventName":"Increase, Vitellogenin synthesis in liver"},{"keyEventId":220,"keyEventName":"Increase, Plasma vitellogenin concentrations"}],"reference":"https://aopwiki.org/aops/29"}
{"aopId":29,"aopName":"Estrogen receptor agonism leading to reproductive dysfunction","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Altered, Larval development","adverseOutcomeId":339,"keyEvents":[{"keyEventId":111,"keyEventName":"Agonism, Estrogen receptor"},{"keyEventId":252,"keyEventName":"Increase, Renal pathology due to VTG deposition"},{"keyEventId":364,"keyEventName":"Impaired development of, Reproductive organs"},{"keyEventId":363,"keyEventName":"Altered, Reproductive behaviour"},{"keyEventId":339,"keyEventName":"Altered, Larval development"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":307,"keyEventName":"Increase, Vitellogenin synthesis in liver"},{"keyEventId":220,"keyEventName":"Increase, Plasma vitellogenin concentrations"}],"reference":"https://aopwiki.org/aops/29"}
{"aopId":29,"aopName":"Estrogen receptor agonism leading to reproductive dysfunction","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Impaired development of, Reproductive organs","adverseOutcomeId":364,"keyEvents":[{"keyEventId":111,"keyEventName":"Agonism, Estrogen receptor"},{"keyEventId":252,"keyEventName":"Increase, Renal pathology due to VTG deposition"},{"keyEventId":364,"keyEventName":"Impaired development of, Reproductive organs"},{"keyEventId":363,"keyEventName":"Altered, Reproductive behaviour"},{"keyEventId":339,"keyEventName":"Altered, Larval development"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":307,"keyEventName":"Increase, Vitellogenin synthesis in liver"},{"keyEventId":220,"keyEventName":"Increase, Plasma vitellogenin concentrations"}],"reference":"https://aopwiki.org/aops/29"}
{"aopId":112,"aopName":"Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat)","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Increase, Endometrial adenocarcinomas","adverseOutcomeId":773,"keyEvents":[{"keyEventId":773,"keyEventName":"Increase, Endometrial adenocarcinomas"},{"keyEventId":747,"keyEventName":"Decreased, Prolactin"},{"keyEventId":748,"keyEventName":"Increased, Estrogen receptor (ER) activity"},{"keyEventId":749,"keyEventName":"Decreased, Progesterone from corpus luteum"},{"keyEventId":772,"keyEventName":"Increase, Hyperplasia (glandular epithelial cells of endometrium)"},{"keyEventId":746,"keyEventName":"Increase, Dopaminergic activity"}],"reference":"https://aopwiki.org/aops/112"}
{"aopId":167,"aopName":"Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse.","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Increased, adenosquamous carcinomas of endometrium","adverseOutcomeId":1070,"keyEvents":[{"keyEventId":1070,"keyEventName":"Increased, adenosquamous carcinomas of endometrium"},{"keyEventId":1067,"keyEventName":"Proliferation/Clonal Expansion, aberrant basal cells"},{"keyEventId":1069,"keyEventName":"Increased, Hyperplasia (glandular epithelial cells of endometrium)"},{"keyEventId":1065,"keyEventName":"Activation, estrogen receptor alpha"},{"keyEventId":1064,"keyEventName":"prepubertal increase, Estrogen receptor (ER) activity"},{"keyEventId":1068,"keyEventName":"squamous metaplasia, aberrant basal cells"},{"keyEventId":1066,"keyEventName":"Promotion, SIX-1 postive basal-type progenitor cells"}],"reference":"https://aopwiki.org/aops/167"}
{"aopId":52,"aopName":"ER agonism leading to skewed sex ratios due to altered sexual differentiation in males","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"skewed, sex ratio","adverseOutcomeId":417,"keyEvents":[{"keyEventId":111,"keyEventName":"Agonism, Estrogen receptor"},{"keyEventId":417,"keyEventName":"skewed, sex ratio"}],"reference":"https://aopwiki.org/aops/52"}
{"aopId":67,"aopName":"Modulation of Adult Leydig Cell Function Subsequent to Estradiaol Activation in the Fetal Testis","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Decreased sperm quantity / quality in the adult, Decreased fertility ","adverseOutcomeId":505,"keyEvents":[{"keyEventId":656,"keyEventName":"Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells"},{"keyEventId":659,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists"},{"keyEventId":658,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased estradiol"},{"keyEventId":655,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"},{"keyEventId":505,"keyEventName":"Decreased sperm quantity / quality in the adult, Decreased fertility "},{"keyEventId":660,"keyEventName":"decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells"}],"reference":"https://aopwiki.org/aops/67"}
{"aopId":200,"aopName":"Estrogen receptor activation leading to breast cancer  ","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"N/A, Breast Cancer","adverseOutcomeId":1193,"keyEvents":[{"keyEventId":1183,"keyEventName":"Decreased, Apoptosis (Epithelial Cells)"},{"keyEventId":1195,"keyEventName":"modulation, Extracellular Matrix Composition "},{"keyEventId":1241,"keyEventName":"Increased, Motility"},{"keyEventId":1242,"keyEventName":"Increased, Second Messenger Production"},{"keyEventId":177,"keyEventName":"N/A, Mitochondrial dysfunction 1"},{"keyEventId":1193,"keyEventName":"N/A, Breast Cancer"},{"keyEventId":1188,"keyEventName":"Increased, ER binding to T.F. to DNA (non-classical pathway)"},{"keyEventId":1194,"keyEventName":"Increase, DNA damage"},{"keyEventId":1197,"keyEventName":"Activation, Fibroblasts"},{"keyEventId":1191,"keyEventName":"Increased, Non-genomic signaling"},{"keyEventId":1189,"keyEventName":"Increased, Proliferation (Endothelial cells) "},{"keyEventId":1181,"keyEventName":"Activation, Estrogen receptor"},{"keyEventId":1182,"keyEventName":"Increase, Cell Proliferation (Epithelial Cells)"},{"keyEventId":1196,"keyEventName":"Increased, Invasion"},{"keyEventId":1240,"keyEventName":"Altered, Protein Production"},{"keyEventId":1187,"keyEventName":"Increased, ER binding to DNA (classical pathway) "},{"keyEventId":1198,"keyEventName":"Activation, Macrophages"},{"keyEventId":1239,"keyEventName":"Altered, Gene Expression"},{"keyEventId":1088,"keyEventName":"Increased, Oxidative Stress"},{"keyEventId":1192,"keyEventName":"Increased, Ductal Hyperplasia "},{"keyEventId":1190,"keyEventName":"Increased, Migration (Endothelial Cells)"},{"keyEventId":1213,"keyEventName":"Increased, Angiogenesis"}],"reference":"https://aopwiki.org/aops/200"}
{"aopId":165,"aopName":"Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Promotion, ovarian granular cell tumors","adverseOutcomeId":1054,"keyEvents":[{"keyEventId":1054,"keyEventName":"Promotion, ovarian granular cell tumors"},{"keyEventId":1047,"keyEventName":"Increased, secretion of GnRH from hypothalamus"},{"keyEventId":1049,"keyEventName":"Increased, secrection of FSH from anterior pituitary"},{"keyEventId":1056,"keyEventName":"Decrease, E2 blood concentrations at hypothalamus"},{"keyEventId":1046,"keyEventName":"Suppression, Estrogen receptor (ER) activity"},{"keyEventId":1045,"keyEventName":"Decreased, Ovarian E2"},{"keyEventId":1050,"keyEventName":"Increased, secretion of LH from anterior pituitary"},{"keyEventId":1051,"keyEventName":"Hyperplasia, ovarian stromal cells"},{"keyEventId":1052,"keyEventName":"Hyperplasia, ovarian epithelium"},{"keyEventId":1053,"keyEventName":"Promotion, ovarian adenomas"}],"reference":"https://aopwiki.org/aops/165"}
{"aopId":165,"aopName":"Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Promotion, ovarian adenomas","adverseOutcomeId":1053,"keyEvents":[{"keyEventId":1054,"keyEventName":"Promotion, ovarian granular cell tumors"},{"keyEventId":1047,"keyEventName":"Increased, secretion of GnRH from hypothalamus"},{"keyEventId":1049,"keyEventName":"Increased, secrection of FSH from anterior pituitary"},{"keyEventId":1056,"keyEventName":"Decrease, E2 blood concentrations at hypothalamus"},{"keyEventId":1046,"keyEventName":"Suppression, Estrogen receptor (ER) activity"},{"keyEventId":1045,"keyEventName":"Decreased, Ovarian E2"},{"keyEventId":1050,"keyEventName":"Increased, secretion of LH from anterior pituitary"},{"keyEventId":1051,"keyEventName":"Hyperplasia, ovarian stromal cells"},{"keyEventId":1052,"keyEventName":"Hyperplasia, ovarian epithelium"},{"keyEventId":1053,"keyEventName":"Promotion, ovarian adenomas"}],"reference":"https://aopwiki.org/aops/165"}
{"aopId":30,"aopName":"Estrogen receptor antagonism leading to reproductive dysfunction","targetName":"estrogen receptor","targetId":"ENSG00000091831","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":112,"keyEventName":"Antagonism, Estrogen receptor"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/30"}
{"aopId":154,"aopName":"Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response","targetName":"interleukin-2","targetId":"ENSG00000109471","adverseOutcome":"Impairment, T-cell dependent antibody response","adverseOutcomeId":984,"keyEvents":[{"keyEventId":979,"keyEventName":"Interference, nuclear localization of NFAT"},{"keyEventId":1202,"keyEventName":"Suppression, IL-2 and IL-4 production"},{"keyEventId":980,"keyEventName":"Inhibition, Calcineurin Activity"},{"keyEventId":984,"keyEventName":"Impairment, T-cell dependent antibody response"},{"keyEventId":981,"keyEventName":"Reduction, NFAT/AP-1 complex formation"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/154"}
{"aopId":149,"aopName":"Peptide Oxidation Leading to Hypertension","targetName":"nitric oxide synthase, endothelial","targetId":"ENSG00000164867","adverseOutcome":"Hypertension","adverseOutcomeId":952,"keyEvents":[{"keyEventId":937,"keyEventName":"KE7 : Impaired, Vasodilation"},{"keyEventId":209,"keyEventName":"Peptide Oxidation"},{"keyEventId":933,"keyEventName":"KE6 : Depletion, Nitric Oxide"},{"keyEventId":952,"keyEventName":"Hypertension"},{"keyEventId":951,"keyEventName":"KE8 : Increase, Vascular Resistance"},{"keyEventId":935,"keyEventName":"KE2 : Decrease, GTPCH-1"},{"keyEventId":927,"keyEventName":"KE1 : S-Glutathionylation, eNOS"},{"keyEventId":934,"keyEventName":"KE3 : Decrease, Tetrahydrobiopterin"},{"keyEventId":973,"keyEventName":"KE5 : Decrease, AKT/eNOS activity"},{"keyEventId":932,"keyEventName":"KE4 : Uncoupling, eNOS"}],"status":"Under Development","reference":"https://aopwiki.org/aops/149"}
{"aopId":120,"aopName":"Inhibition of 5α-reductase leading to Leydig cell tumors (in rat)","targetName":"3-oxo-5-alpha-steroid 4-dehydrogenase 2 (rat)","adverseOutcome":"Increase, Leydig cell tumors","adverseOutcomeId":745,"keyEvents":[{"keyEventId":790,"keyEventName":"Inhibition, 5α-reductase activity"},{"keyEventId":792,"keyEventName":"Decrease, Bioactivation of testosterone"},{"keyEventId":791,"keyEventName":"Increased, Leutinizing hormone (LH)"},{"keyEventId":745,"keyEventName":"Increase, Leydig cell tumors"},{"keyEventId":744,"keyEventName":"Increase, Hyperplasia (Leydig cells)"}],"reference":"https://aopwiki.org/aops/120"}
{"aopId":196,"aopName":"Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation","targetName":"transient receptor potential cation channel TRPV1","adverseOutcome":"Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea","adverseOutcomeId":1223,"keyEvents":[{"keyEventId":1215,"keyEventName":"TRPA1 activation, TRPA1 Receptor"},{"keyEventId":1223,"keyEventName":"Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea"},{"keyEventId":1435,"keyEventName":"Increased neurokinin A (NKA) by neuronal cells"},{"keyEventId":1226,"keyEventName":"Increased Respiratory irritability and Chronic Cough, "},{"keyEventId":1218,"keyEventName":"Opening of calcium channel, Calcium influx"},{"keyEventId":1220,"keyEventName":"Trigeminal nerve activation"},{"keyEventId":1433,"keyEventName":"Increased CGRP, neuronal release of CGRP"},{"keyEventId":1434,"keyEventName":"Irritation of nasal mucosa inducing sneeze reflex"},{"keyEventId":1222,"keyEventName":"SP (Substance P) release, Local increase of SP"}],"reference":"https://aopwiki.org/aops/196"}
{"aopId":196,"aopName":"Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation","targetName":"transient receptor potential cation channel TRPV1","adverseOutcome":"Irritation of nasal mucosa inducing sneeze reflex","adverseOutcomeId":1434,"keyEvents":[{"keyEventId":1215,"keyEventName":"TRPA1 activation, TRPA1 Receptor"},{"keyEventId":1223,"keyEventName":"Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea"},{"keyEventId":1435,"keyEventName":"Increased neurokinin A (NKA) by neuronal cells"},{"keyEventId":1226,"keyEventName":"Increased Respiratory irritability and Chronic Cough, "},{"keyEventId":1218,"keyEventName":"Opening of calcium channel, Calcium influx"},{"keyEventId":1220,"keyEventName":"Trigeminal nerve activation"},{"keyEventId":1433,"keyEventName":"Increased CGRP, neuronal release of CGRP"},{"keyEventId":1434,"keyEventName":"Irritation of nasal mucosa inducing sneeze reflex"},{"keyEventId":1222,"keyEventName":"SP (Substance P) release, Local increase of SP"}],"reference":"https://aopwiki.org/aops/196"}
{"aopId":196,"aopName":"Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation","targetName":"transient receptor potential cation channel TRPV1","adverseOutcome":"Increased Respiratory irritability and Chronic Cough, ","adverseOutcomeId":1226,"keyEvents":[{"keyEventId":1215,"keyEventName":"TRPA1 activation, TRPA1 Receptor"},{"keyEventId":1223,"keyEventName":"Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea"},{"keyEventId":1435,"keyEventName":"Increased neurokinin A (NKA) by neuronal cells"},{"keyEventId":1226,"keyEventName":"Increased Respiratory irritability and Chronic Cough, "},{"keyEventId":1218,"keyEventName":"Opening of calcium channel, Calcium influx"},{"keyEventId":1220,"keyEventName":"Trigeminal nerve activation"},{"keyEventId":1433,"keyEventName":"Increased CGRP, neuronal release of CGRP"},{"keyEventId":1434,"keyEventName":"Irritation of nasal mucosa inducing sneeze reflex"},{"keyEventId":1222,"keyEventName":"SP (Substance P) release, Local increase of SP"}],"reference":"https://aopwiki.org/aops/196"}
{"aopId":65,"aopName":"XX Inhibition of Sodium Iodide Symporter and Subsequent Adverse Neurodevelopmental Outcomes in Mammals","targetName":"sodium/iodide cotransporter","targetId":"ENSG00000105641","adverseOutcome":"Cognitive Function, Decreased ","adverseOutcomeId":402,"keyEvents":[{"keyEventId":186,"keyEventName":"Altered, Neuroanatomy"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":424,"keyEventName":"Inhibition, Na+/I- symporter (NIS)"},{"keyEventId":402,"keyEventName":"Cognitive Function, Decreased "},{"keyEventId":192,"keyEventName":"Altered, Neurophysiology"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "}],"reference":"https://aopwiki.org/aops/65"}
{"aopId":54,"aopName":"Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment ","targetName":"sodium/iodide cotransporter","targetId":"ENSG00000105641","adverseOutcomeId":341,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":851,"keyEventName":"Decrease of GABAergic interneurons"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":424,"keyEventName":"Inhibition, Na+/I- symporter (NIS)"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":386,"keyEventName":"Decrease of neuronal network function"},{"keyEventId":425,"keyEventName":"Decrease of Thyroidal iodide"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "},{"keyEventId":385,"keyEventName":"Decrease of synaptogenesis"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/54"}
{"aopId":54,"aopName":"Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment ","targetName":"sodium/iodide cotransporter","targetId":"ENSG00000105641","adverseOutcome":"Impairment, Learning and memory","adverseOutcomeId":341,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":851,"keyEventName":"Decrease of GABAergic interneurons"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":424,"keyEventName":"Inhibition, Na+/I- symporter (NIS)"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":386,"keyEventName":"Decrease of neuronal network function"},{"keyEventId":425,"keyEventName":"Decrease of Thyroidal iodide"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "},{"keyEventId":385,"keyEventName":"Decrease of synaptogenesis"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/54"}
{"aopId":176,"aopName":"Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis","targetName":"sodium/iodide cotransporter","targetId":"ENSG00000105641","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":424,"keyEventName":"Inhibition, Na+/I- symporter (NIS)"},{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":425,"keyEventName":"Decrease of Thyroidal iodide"}],"reference":"https://aopwiki.org/aops/176"}
{"aopId":134,"aopName":"Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals","targetName":"sodium/iodide cotransporter","targetId":"ENSG00000105641","adverseOutcome":"Cognitive Function, Decreased ","adverseOutcomeId":402,"keyEvents":[{"keyEventId":758,"keyEventName":"Hippocampal Physiology, Altered"},{"keyEventId":756,"keyEventName":"Hippocampal gene expression, Altered "},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":424,"keyEventName":"Inhibition, Na+/I- symporter (NIS)"},{"keyEventId":402,"keyEventName":"Cognitive Function, Decreased "},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":426,"keyEventName":"Decreased, Thyroxine (T4) in serum"},{"keyEventId":757,"keyEventName":"Hippocampal anatomy, Altered "},{"keyEventId":425,"keyEventName":"Decrease of Thyroidal iodide"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "}],"reference":"https://aopwiki.org/aops/134"}
{"aopId":187,"aopName":"Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage","targetName":"osteocalcin","targetId":"ENSG00000242252","adverseOutcome":"Impaired recruitment , Population trajectory","adverseOutcomeId":1136,"keyEvents":[{"keyEventId":1135,"keyEventName":"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"},{"keyEventId":1122,"keyEventName":"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "},{"keyEventId":1169,"keyEventName":"Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin"},{"keyEventId":1130,"keyEventName":"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"},{"keyEventId":1133,"keyEventName":"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"},{"keyEventId":1131,"keyEventName":"Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "},{"keyEventId":1134,"keyEventName":"Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone"},{"keyEventId":1132,"keyEventName":"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"},{"keyEventId":1136,"keyEventName":"Impaired recruitment , Population trajectory"},{"keyEventId":1138,"keyEventName":"Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP"},{"keyEventId":1151,"keyEventName":"Osteoporosis and vascular calcification, Bone deterioration"}],"status":"Under Development","reference":"https://aopwiki.org/aops/187"}
{"aopId":171,"aopName":"Chronic cytotoxicity of the serous membrane leading to pleural/peritoneal mesotheliomas in the rat.","targetName":"eukaryotic protein","adverseOutcome":"Increased, mesotheliomas","adverseOutcomeId":1090,"keyEvents":[{"keyEventId":1090,"keyEventName":"Increased, mesotheliomas"},{"keyEventId":1089,"keyEventName":"Increased, Cell Proliferation (mesothelium)"},{"keyEventId":1086,"keyEventName":"persistent, cytotoxicity (pleura or peritoneum)"},{"keyEventId":1087,"keyEventName":"Increased, inflammation"},{"keyEventId":1088,"keyEventName":"Increased, Oxidative Stress"},{"keyEventId":1032,"keyEventName":"Increased, secretion of local growth factors"}],"reference":"https://aopwiki.org/aops/171"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"hepatocyte nuclear factor 3-beta","targetId":"ENSG00000125798","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"hepatocyte nuclear factor 3-beta","targetId":"ENSG00000125798","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":148,"aopName":"EGFR Activation Leading to Decreased Lung Function","targetName":"epidermal growth factor receptor","targetId":"ENSG00000146648","adverseOutcome":"Decrease, Lung function","adverseOutcomeId":1250,"keyEvents":[{"keyEventId":919,"keyEventName":"Occurrence, Transdifferentiation of ciliated epithelial cells"},{"keyEventId":1250,"keyEventName":"Decrease, Lung function"},{"keyEventId":920,"keyEventName":"Occurrence, Metaplasia of goblet cells"},{"keyEventId":914,"keyEventName":"Decrease, Apoptosis of ciliated epithelial cells"},{"keyEventId":921,"keyEventName":"Occurrence, Hyperplasia of goblet cells"},{"keyEventId":1251,"keyEventName":"Chronic, Mucus hypersecretion"},{"keyEventId":923,"keyEventName":"Increase, Proliferation of goblet cells"},{"keyEventId":924,"keyEventName":"Activation, Sp1"},{"keyEventId":962,"keyEventName":"Increase, Mucin production"},{"keyEventId":941,"keyEventName":"Activation, EGFR"}],"status":"Under Development","reference":"https://aopwiki.org/aops/148"}
{"aopId":201,"aopName":"Juvenile hormone receptor agonism leading to male offspring induction associated population decline","targetName":"protein doublesex (fruit fly)","adverseOutcome":"Increased, Male offspring","adverseOutcomeId":1208,"keyEvents":[{"keyEventId":1210,"keyEventName":"Alteration, Food-web structures"},{"keyEventId":1208,"keyEventName":"Increased, Male offspring"},{"keyEventId":1205,"keyEventName":"Activation, Juvenile hormone receptor"},{"keyEventId":1209,"keyEventName":"Induction, Male reproductive tract"},{"keyEventId":1206,"keyEventName":"Induction, Doublesex1 gene"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/201"}
{"aopId":201,"aopName":"Juvenile hormone receptor agonism leading to male offspring induction associated population decline","targetName":"protein doublesex (fruit fly)","adverseOutcome":"Decline, Population","adverseOutcomeId":361,"keyEvents":[{"keyEventId":1210,"keyEventName":"Alteration, Food-web structures"},{"keyEventId":1208,"keyEventName":"Increased, Male offspring"},{"keyEventId":1205,"keyEventName":"Activation, Juvenile hormone receptor"},{"keyEventId":1209,"keyEventName":"Induction, Male reproductive tract"},{"keyEventId":1206,"keyEventName":"Induction, Doublesex1 gene"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/201"}
{"aopId":201,"aopName":"Juvenile hormone receptor agonism leading to male offspring induction associated population decline","targetName":"protein doublesex (fruit fly)","adverseOutcome":"Alteration, Food-web structures","adverseOutcomeId":1210,"keyEvents":[{"keyEventId":1210,"keyEventName":"Alteration, Food-web structures"},{"keyEventId":1208,"keyEventName":"Increased, Male offspring"},{"keyEventId":1205,"keyEventName":"Activation, Juvenile hormone receptor"},{"keyEventId":1209,"keyEventName":"Induction, Male reproductive tract"},{"keyEventId":1206,"keyEventName":"Induction, Doublesex1 gene"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/201"}
{"aopId":207,"aopName":"NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans","targetName":"hypoxia-inducible factor 1 (Caenorhabditis elegans)","adverseOutcome":"Reproductive failure","adverseOutcomeId":1277,"keyEvents":[{"keyEventId":1277,"keyEventName":"Reproductive failure"},{"keyEventId":1278,"keyEventName":"ROS formation"},{"keyEventId":1262,"keyEventName":"Apoptosis"},{"keyEventId":1280,"keyEventName":"Activation, HIF-1"},{"keyEventId":1281,"keyEventName":"Increased, DNA Damage-Repair"},{"keyEventId":1279,"keyEventName":"Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":1174,"keyEventName":"Activation, NADPH Oxidase"}],"reference":"https://aopwiki.org/aops/207"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"hypoxia-inducible factor 1 (Caenorhabditis elegans)","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"hypoxia-inducible factor 1 (Caenorhabditis elegans)","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"hypoxia-inducible factor 1 (Caenorhabditis elegans)","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"hypoxia-inducible factor 1 (Caenorhabditis elegans)","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"hypoxia-inducible factor 1 (Caenorhabditis elegans)","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"hypoxia-inducible factor 1 (Caenorhabditis elegans)","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":131,"aopName":"Aryl hydrocarbon receptor activation leading to uroporphyria","targetName":"uroporphyrinogen decarboxylase","targetId":"ENSG00000126088","adverseOutcome":"Uroporphyria","adverseOutcomeId":369,"keyEvents":[{"keyEventId":18,"keyEventName":"Activation, AhR"},{"keyEventId":846,"keyEventName":"Accumulation, Highly carboxylated porphyrins"},{"keyEventId":369,"keyEventName":"Uroporphyria"},{"keyEventId":845,"keyEventName":"Inhibition, UROD"},{"keyEventId":844,"keyEventName":"Oxidation, Uroporphyrinogen"},{"keyEventId":850,"keyEventName":"Induction, CYP1A2/CYP1A5"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/131"}
{"aopId":10,"aopName":"Binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain","targetName":"gamma-aminobutyric acid receptor subunit alpha-6","targetId":"ENSG00000145863","adverseOutcome":"Occurrence, Epileptic seizure","adverseOutcomeId":613,"keyEvents":[{"keyEventId":669,"keyEventName":"Reduction, Neuronal synaptic inhibition"},{"keyEventId":616,"keyEventName":"Occurrence, A paroxysmal depolarizing shift"},{"keyEventId":682,"keyEventName":"Generation, Amplified excitatory postsynaptic potential (EPSP)"},{"keyEventId":667,"keyEventName":"Binding at picrotoxin site, iGABAR chloride channel"},{"keyEventId":613,"keyEventName":"Occurrence, Epileptic seizure"},{"keyEventId":64,"keyEventName":"Reduction, Ionotropic GABA receptor chloride channel conductance"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/10"}
{"aopId":209,"aopName":"Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP ","targetName":"glutathione synthetase","targetId":"ENSG00000100983","adverseOutcome":"Hepatotoxicity","adverseOutcomeId":1291,"keyEvents":[{"keyEventId":1284,"keyEventName":"Up Regulation, SREBF2"},{"keyEventId":1288,"keyEventName":"Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"},{"keyEventId":1285,"keyEventName":"Up Regulation, Unsaturated fatty acid"},{"keyEventId":1291,"keyEventName":"Hepatotoxicity"},{"keyEventId":1287,"keyEventName":"Glutathione synthesis"},{"keyEventId":1286,"keyEventName":"Down Regulation, GSS and GSTs gene"},{"keyEventId":1289,"keyEventName":"Perturbation of cholesterol"},{"keyEventId":1290,"keyEventName":"Glutathione homeostasis"}],"reference":"https://aopwiki.org/aops/209"}
{"aopId":157,"aopName":"Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation ","targetName":"type I iodothyronine deiodinase","targetId":"ENSG00000211452","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1004,"keyEventName":"Reduced, Posterior swim bladder inflation"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":1009,"keyEventName":"Inhibition, Deiodinase 1"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/157"}
{"aopId":157,"aopName":"Deiodinase 1 inhibition leading to increased mortality via reduced posterior swim bladder inflation ","targetName":"type I iodothyronine deiodinase","targetId":"ENSG00000211452","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1004,"keyEventName":"Reduced, Posterior swim bladder inflation"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":1009,"keyEventName":"Inhibition, Deiodinase 1"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/157"}
{"aopId":158,"aopName":"Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation","targetName":"type I iodothyronine deiodinase","targetId":"ENSG00000211452","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1007,"keyEventName":"Reduced, Anterior swim bladder inflation"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":1009,"keyEventName":"Inhibition, Deiodinase 1"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/158"}
{"aopId":158,"aopName":"Deiodinase 1 inhibition leading to increased mortality via reduced anterior swim bladder inflation","targetName":"type I iodothyronine deiodinase","targetId":"ENSG00000211452","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1007,"keyEventName":"Reduced, Anterior swim bladder inflation"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":1009,"keyEventName":"Inhibition, Deiodinase 1"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/158"}
{"aopId":189,"aopName":"Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis","targetName":"type I iodothyronine deiodinase","targetId":"ENSG00000211452","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":1116,"keyEventName":"Decreased, Triiodothyronine (T3) in tissues"},{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":1009,"keyEventName":"Inhibition, Deiodinase 1"}],"reference":"https://aopwiki.org/aops/189"}
{"aopId":62,"aopName":"AKT2 activation leading to hepatic steatosis","targetName":"RAC-beta serine/threonine-protein kinase","targetId":"ENSG00000105221","adverseOutcomeId":459,"keyEvents":[{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":486,"keyEventName":"systemic inflammation leading to hepatic steatosis"},{"keyEventId":484,"keyEventName":"Activation, AKT2"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/62"}
{"aopId":62,"aopName":"AKT2 activation leading to hepatic steatosis","targetName":"RAC-beta serine/threonine-protein kinase","targetId":"ENSG00000105221","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":486,"keyEventName":"systemic inflammation leading to hepatic steatosis"},{"keyEventId":484,"keyEventName":"Activation, AKT2"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/62"}
{"aopId":63,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":685,"keyEventName":"Reduced, Prostaglandins, ovary"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":488,"keyEventName":"Decrease, Ovulation"}],"reference":"https://aopwiki.org/aops/63"}
{"aopId":63,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":685,"keyEventName":"Reduced, Prostaglandins, ovary"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":488,"keyEventName":"Decrease, Ovulation"}],"reference":"https://aopwiki.org/aops/63"}
{"aopId":103,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":696,"keyEventName":"Increased, Chromosome misseggregation"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":695,"keyEventName":"Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"}],"reference":"https://aopwiki.org/aops/103"}
{"aopId":103,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":696,"keyEventName":"Increased, Chromosome misseggregation"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":695,"keyEventName":"Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"}],"reference":"https://aopwiki.org/aops/103"}
{"aopId":28,"aopName":"Cyclooxygenase inhibition leading reproductive failure","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"N/A, Reproductive failure","adverseOutcomeId":253,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":106,"keyEventName":"Reduction, Eggshell thickness"},{"keyEventId":253,"keyEventName":"N/A, Reproductive failure"},{"keyEventId":49,"keyEventName":"Reduction, Ca and HCO3 transport to shell gland"},{"keyEventId":119,"keyEventName":"N/A, Gap"},{"keyEventId":243,"keyEventName":"Reduction, Prostaglandin E2 concentration"}],"reference":"https://aopwiki.org/aops/28"}
{"aopId":100,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":672,"keyEventName":"Reduced, Prostaglandin F2alpha synthesis, ovary  "},{"keyEventId":673,"keyEventName":"Reduced, Spawning behavior"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":671,"keyEventName":"Reduced, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":674,"keyEventName":"Reduced, Ability to attract spawning mates"}],"reference":"https://aopwiki.org/aops/100"}
{"aopId":100,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":672,"keyEventName":"Reduced, Prostaglandin F2alpha synthesis, ovary  "},{"keyEventId":673,"keyEventName":"Reduced, Spawning behavior"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":671,"keyEventName":"Reduced, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":674,"keyEventName":"Reduced, Ability to attract spawning mates"}],"reference":"https://aopwiki.org/aops/100"}
{"aopId":101,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":681,"keyEventName":"Decreased, Prostaglandin F2alpha synthesis, ovary  "},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":671,"keyEventName":"Reduced, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":674,"keyEventName":"Reduced, Ability to attract spawning mates"},{"keyEventId":678,"keyEventName":"Reduced, Pheromone release"}],"reference":"https://aopwiki.org/aops/101"}
{"aopId":101,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":681,"keyEventName":"Decreased, Prostaglandin F2alpha synthesis, ovary  "},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":671,"keyEventName":"Reduced, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":674,"keyEventName":"Reduced, Ability to attract spawning mates"},{"keyEventId":678,"keyEventName":"Reduced, Pheromone release"}],"reference":"https://aopwiki.org/aops/101"}
{"aopId":102,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":694,"keyEventName":"Reduced, Meiotic prophase I/metaphase I transition, oocyte"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":693,"keyEventName":"Increased, cyclic adenosine monophosphate"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "}],"reference":"https://aopwiki.org/aops/102"}
{"aopId":102,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition","targetName":"prostaglandin G/H synthase 2","targetId":"ENSG00000073756","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":694,"keyEventName":"Reduced, Meiotic prophase I/metaphase I transition, oocyte"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":693,"keyEventName":"Increased, cyclic adenosine monophosphate"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "}],"reference":"https://aopwiki.org/aops/102"}
{"aopId":207,"aopName":"NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans","targetName":"map kinase p38","adverseOutcome":"Reproductive failure","adverseOutcomeId":1277,"keyEvents":[{"keyEventId":1277,"keyEventName":"Reproductive failure"},{"keyEventId":1278,"keyEventName":"ROS formation"},{"keyEventId":1262,"keyEventName":"Apoptosis"},{"keyEventId":1280,"keyEventName":"Activation, HIF-1"},{"keyEventId":1281,"keyEventName":"Increased, DNA Damage-Repair"},{"keyEventId":1279,"keyEventName":"Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":1174,"keyEventName":"Activation, NADPH Oxidase"}],"reference":"https://aopwiki.org/aops/207"}
{"aopId":200,"aopName":"Estrogen receptor activation leading to breast cancer  ","targetName":"serotransferrin","targetId":"ENSG00000091513","adverseOutcome":"N/A, Breast Cancer","adverseOutcomeId":1193,"keyEvents":[{"keyEventId":1183,"keyEventName":"Decreased, Apoptosis (Epithelial Cells)"},{"keyEventId":1195,"keyEventName":"modulation, Extracellular Matrix Composition "},{"keyEventId":1241,"keyEventName":"Increased, Motility"},{"keyEventId":1242,"keyEventName":"Increased, Second Messenger Production"},{"keyEventId":177,"keyEventName":"N/A, Mitochondrial dysfunction 1"},{"keyEventId":1193,"keyEventName":"N/A, Breast Cancer"},{"keyEventId":1188,"keyEventName":"Increased, ER binding to T.F. to DNA (non-classical pathway)"},{"keyEventId":1194,"keyEventName":"Increase, DNA damage"},{"keyEventId":1197,"keyEventName":"Activation, Fibroblasts"},{"keyEventId":1191,"keyEventName":"Increased, Non-genomic signaling"},{"keyEventId":1189,"keyEventName":"Increased, Proliferation (Endothelial cells) "},{"keyEventId":1181,"keyEventName":"Activation, Estrogen receptor"},{"keyEventId":1182,"keyEventName":"Increase, Cell Proliferation (Epithelial Cells)"},{"keyEventId":1196,"keyEventName":"Increased, Invasion"},{"keyEventId":1240,"keyEventName":"Altered, Protein Production"},{"keyEventId":1187,"keyEventName":"Increased, ER binding to DNA (classical pathway) "},{"keyEventId":1198,"keyEventName":"Activation, Macrophages"},{"keyEventId":1239,"keyEventName":"Altered, Gene Expression"},{"keyEventId":1088,"keyEventName":"Increased, Oxidative Stress"},{"keyEventId":1192,"keyEventName":"Increased, Ductal Hyperplasia "},{"keyEventId":1190,"keyEventName":"Increased, Migration (Endothelial Cells)"},{"keyEventId":1213,"keyEventName":"Increased, Angiogenesis"}],"reference":"https://aopwiki.org/aops/200"}
{"aopId":113,"aopName":"Glutamate-gated chloride channel activation leading to acute mortality","targetName":"glutamate-gated chloride channel (fruit fly)","adverseOutcome":"Decreased, population 1","adverseOutcomeId":765,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":765,"keyEventName":"Decreased, population 1"},{"keyEventId":761,"keyEventName":"Increased, Chloride conductance"},{"keyEventId":763,"keyEventName":"hyperpolarisation, neuron"},{"keyEventId":760,"keyEventName":"Activation, Glutamate-gated chloride channel"},{"keyEventId":764,"keyEventName":"N/A, Ataxia, paralysis, or hyperactivity"}],"reference":"https://aopwiki.org/aops/113"}
{"aopId":113,"aopName":"Glutamate-gated chloride channel activation leading to acute mortality","targetName":"glutamate-gated chloride channel (fruit fly)","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":765,"keyEventName":"Decreased, population 1"},{"keyEventId":761,"keyEventName":"Increased, Chloride conductance"},{"keyEventId":763,"keyEventName":"hyperpolarisation, neuron"},{"keyEventId":760,"keyEventName":"Activation, Glutamate-gated chloride channel"},{"keyEventId":764,"keyEventName":"N/A, Ataxia, paralysis, or hyperactivity"}],"reference":"https://aopwiki.org/aops/113"}
{"aopId":161,"aopName":"Glutamate-gated chloride channel activation leading to neurotransmission inhibition associated mortality","targetName":"glutamate-gated chloride channel (fruit fly)","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1019,"keyEventName":"Induction, pharyngeal muscle paralysis"},{"keyEventId":1015,"keyEventName":"Increased, Neuronal synaptic inhibition"},{"keyEventId":1016,"keyEventName":"Inhibition, Feeding"},{"keyEventId":761,"keyEventName":"Increased, Chloride conductance"},{"keyEventId":1012,"keyEventName":"Increased, Inhibitory postsynaptic potential"},{"keyEventId":1018,"keyEventName":"Activation, Glutamate-gated chloride channels"}],"reference":"https://aopwiki.org/aops/161"}
{"aopId":108,"aopName":"Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat)","targetName":"Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial (rat)","adverseOutcome":"Increase, hepatocellular adenomas and carcinomas","adverseOutcomeId":719,"keyEvents":[{"keyEventId":719,"keyEventName":"Increase, hepatocellular adenomas and carcinomas"},{"keyEventId":209,"keyEventName":"Peptide Oxidation"},{"keyEventId":724,"keyEventName":"Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme"},{"keyEventId":769,"keyEventName":"Increase, Oxidative metabolism"},{"keyEventId":726,"keyEventName":"Increased, Induction of pyruvate dehydrogenase (PDH)"},{"keyEventId":768,"keyEventName":"Increase, Cytotoxicity"}],"reference":"https://aopwiki.org/aops/108"}
{"aopId":99,"aopName":"Histamine (H2) receptor antagonism leading to reduced survival","targetName":"histamine H2 receptor","targetId":"ENSG00000113749","adverseOutcomeId":588,"keyEvents":[{"keyEventId":635,"keyEventName":"Decreased, locomotion"},{"keyEventId":638,"keyEventName":"Antagonism, Histamine Receptor (H2)"},{"keyEventId":636,"keyEventName":"Decreased, survival"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":633,"keyEventName":"Decrease, histaminergic neuron excitation"},{"keyEventId":634,"keyEventName":"N/A, sedation"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/99"}
{"aopId":99,"aopName":"Histamine (H2) receptor antagonism leading to reduced survival","targetName":"histamine H2 receptor","targetId":"ENSG00000113749","adverseOutcome":"Increased, predation","adverseOutcomeId":588,"keyEvents":[{"keyEventId":635,"keyEventName":"Decreased, locomotion"},{"keyEventId":638,"keyEventName":"Antagonism, Histamine Receptor (H2)"},{"keyEventId":636,"keyEventName":"Decreased, survival"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":633,"keyEventName":"Decrease, histaminergic neuron excitation"},{"keyEventId":634,"keyEventName":"N/A, sedation"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/99"}
{"aopId":99,"aopName":"Histamine (H2) receptor antagonism leading to reduced survival","targetName":"histamine H2 receptor","targetId":"ENSG00000113749","adverseOutcome":"Decreased, survival","adverseOutcomeId":636,"keyEvents":[{"keyEventId":635,"keyEventName":"Decreased, locomotion"},{"keyEventId":638,"keyEventName":"Antagonism, Histamine Receptor (H2)"},{"keyEventId":636,"keyEventName":"Decreased, survival"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":633,"keyEventName":"Decrease, histaminergic neuron excitation"},{"keyEventId":634,"keyEventName":"N/A, sedation"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/99"}
{"aopId":150,"aopName":"Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF","targetName":"vascular endothelial growth factor A","targetId":"ENSG00000112715","adverseOutcomeId":947,"keyEvents":[{"keyEventId":947,"keyEventName":"Increase, Early Life Stage Mortality"},{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":317,"keyEventName":"Altered, Cardiovascular development/function"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/150"}
{"aopId":150,"aopName":"Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF","targetName":"vascular endothelial growth factor A","targetId":"ENSG00000112715","adverseOutcome":"Increase, Early Life Stage Mortality","adverseOutcomeId":947,"keyEvents":[{"keyEventId":947,"keyEventName":"Increase, Early Life Stage Mortality"},{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":317,"keyEventName":"Altered, Cardiovascular development/function"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/150"}
{"aopId":151,"aopName":"AhR activation leading to preeclampsia","targetName":"vascular endothelial growth factor A","targetId":"ENSG00000112715","adverseOutcome":"increase, Preeclampsia","adverseOutcomeId":1893,"keyEvents":[{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":1892,"keyEventName":"increase, placental insufficiency"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":1893,"keyEventName":"increase, Preeclampsia"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":1891,"keyEventName":"abnormal, placental labyrinth vasculature morphology"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"Under Development","reference":"https://aopwiki.org/aops/151"}
{"aopId":274,"aopName":"Histone deacetylase inhibition leads to impeded craniofacial development","targetName":"histone deacetylase 1","targetId":"ENSG00000116478","adverseOutcome":"Facial cartilage structures are reduced in size and morphologically distorted","adverseOutcomeId":1559,"keyEvents":[{"keyEventId":1557,"keyEventName":"Neural crest cell migration, reduced"},{"keyEventId":1502,"keyEventName":"Histone deacetylase inhibition"},{"keyEventId":1559,"keyEventName":"Facial cartilage structures are reduced in size and morphologically distorted"},{"keyEventId":1558,"keyEventName":"Collagen production, reduced"}],"reference":"https://aopwiki.org/aops/274"}
{"aopId":275,"aopName":"Histone deacetylase inhibition leads to neural tube defects","targetName":"histone deacetylase 1","targetId":"ENSG00000116478","adverseOutcome":"Neural tube defects","adverseOutcomeId":1561,"keyEvents":[{"keyEventId":1239,"keyEventName":"Altered, Gene Expression"},{"keyEventId":1502,"keyEventName":"Histone deacetylase inhibition"},{"keyEventId":1503,"keyEventName":"Histone acetylation, increase"},{"keyEventId":1561,"keyEventName":"Neural tube defects"},{"keyEventId":1560,"keyEventName":"Altered differentiation"}],"reference":"https://aopwiki.org/aops/275"}
{"aopId":212,"aopName":"Histone deacetylase inhibition leading to testicular atrophy","targetName":"histone deacetylase 1","targetId":"ENSG00000116478","adverseOutcome":"Testicular atrophy","adverseOutcomeId":1506,"keyEvents":[{"keyEventId":1262,"keyEventName":"Apoptosis"},{"keyEventId":1505,"keyEventName":"Cell cycle, disrupted"},{"keyEventId":1502,"keyEventName":"Histone deacetylase inhibition"},{"keyEventId":1515,"keyEventName":"Spermatocyte depletion"},{"keyEventId":1503,"keyEventName":"Histone acetylation, increase"},{"keyEventId":1506,"keyEventName":"Testicular atrophy"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/212"}
{"aopId":208,"aopName":"Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) and Transforming growth factor (TGF)-beta pathways activation leading to reproductive failure","targetName":"Janus kinase","adverseOutcome":"Reproductive failure","adverseOutcomeId":1277,"keyEvents":[{"keyEventId":1277,"keyEventName":"Reproductive failure"},{"keyEventId":1283,"keyEventName":"Activation, TGF-beta pathway"},{"keyEventId":1282,"keyEventName":"Activation, JAK/STAT pathway"}],"reference":"https://aopwiki.org/aops/208"}
{"aopId":149,"aopName":"Peptide Oxidation Leading to Hypertension","targetName":"AKT kinase","adverseOutcome":"Hypertension","adverseOutcomeId":952,"keyEvents":[{"keyEventId":937,"keyEventName":"KE7 : Impaired, Vasodilation"},{"keyEventId":209,"keyEventName":"Peptide Oxidation"},{"keyEventId":933,"keyEventName":"KE6 : Depletion, Nitric Oxide"},{"keyEventId":952,"keyEventName":"Hypertension"},{"keyEventId":951,"keyEventName":"KE8 : Increase, Vascular Resistance"},{"keyEventId":935,"keyEventName":"KE2 : Decrease, GTPCH-1"},{"keyEventId":927,"keyEventName":"KE1 : S-Glutathionylation, eNOS"},{"keyEventId":934,"keyEventName":"KE3 : Decrease, Tetrahydrobiopterin"},{"keyEventId":973,"keyEventName":"KE5 : Decrease, AKT/eNOS activity"},{"keyEventId":932,"keyEventName":"KE4 : Uncoupling, eNOS"}],"status":"Under Development","reference":"https://aopwiki.org/aops/149"}
{"aopId":34,"aopName":"LXR activation leading to hepatic steatosis","targetName":"oxysterols receptor LXR-alpha","targetId":"ENSG00000025434","adverseOutcome":"N/A, Liver Steatosis","adverseOutcomeId":345,"keyEvents":[{"keyEventId":89,"keyEventName":"Synthesis, De Novo FA"},{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":264,"keyEventName":"Activation, SREBP-1c"},{"keyEventId":116,"keyEventName":"Activation, FAS"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":115,"keyEventName":"Increase, FA Influx"},{"keyEventId":345,"keyEventName":"N/A, Liver Steatosis"},{"keyEventId":258,"keyEventName":"Activation, SCD-1"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":167,"keyEventName":"Activation, LXR"}],"reference":"https://aopwiki.org/aops/34"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"oxysterols receptor LXR-alpha","targetId":"ENSG00000025434","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"oxysterols receptor LXR-alpha","targetId":"ENSG00000025434","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"oxysterols receptor LXR-alpha","targetId":"ENSG00000025434","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"oxysterols receptor LXR-alpha","targetId":"ENSG00000025434","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":73,"aopName":"Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity","targetName":"dopamine beta-hydroxylase","targetId":"ENSG00000123454","adverseOutcome":"Decreased, Decreased fecundity ","adverseOutcomeId":527,"keyEvents":[{"keyEventId":526,"keyEventName":"Inhibition, Inhibition of Dopamine-beta-hydroxylase"},{"keyEventId":532,"keyEventName":"Delayed, Ovulation"},{"keyEventId":533,"keyEventName":"Decreased, Cortical granule release/distribution upon fertilization"},{"keyEventId":527,"keyEventName":"Decreased, Decreased fecundity "},{"keyEventId":528,"keyEventName":"Decreased, Synthesis of NE"},{"keyEventId":534,"keyEventName":"Altered, Formation of cortical envelope"},{"keyEventId":536,"keyEventName":"Altered, Chromosome number (polyploid) zygote"},{"keyEventId":530,"keyEventName":"Decreased, GnRH pulsatility/release"},{"keyEventId":529,"keyEventName":"Decreased, GnRH cfos activity"},{"keyEventId":531,"keyEventName":"Decreased, LH Surge"},{"keyEventId":535,"keyEventName":"Abnormal, Sperm penetration (polyspermy)"}],"reference":"https://aopwiki.org/aops/73"}
{"aopId":187,"aopName":"Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage","targetName":"matrix Gla protein (mouse)","adverseOutcome":"Impaired recruitment , Population trajectory","adverseOutcomeId":1136,"keyEvents":[{"keyEventId":1135,"keyEventName":"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"},{"keyEventId":1122,"keyEventName":"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "},{"keyEventId":1169,"keyEventName":"Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin"},{"keyEventId":1130,"keyEventName":"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"},{"keyEventId":1133,"keyEventName":"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"},{"keyEventId":1131,"keyEventName":"Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "},{"keyEventId":1134,"keyEventName":"Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone"},{"keyEventId":1132,"keyEventName":"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"},{"keyEventId":1136,"keyEventName":"Impaired recruitment , Population trajectory"},{"keyEventId":1138,"keyEventName":"Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP"},{"keyEventId":1151,"keyEventName":"Osteoporosis and vascular calcification, Bone deterioration"}],"status":"Under Development","reference":"https://aopwiki.org/aops/187"}
{"aopId":148,"aopName":"EGFR Activation Leading to Decreased Lung Function","targetName":"transcription factor Sp1","targetId":"ENSG00000185591","adverseOutcome":"Decrease, Lung function","adverseOutcomeId":1250,"keyEvents":[{"keyEventId":919,"keyEventName":"Occurrence, Transdifferentiation of ciliated epithelial cells"},{"keyEventId":1250,"keyEventName":"Decrease, Lung function"},{"keyEventId":920,"keyEventName":"Occurrence, Metaplasia of goblet cells"},{"keyEventId":914,"keyEventName":"Decrease, Apoptosis of ciliated epithelial cells"},{"keyEventId":921,"keyEventName":"Occurrence, Hyperplasia of goblet cells"},{"keyEventId":1251,"keyEventName":"Chronic, Mucus hypersecretion"},{"keyEventId":923,"keyEventName":"Increase, Proliferation of goblet cells"},{"keyEventId":924,"keyEventName":"Activation, Sp1"},{"keyEventId":962,"keyEventName":"Increase, Mucin production"},{"keyEventId":941,"keyEventName":"Activation, EGFR"}],"status":"Under Development","reference":"https://aopwiki.org/aops/148"}
{"aopId":149,"aopName":"Peptide Oxidation Leading to Hypertension","targetName":"GTP cyclohydrolase 1","targetId":"ENSG00000131979","adverseOutcome":"Hypertension","adverseOutcomeId":952,"keyEvents":[{"keyEventId":937,"keyEventName":"KE7 : Impaired, Vasodilation"},{"keyEventId":209,"keyEventName":"Peptide Oxidation"},{"keyEventId":933,"keyEventName":"KE6 : Depletion, Nitric Oxide"},{"keyEventId":952,"keyEventName":"Hypertension"},{"keyEventId":951,"keyEventName":"KE8 : Increase, Vascular Resistance"},{"keyEventId":935,"keyEventName":"KE2 : Decrease, GTPCH-1"},{"keyEventId":927,"keyEventName":"KE1 : S-Glutathionylation, eNOS"},{"keyEventId":934,"keyEventName":"KE3 : Decrease, Tetrahydrobiopterin"},{"keyEventId":973,"keyEventName":"KE5 : Decrease, AKT/eNOS activity"},{"keyEventId":932,"keyEventName":"KE4 : Uncoupling, eNOS"}],"status":"Under Development","reference":"https://aopwiki.org/aops/149"}
{"aopId":366,"aopName":"Competitive binding to thyroid hormone carrier protein transthyretin (TTR) leading to altered amphibian metamorphosis ","targetName":"transthyretin","targetId":"ENSG00000118271","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":959,"keyEventName":"Increased, Free serum thyroxine (T4)"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":1158,"keyEventName":"Increased, Hepatic thyroid hormone uptake/transport"},{"keyEventId":401,"keyEventName":"Increase, Biliary excretion TH glucuronide"},{"keyEventId":957,"keyEventName":"Binding, Transthyretin in serum"},{"keyEventId":1830,"keyEventName":"Displacement, Serum thyroxine (T4) from carrier protein"}],"reference":"https://aopwiki.org/aops/366"}
{"aopId":152,"aopName":"Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity ","targetName":"transthyretin","targetId":"ENSG00000118271","adverseOutcome":"Cognitive Function, Decreased ","adverseOutcomeId":402,"keyEvents":[{"keyEventId":958,"keyEventName":"Displacement, Serum thyroxine (T4) from transthyretin"},{"keyEventId":758,"keyEventName":"Hippocampal Physiology, Altered"},{"keyEventId":961,"keyEventName":"Increased, Clearance of thyroxine from serum"},{"keyEventId":756,"keyEventName":"Hippocampal gene expression, Altered "},{"keyEventId":960,"keyEventName":"Increased, Uptake of thyroxine into tissue"},{"keyEventId":959,"keyEventName":"Increased, Free serum thyroxine (T4)"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":402,"keyEventName":"Cognitive Function, Decreased "},{"keyEventId":957,"keyEventName":"Binding, Transthyretin in serum"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "},{"keyEventId":757,"keyEventName":"Hippocampal anatomy, Altered "}],"status":"Under Development","reference":"https://aopwiki.org/aops/152"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"aromatase isoform 1","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"aromatase isoform 1","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"aromatase isoform 1","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"aromatase isoform 1","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"aromatase isoform 1","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"aromatase isoform 1","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":57,"aopName":"AhR activation leading to hepatic steatosis","targetName":"low-density lipoprotein receptor","targetId":"ENSG00000130164","adverseOutcome":"Accumulation, Liver lipid","adverseOutcomeId":455,"keyEvents":[{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":467,"keyEventName":"Increased, LDL uptake"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":466,"keyEventName":"Up Regulation, LDLR (low density lipoprotein receptor)"},{"keyEventId":80,"keyEventName":"Up Regulation, CYP1A1"},{"keyEventId":455,"keyEventName":"Accumulation, Liver lipid"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":450,"keyEventName":"Suppression, VLDL secretion"},{"keyEventId":216,"keyEventName":"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/57"}
{"aopId":405,"aopName":"Organo-Phosphate Chemicals induced inhibition of AChE  leading to impaired cognitive function","targetName":"acetylcholinesterase","targetId":"ENSG00000087085","adverseOutcome":"Cognitive Function, Decreased ","adverseOutcomeId":402,"keyEvents":[{"keyEventId":39,"keyEventName":"Increased Cholinergic Signaling"},{"keyEventId":402,"keyEventName":"Cognitive Function, Decreased "},{"keyEventId":10,"keyEventName":"Acetylcholine accumulation in synapses"},{"keyEventId":12,"keyEventName":"Acetylcholinesterase (AchE) Inhibition"},{"keyEventId":386,"keyEventName":"Decrease of neuronal network function"}],"reference":"https://aopwiki.org/aops/405"}
{"aopId":312,"aopName":"Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement​","targetName":"acetylcholinesterase","targetId":"ENSG00000087085","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":39,"keyEventName":"Increased Cholinergic Signaling"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1705,"keyEventName":"Impaired coordination and movement"},{"keyEventId":10,"keyEventName":"Acetylcholine accumulation in synapses"},{"keyEventId":12,"keyEventName":"Acetylcholinesterase (AchE) Inhibition"}],"reference":"https://aopwiki.org/aops/312"}
{"aopId":312,"aopName":"Acetylcholinesterase Inhibition leading to Acute Mortality via Impaired Coordination & Movement​","targetName":"acetylcholinesterase","targetId":"ENSG00000087085","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":39,"keyEventName":"Increased Cholinergic Signaling"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1705,"keyEventName":"Impaired coordination and movement"},{"keyEventId":10,"keyEventName":"Acetylcholine accumulation in synapses"},{"keyEventId":12,"keyEventName":"Acetylcholinesterase (AchE) Inhibition"}],"reference":"https://aopwiki.org/aops/312"}
{"aopId":16,"aopName":"Acetylcholinesterase inhibition leading to acute mortality","targetName":"acetylcholinesterase","targetId":"ENSG00000087085","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":39,"keyEventName":"Increased Cholinergic Signaling"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1703,"keyEventName":"Dysregulation of heart rate and vascular tone"},{"keyEventId":445,"keyEventName":"Respiratory distress/arrest"},{"keyEventId":10,"keyEventName":"Acetylcholine accumulation in synapses"},{"keyEventId":12,"keyEventName":"Acetylcholinesterase (AchE) Inhibition"}],"status":"Under Development","reference":"https://aopwiki.org/aops/16"}
{"aopId":16,"aopName":"Acetylcholinesterase inhibition leading to acute mortality","targetName":"acetylcholinesterase","targetId":"ENSG00000087085","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":39,"keyEventName":"Increased Cholinergic Signaling"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1703,"keyEventName":"Dysregulation of heart rate and vascular tone"},{"keyEventId":445,"keyEventName":"Respiratory distress/arrest"},{"keyEventId":10,"keyEventName":"Acetylcholine accumulation in synapses"},{"keyEventId":12,"keyEventName":"Acetylcholinesterase (AchE) Inhibition"}],"status":"Under Development","reference":"https://aopwiki.org/aops/16"}
{"aopId":281,"aopName":"Acetylcholinesterase Inhibition Leading to Neurodegeneration","targetName":"acetylcholinesterase","targetId":"ENSG00000087085","adverseOutcomeId":352,"keyEvents":[{"keyEventId":352,"keyEventName":"N/A, Neurodegeneration"},{"keyEventId":388,"keyEventName":"Overactivation, NMDARs"},{"keyEventId":1623,"keyEventName":"Occurrence, Focal Seizure"},{"keyEventId":1788,"keyEventName":"Status epilepticus"},{"keyEventId":1602,"keyEventName":"Activation, Muscarinic Acetylcholine Receptors"},{"keyEventId":389,"keyEventName":"Increased, Intracellular Calcium overload"},{"keyEventId":10,"keyEventName":"Acetylcholine accumulation in synapses"},{"keyEventId":12,"keyEventName":"Acetylcholinesterase (AchE) Inhibition"},{"keyEventId":55,"keyEventName":"Cell injury/death"}],"reference":"https://aopwiki.org/aops/281"}
{"aopId":281,"aopName":"Acetylcholinesterase Inhibition Leading to Neurodegeneration","targetName":"acetylcholinesterase","targetId":"ENSG00000087085","adverseOutcome":"N/A, Neurodegeneration","adverseOutcomeId":352,"keyEvents":[{"keyEventId":352,"keyEventName":"N/A, Neurodegeneration"},{"keyEventId":388,"keyEventName":"Overactivation, NMDARs"},{"keyEventId":1623,"keyEventName":"Occurrence, Focal Seizure"},{"keyEventId":1788,"keyEventName":"Status epilepticus"},{"keyEventId":1602,"keyEventName":"Activation, Muscarinic Acetylcholine Receptors"},{"keyEventId":389,"keyEventName":"Increased, Intracellular Calcium overload"},{"keyEventId":10,"keyEventName":"Acetylcholine accumulation in synapses"},{"keyEventId":12,"keyEventName":"Acetylcholinesterase (AchE) Inhibition"},{"keyEventId":55,"keyEventName":"Cell injury/death"}],"reference":"https://aopwiki.org/aops/281"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"apolipoprotein B-100","targetId":"ENSG00000084674","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"apolipoprotein B-100","targetId":"ENSG00000084674","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":68,"aopName":"Modulation of Adult Leydig Cell Function Subsequent to Alterations in the Fetal Testis Protome","targetName":"COUP transcription factor 2","targetId":"ENSG00000185551","adverseOutcome":"Decreased sperm quantity / quality in the adult, Decreased fertility ","adverseOutcomeId":505,"keyEvents":[{"keyEventId":656,"keyEventName":"Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells"},{"keyEventId":655,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"},{"keyEventId":657,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells"},{"keyEventId":661,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Alterations in the fetal testis proteome"},{"keyEventId":505,"keyEventName":"Decreased sperm quantity / quality in the adult, Decreased fertility "}],"reference":"https://aopwiki.org/aops/68"}
{"aopId":67,"aopName":"Modulation of Adult Leydig Cell Function Subsequent to Estradiaol Activation in the Fetal Testis","targetName":"COUP transcription factor 2","targetId":"ENSG00000185551","adverseOutcome":"Decreased sperm quantity / quality in the adult, Decreased fertility ","adverseOutcomeId":505,"keyEvents":[{"keyEventId":656,"keyEventName":"Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells"},{"keyEventId":659,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists"},{"keyEventId":658,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased estradiol"},{"keyEventId":655,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"},{"keyEventId":505,"keyEventName":"Decreased sperm quantity / quality in the adult, Decreased fertility "},{"keyEventId":660,"keyEventName":"decreased testosterone by fetal Leydig cells, Dysgenesis of fetal Leydig cells"}],"reference":"https://aopwiki.org/aops/67"}
{"aopId":74,"aopName":"Modulation of Adult Leydig Cell Function Subsequent to Hypermethylation in the Fetal Testis","targetName":"COUP transcription factor 2","targetId":"ENSG00000185551","adverseOutcome":"Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis","adverseOutcomeId":543,"keyEvents":[{"keyEventId":541,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Decreased COUP-TFII stem Leydig cells"},{"keyEventId":540,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Dysgensis of fetal Leydig cells"},{"keyEventId":655,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"},{"keyEventId":543,"keyEventName":"Decreased fertility in the adult, Decreased sperm quantity and/or quality in the adult testis"},{"keyEventId":662,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Hypermethylation in the fetal testis"}],"reference":"https://aopwiki.org/aops/74"}
{"aopId":66,"aopName":"Modulation of Adult Leydig Cell Function Subsequent Glucocorticoid Activation in the Fetal Testis","targetName":"COUP transcription factor 2","targetId":"ENSG00000185551","adverseOutcome":"Decreased sperm quantity / quality in the adult, Decreased fertility ","adverseOutcomeId":505,"keyEvents":[{"keyEventId":656,"keyEventName":"Decreased number and function of adult Leydig cells, Decreased COUP-TFII stem Leydig cells"},{"keyEventId":653,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased corticosterone"},{"keyEventId":655,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Increased COUP-TFII in fetal Leydig cells"},{"keyEventId":657,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Dysgenesis of fetal Leydig cells"},{"keyEventId":654,"keyEventName":"Decreased testosterone by the fetal Leydig cells, Activation by other glucocorticoid receptor agonists"},{"keyEventId":505,"keyEventName":"Decreased sperm quantity / quality in the adult, Decreased fertility "}],"reference":"https://aopwiki.org/aops/66"}
{"aopId":6,"aopName":"Antagonist binding to PPARα leading to body-weight loss","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcome":"Decreased, Body Weight","adverseOutcomeId":864,"keyEvents":[{"keyEventId":858,"keyEventName":"Decreased, PPARalpha transactivation of gene expression"},{"keyEventId":861,"keyEventName":"Decreased, Ketogenesis (production of ketone bodies)"},{"keyEventId":1000,"keyEventName":"stabilization, PPAR alpha co-repressor"},{"keyEventId":864,"keyEventName":"Decreased, Body Weight"},{"keyEventId":863,"keyEventName":"Increased, Catabolism of Muscle Protein"},{"keyEventId":1528,"keyEventName":"Fatty Acid Beta Oxidation, Decreased"},{"keyEventId":862,"keyEventName":"Not Increased, Circulating Ketone Bodies"},{"keyEventId":998,"keyEventName":"Binding of antagonist, PPAR alpha"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/6"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":51,"aopName":"PPARα activation leading to impaired fertility in adult male rodents ","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":415,"keyEventName":"Hyperplasia, Leydig cell"},{"keyEventId":416,"keyEventName":"Increase proliferation, Leydig cell "},{"keyEventId":414,"keyEventName":"Increase, Luteinizing hormone (LH) "}],"status":"Under Development","reference":"https://aopwiki.org/aops/51"}
{"aopId":51,"aopName":"PPARα activation leading to impaired fertility in adult male rodents ","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcome":"impaired, Fertility","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":415,"keyEventName":"Hyperplasia, Leydig cell"},{"keyEventId":416,"keyEventName":"Increase proliferation, Leydig cell "},{"keyEventId":414,"keyEventName":"Increase, Luteinizing hormone (LH) "}],"status":"Under Development","reference":"https://aopwiki.org/aops/51"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":37,"aopName":"PPARα activation leading to hepatocellular adenomas and carcinomas in rodents","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcome":"Increase, hepatocellular adenomas and carcinomas","adverseOutcomeId":719,"keyEvents":[{"keyEventId":719,"keyEventName":"Increase, hepatocellular adenomas and carcinomas"},{"keyEventId":716,"keyEventName":"Increase, cell proliferation (hepatocytes)"},{"keyEventId":1170,"keyEventName":"Increase, Phenotypic enzyme activity"},{"keyEventId":1171,"keyEventName":"Increase, Clonal Expansion of Altered Hepatic Foci"},{"keyEventId":227,"keyEventName":"Activation, PPARα"}],"status":"Under Development","reference":"https://aopwiki.org/aops/37"}
{"aopId":166,"aopName":"PPARalpha activation leading to pancreatic acinar tumors in the rat and mouse","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcome":"Increased, Pancreatic acinar tumors","adverseOutcomeId":1063,"keyEvents":[{"keyEventId":1057,"keyEventName":"Increased, PPAR-alpha activation"},{"keyEventId":1063,"keyEventName":"Increased, Pancreatic acinar tumors"},{"keyEventId":1058,"keyEventName":"Decreased, bile flow"},{"keyEventId":1061,"keyEventName":"prolonged, elevation of serun CCK"},{"keyEventId":1060,"keyEventName":"Alteration, lipid metabolism"},{"keyEventId":1062,"keyEventName":"Increased, Cellular proliferation / hyperplasia of acinar cells"},{"keyEventId":1059,"keyEventName":"Increased, cholestasis"}],"reference":"https://aopwiki.org/aops/166"}
{"aopId":36,"aopName":"Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcomeId":459,"keyEvents":[{"keyEventId":233,"keyEventName":"Decreased, PPAR-gamma activation"},{"keyEventId":232,"keyEventName":"Decreased, PPAR-beta activation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":8,"keyEventName":"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"},{"keyEventId":140,"keyEventName":"Decreased, HSD17B10 expression"},{"keyEventId":231,"keyEventName":"Decreased, PPAR-alpha activation"}],"reference":"https://aopwiki.org/aops/36"}
{"aopId":36,"aopName":"Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":233,"keyEventName":"Decreased, PPAR-gamma activation"},{"keyEventId":232,"keyEventName":"Decreased, PPAR-beta activation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":8,"keyEventName":"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"},{"keyEventId":140,"keyEventName":"Decreased, HSD17B10 expression"},{"keyEventId":231,"keyEventName":"Decreased, PPAR-alpha activation"}],"reference":"https://aopwiki.org/aops/36"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcome":"impaired, Fertility","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"peroxisome proliferator-activated receptor alpha","targetId":"ENSG00000186951","adverseOutcome":"Malformation, Male reproductive tract","adverseOutcomeId":348,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":108,"aopName":"Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat)","targetName":"pyruvate dehydrogenase [ubiquinone]","adverseOutcome":"Increase, hepatocellular adenomas and carcinomas","adverseOutcomeId":719,"keyEvents":[{"keyEventId":719,"keyEventName":"Increase, hepatocellular adenomas and carcinomas"},{"keyEventId":209,"keyEventName":"Peptide Oxidation"},{"keyEventId":724,"keyEventName":"Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme"},{"keyEventId":769,"keyEventName":"Increase, Oxidative metabolism"},{"keyEventId":726,"keyEventName":"Increased, Induction of pyruvate dehydrogenase (PDH)"},{"keyEventId":768,"keyEventName":"Increase, Cytotoxicity"}],"reference":"https://aopwiki.org/aops/108"}
{"aopId":276,"aopName":"Inhibition of complex I of the electron transport chain leading to chemical induced Fanconi syndrome","targetName":"NADH-ubiquinone oxidoreductase chain 1","targetId":"ENSG00000198888","adverseOutcome":"Chemical induced Fanconi syndrome","adverseOutcomeId":1564,"keyEvents":[{"keyEventId":1477,"keyEventName":"Decrease, Oxidative phosphorylation"},{"keyEventId":1564,"keyEventName":"Chemical induced Fanconi syndrome"},{"keyEventId":1562,"keyEventName":"Decreased Na/K ATPase activity"},{"keyEventId":888,"keyEventName":"Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)"},{"keyEventId":1563,"keyEventName":"Decreased proximal tubular vectorial transport"},{"keyEventId":887,"keyEventName":"Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"}],"reference":"https://aopwiki.org/aops/276"}
{"aopId":3,"aopName":"Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits","targetName":"NADH-ubiquinone oxidoreductase chain 1","targetId":"ENSG00000198888","adverseOutcome":"Parkinsonian motor deficits","adverseOutcomeId":896,"keyEvents":[{"keyEventId":890,"keyEventName":"Degeneration of dopaminergic neurons of the nigrostriatal pathway"},{"keyEventId":188,"keyEventName":"Neuroinflammation"},{"keyEventId":177,"keyEventName":"N/A, Mitochondrial dysfunction 1"},{"keyEventId":889,"keyEventName":"Impaired, Proteostasis"},{"keyEventId":888,"keyEventName":"Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)"},{"keyEventId":896,"keyEventName":"Parkinsonian motor deficits"},{"keyEventId":887,"keyEventName":"Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/3"}
{"aopId":273,"aopName":"Mitochondrial complex inhibition leading to liver injury","targetName":"NADH-ubiquinone oxidoreductase chain 1","targetId":"ENSG00000198888","adverseOutcome":"Necrotic Tissue","adverseOutcomeId":1548,"keyEvents":[{"keyEventId":1548,"keyEventName":"Necrotic Tissue"},{"keyEventId":1543,"keyEventName":"Mitochondrial Complex IV inhibition"},{"keyEventId":177,"keyEventName":"N/A, Mitochondrial dysfunction 1"},{"keyEventId":889,"keyEventName":"Impaired, Proteostasis"},{"keyEventId":1546,"keyEventName":"Increased reactive oxygen species (in the mitochondria)"},{"keyEventId":888,"keyEventName":"Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)"},{"keyEventId":1544,"keyEventName":"Mitochondrial Complex V inhibition"},{"keyEventId":55,"keyEventName":"Cell injury/death"},{"keyEventId":1654,"keyEventName":"Binding of inhibitor to mitochondrial complex IV"},{"keyEventId":1547,"keyEventName":"Mitochondrial Injury"},{"keyEventId":1545,"keyEventName":"Decrease in mitochondrial oxidative phosphorylation"},{"keyEventId":1549,"keyEventName":"Liver Injury"},{"keyEventId":1655,"keyEventName":"Binding of inhibitor to mitochondrial complex V"},{"keyEventId":1542,"keyEventName":"Increase, Mitochondrial complex III antagonism"},{"keyEventId":1653,"keyEventName":"Binding of inhibitor to mitochondrial complex III"},{"keyEventId":887,"keyEventName":"Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"}],"reference":"https://aopwiki.org/aops/273"}
{"aopId":273,"aopName":"Mitochondrial complex inhibition leading to liver injury","targetName":"NADH-ubiquinone oxidoreductase chain 1","targetId":"ENSG00000198888","adverseOutcome":"Liver Injury","adverseOutcomeId":1549,"keyEvents":[{"keyEventId":1548,"keyEventName":"Necrotic Tissue"},{"keyEventId":1543,"keyEventName":"Mitochondrial Complex IV inhibition"},{"keyEventId":177,"keyEventName":"N/A, Mitochondrial dysfunction 1"},{"keyEventId":889,"keyEventName":"Impaired, Proteostasis"},{"keyEventId":1546,"keyEventName":"Increased reactive oxygen species (in the mitochondria)"},{"keyEventId":888,"keyEventName":"Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I)"},{"keyEventId":1544,"keyEventName":"Mitochondrial Complex V inhibition"},{"keyEventId":55,"keyEventName":"Cell injury/death"},{"keyEventId":1654,"keyEventName":"Binding of inhibitor to mitochondrial complex IV"},{"keyEventId":1547,"keyEventName":"Mitochondrial Injury"},{"keyEventId":1545,"keyEventName":"Decrease in mitochondrial oxidative phosphorylation"},{"keyEventId":1549,"keyEventName":"Liver Injury"},{"keyEventId":1655,"keyEventName":"Binding of inhibitor to mitochondrial complex V"},{"keyEventId":1542,"keyEventName":"Increase, Mitochondrial complex III antagonism"},{"keyEventId":1653,"keyEventName":"Binding of inhibitor to mitochondrial complex III"},{"keyEventId":887,"keyEventName":"Inhibition, NADH-ubiquinone oxidoreductase  (complex I)"}],"reference":"https://aopwiki.org/aops/273"}
{"aopId":347,"aopName":"Toll-like receptor 4 activation and peroxisome proliferator-activated receptor gamma inactivation leading to pulmonary fibrosis","targetName":"TGF-beta","adverseOutcome":"Pulmonary fibrosis","adverseOutcomeId":1458,"keyEvents":[{"keyEventId":1795,"keyEventName":"Latent Transforming growth Factor beta expression"},{"keyEventId":1794,"keyEventName":"Pin-1 activation"},{"keyEventId":1792,"keyEventName":"Toll-like receptor 4 activation"},{"keyEventId":1457,"keyEventName":"Induction, Epithelial Mesenchymal Transition"},{"keyEventId":1458,"keyEventName":"Pulmonary fibrosis"},{"keyEventId":1292,"keyEventName":"Activation, JNK"},{"keyEventId":1283,"keyEventName":"Activation, TGF-beta pathway"},{"keyEventId":1793,"keyEventName":"Activator protein 1 activation"},{"keyEventId":1270,"keyEventName":"Inactivation of PPARγ"}],"reference":"https://aopwiki.org/aops/347"}
{"aopId":208,"aopName":"Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) and Transforming growth factor (TGF)-beta pathways activation leading to reproductive failure","targetName":"TGF-beta","adverseOutcome":"Reproductive failure","adverseOutcomeId":1277,"keyEvents":[{"keyEventId":1277,"keyEventName":"Reproductive failure"},{"keyEventId":1283,"keyEventName":"Activation, TGF-beta pathway"},{"keyEventId":1282,"keyEventName":"Activation, JAK/STAT pathway"}],"reference":"https://aopwiki.org/aops/208"}
{"aopId":334,"aopName":"Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration","targetName":"teratocarcinoma-derived growth factor 1","targetId":"ENSG00000241186","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":1761,"keyEventName":"Inhibition, Fin regeneration"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1759,"keyEventName":"Increase, Cripto-1 expression"},{"keyEventId":1760,"keyEventName":"Inhibition, Activin signaling"}],"reference":"https://aopwiki.org/aops/334"}
{"aopId":154,"aopName":"Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response","targetName":"NFAT protein","adverseOutcome":"Impairment, T-cell dependent antibody response","adverseOutcomeId":984,"keyEvents":[{"keyEventId":979,"keyEventName":"Interference, nuclear localization of NFAT"},{"keyEventId":1202,"keyEventName":"Suppression, IL-2 and IL-4 production"},{"keyEventId":980,"keyEventName":"Inhibition, Calcineurin Activity"},{"keyEventId":984,"keyEventName":"Impairment, T-cell dependent antibody response"},{"keyEventId":981,"keyEventName":"Reduction, NFAT/AP-1 complex formation"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/154"}
{"aopId":63,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":685,"keyEventName":"Reduced, Prostaglandins, ovary"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":488,"keyEventName":"Decrease, Ovulation"}],"reference":"https://aopwiki.org/aops/63"}
{"aopId":63,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":685,"keyEventName":"Reduced, Prostaglandins, ovary"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":488,"keyEventName":"Decrease, Ovulation"}],"reference":"https://aopwiki.org/aops/63"}
{"aopId":103,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":696,"keyEventName":"Increased, Chromosome misseggregation"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":695,"keyEventName":"Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"}],"reference":"https://aopwiki.org/aops/103"}
{"aopId":103,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":696,"keyEventName":"Increased, Chromosome misseggregation"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":695,"keyEventName":"Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"}],"reference":"https://aopwiki.org/aops/103"}
{"aopId":28,"aopName":"Cyclooxygenase inhibition leading reproductive failure","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"N/A, Reproductive failure","adverseOutcomeId":253,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":106,"keyEventName":"Reduction, Eggshell thickness"},{"keyEventId":253,"keyEventName":"N/A, Reproductive failure"},{"keyEventId":49,"keyEventName":"Reduction, Ca and HCO3 transport to shell gland"},{"keyEventId":119,"keyEventName":"N/A, Gap"},{"keyEventId":243,"keyEventName":"Reduction, Prostaglandin E2 concentration"}],"reference":"https://aopwiki.org/aops/28"}
{"aopId":177,"aopName":"Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1106,"keyEventName":"Occurrence, cardiac arrhythmia"},{"keyEventId":1104,"keyEventName":"Decreased, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":1097,"keyEventName":"Occurrence, renal proximal tubular necrosis"},{"keyEventId":1103,"keyEventName":"Inhibition, Cyclooxygenase 1 activity"},{"keyEventId":1096,"keyEventName":"Increased, blood uric acid concentration"},{"keyEventId":1088,"keyEventName":"Increased, Oxidative Stress"},{"keyEventId":1098,"keyEventName":"Increased, blood potassium concentration"},{"keyEventId":1105,"keyEventName":"Occurrence, renal ischemia"},{"keyEventId":1102,"keyEventName":"Occurrence, tophi (urate) deposition"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/177"}
{"aopId":177,"aopName":"Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Decline, Population","adverseOutcomeId":361,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1106,"keyEventName":"Occurrence, cardiac arrhythmia"},{"keyEventId":1104,"keyEventName":"Decreased, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":1097,"keyEventName":"Occurrence, renal proximal tubular necrosis"},{"keyEventId":1103,"keyEventName":"Inhibition, Cyclooxygenase 1 activity"},{"keyEventId":1096,"keyEventName":"Increased, blood uric acid concentration"},{"keyEventId":1088,"keyEventName":"Increased, Oxidative Stress"},{"keyEventId":1098,"keyEventName":"Increased, blood potassium concentration"},{"keyEventId":1105,"keyEventName":"Occurrence, renal ischemia"},{"keyEventId":1102,"keyEventName":"Occurrence, tophi (urate) deposition"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/177"}
{"aopId":100,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":672,"keyEventName":"Reduced, Prostaglandin F2alpha synthesis, ovary  "},{"keyEventId":673,"keyEventName":"Reduced, Spawning behavior"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":671,"keyEventName":"Reduced, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":674,"keyEventName":"Reduced, Ability to attract spawning mates"}],"reference":"https://aopwiki.org/aops/100"}
{"aopId":100,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of female spawning behavior","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":672,"keyEventName":"Reduced, Prostaglandin F2alpha synthesis, ovary  "},{"keyEventId":673,"keyEventName":"Reduced, Spawning behavior"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":671,"keyEventName":"Reduced, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":674,"keyEventName":"Reduced, Ability to attract spawning mates"}],"reference":"https://aopwiki.org/aops/100"}
{"aopId":101,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":681,"keyEventName":"Decreased, Prostaglandin F2alpha synthesis, ovary  "},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":671,"keyEventName":"Reduced, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":674,"keyEventName":"Reduced, Ability to attract spawning mates"},{"keyEventId":678,"keyEventName":"Reduced, Pheromone release"}],"reference":"https://aopwiki.org/aops/101"}
{"aopId":101,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via inhibition of pheromone release","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":681,"keyEventName":"Decreased, Prostaglandin F2alpha synthesis, ovary  "},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":671,"keyEventName":"Reduced, Prostaglandin F2alpha concentration, plasma "},{"keyEventId":674,"keyEventName":"Reduced, Ability to attract spawning mates"},{"keyEventId":678,"keyEventName":"Reduced, Pheromone release"}],"reference":"https://aopwiki.org/aops/101"}
{"aopId":102,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":694,"keyEventName":"Reduced, Meiotic prophase I/metaphase I transition, oocyte"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":693,"keyEventName":"Increased, cyclic adenosine monophosphate"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "}],"reference":"https://aopwiki.org/aops/102"}
{"aopId":102,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with meiotic prophase I /metaphase I transition","targetName":"prostaglandin G/H synthase 1","targetId":"ENSG00000095303","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":694,"keyEventName":"Reduced, Meiotic prophase I/metaphase I transition, oocyte"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":693,"keyEventName":"Increased, cyclic adenosine monophosphate"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "}],"reference":"https://aopwiki.org/aops/102"}
{"aopId":27,"aopName":"Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11)","targetName":"bile acid receptor","targetId":"ENSG00000012504","adverseOutcome":"Cholestasis, Pathology","adverseOutcomeId":357,"keyEvents":[{"keyEventId":209,"keyEventName":"Peptide Oxidation"},{"keyEventId":357,"keyEventName":"Cholestasis, Pathology"},{"keyEventId":41,"keyEventName":"Inhibition, Bile Salt Export Pump (ABCB11)"},{"keyEventId":214,"keyEventName":"Bile accumulation, Pathological condition"},{"keyEventId":149,"keyEventName":"Increase, Inflammation"},{"keyEventId":87,"keyEventName":"Release, Cytokine"},{"keyEventId":288,"keyEventName":"Activation of specific nuclear receptors, Transcriptional change"},{"keyEventId":249,"keyEventName":"Production, Reactive oxygen species"}],"status":"Under Development","reference":"https://aopwiki.org/aops/27"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"bile acid receptor","targetId":"ENSG00000012504","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"bile acid receptor","targetId":"ENSG00000012504","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":34,"aopName":"LXR activation leading to hepatic steatosis","targetName":"fatty acid synthase","targetId":"ENSG00000169710","adverseOutcome":"N/A, Liver Steatosis","adverseOutcomeId":345,"keyEvents":[{"keyEventId":89,"keyEventName":"Synthesis, De Novo FA"},{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":264,"keyEventName":"Activation, SREBP-1c"},{"keyEventId":116,"keyEventName":"Activation, FAS"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":115,"keyEventName":"Increase, FA Influx"},{"keyEventId":345,"keyEventName":"N/A, Liver Steatosis"},{"keyEventId":258,"keyEventName":"Activation, SCD-1"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":167,"keyEventName":"Activation, LXR"}],"reference":"https://aopwiki.org/aops/34"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"fatty acid synthase","targetId":"ENSG00000169710","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"fatty acid synthase","targetId":"ENSG00000169710","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":188,"aopName":"Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis","targetName":"iodotyrosine deiodinase 1 (human)","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":1152,"keyEventName":"Inhibition, Iodotyrosine deiodinase (IYD)"},{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":426,"keyEventName":"Decreased, Thyroxine (T4) in serum"},{"keyEventId":425,"keyEventName":"Decrease of Thyroidal iodide"}],"reference":"https://aopwiki.org/aops/188"}
{"aopId":27,"aopName":"Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11)","targetName":"bile salt export pump","targetId":"ENSG00000073734","adverseOutcome":"Cholestasis, Pathology","adverseOutcomeId":357,"keyEvents":[{"keyEventId":209,"keyEventName":"Peptide Oxidation"},{"keyEventId":357,"keyEventName":"Cholestasis, Pathology"},{"keyEventId":41,"keyEventName":"Inhibition, Bile Salt Export Pump (ABCB11)"},{"keyEventId":214,"keyEventName":"Bile accumulation, Pathological condition"},{"keyEventId":149,"keyEventName":"Increase, Inflammation"},{"keyEventId":87,"keyEventName":"Release, Cytokine"},{"keyEventId":288,"keyEventName":"Activation of specific nuclear receptors, Transcriptional change"},{"keyEventId":249,"keyEventName":"Production, Reactive oxygen species"}],"status":"Under Development","reference":"https://aopwiki.org/aops/27"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"carnitine O-palmitoyltransferase 1, liver isoform","targetId":"ENSG00000110090","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"carnitine O-palmitoyltransferase 1, liver isoform","targetId":"ENSG00000110090","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":104,"aopName":"Altered ion channel activity leading impaired heart function","targetName":"ATP-sensitive inward rectifier potassium channel 1","targetId":"ENSG00000151704","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":699,"keyEventName":"Increased, cardiac arrthymia"},{"keyEventId":697,"keyEventName":"impaired, ion channels"},{"keyEventId":698,"keyEventName":"Altered, Action Potential"}],"reference":"https://aopwiki.org/aops/104"}
{"aopId":154,"aopName":"Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response","targetName":"FK506-binding protein 15","targetId":"ENSG00000119321","adverseOutcome":"Impairment, T-cell dependent antibody response","adverseOutcomeId":984,"keyEvents":[{"keyEventId":979,"keyEventName":"Interference, nuclear localization of NFAT"},{"keyEventId":1202,"keyEventName":"Suppression, IL-2 and IL-4 production"},{"keyEventId":980,"keyEventName":"Inhibition, Calcineurin Activity"},{"keyEventId":984,"keyEventName":"Impairment, T-cell dependent antibody response"},{"keyEventId":981,"keyEventName":"Reduction, NFAT/AP-1 complex formation"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/154"}
{"aopId":167,"aopName":"Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse.","targetName":"estrogen receptor alpha complex","adverseOutcome":"Increased, adenosquamous carcinomas of endometrium","adverseOutcomeId":1070,"keyEvents":[{"keyEventId":1070,"keyEventName":"Increased, adenosquamous carcinomas of endometrium"},{"keyEventId":1067,"keyEventName":"Proliferation/Clonal Expansion, aberrant basal cells"},{"keyEventId":1069,"keyEventName":"Increased, Hyperplasia (glandular epithelial cells of endometrium)"},{"keyEventId":1065,"keyEventName":"Activation, estrogen receptor alpha"},{"keyEventId":1064,"keyEventName":"prepubertal increase, Estrogen receptor (ER) activity"},{"keyEventId":1068,"keyEventName":"squamous metaplasia, aberrant basal cells"},{"keyEventId":1066,"keyEventName":"Promotion, SIX-1 postive basal-type progenitor cells"}],"reference":"https://aopwiki.org/aops/167"}
{"aopId":148,"aopName":"EGFR Activation Leading to Decreased Lung Function","targetName":"mucin-5AC","targetId":"ENSG00000215182","adverseOutcome":"Decrease, Lung function","adverseOutcomeId":1250,"keyEvents":[{"keyEventId":919,"keyEventName":"Occurrence, Transdifferentiation of ciliated epithelial cells"},{"keyEventId":1250,"keyEventName":"Decrease, Lung function"},{"keyEventId":920,"keyEventName":"Occurrence, Metaplasia of goblet cells"},{"keyEventId":914,"keyEventName":"Decrease, Apoptosis of ciliated epithelial cells"},{"keyEventId":921,"keyEventName":"Occurrence, Hyperplasia of goblet cells"},{"keyEventId":1251,"keyEventName":"Chronic, Mucus hypersecretion"},{"keyEventId":923,"keyEventName":"Increase, Proliferation of goblet cells"},{"keyEventId":924,"keyEventName":"Activation, Sp1"},{"keyEventId":962,"keyEventName":"Increase, Mucin production"},{"keyEventId":941,"keyEventName":"Activation, EGFR"}],"status":"Under Development","reference":"https://aopwiki.org/aops/148"}
{"aopId":200,"aopName":"Estrogen receptor activation leading to breast cancer  ","targetName":"protein","adverseOutcome":"N/A, Breast Cancer","adverseOutcomeId":1193,"keyEvents":[{"keyEventId":1183,"keyEventName":"Decreased, Apoptosis (Epithelial Cells)"},{"keyEventId":1195,"keyEventName":"modulation, Extracellular Matrix Composition "},{"keyEventId":1241,"keyEventName":"Increased, Motility"},{"keyEventId":1242,"keyEventName":"Increased, Second Messenger Production"},{"keyEventId":177,"keyEventName":"N/A, Mitochondrial dysfunction 1"},{"keyEventId":1193,"keyEventName":"N/A, Breast Cancer"},{"keyEventId":1188,"keyEventName":"Increased, ER binding to T.F. to DNA (non-classical pathway)"},{"keyEventId":1194,"keyEventName":"Increase, DNA damage"},{"keyEventId":1197,"keyEventName":"Activation, Fibroblasts"},{"keyEventId":1191,"keyEventName":"Increased, Non-genomic signaling"},{"keyEventId":1189,"keyEventName":"Increased, Proliferation (Endothelial cells) "},{"keyEventId":1181,"keyEventName":"Activation, Estrogen receptor"},{"keyEventId":1182,"keyEventName":"Increase, Cell Proliferation (Epithelial Cells)"},{"keyEventId":1196,"keyEventName":"Increased, Invasion"},{"keyEventId":1240,"keyEventName":"Altered, Protein Production"},{"keyEventId":1187,"keyEventName":"Increased, ER binding to DNA (classical pathway) "},{"keyEventId":1198,"keyEventName":"Activation, Macrophages"},{"keyEventId":1239,"keyEventName":"Altered, Gene Expression"},{"keyEventId":1088,"keyEventName":"Increased, Oxidative Stress"},{"keyEventId":1192,"keyEventName":"Increased, Ductal Hyperplasia "},{"keyEventId":1190,"keyEventName":"Increased, Migration (Endothelial Cells)"},{"keyEventId":1213,"keyEventName":"Increased, Angiogenesis"}],"reference":"https://aopwiki.org/aops/200"}
{"aopId":194,"aopName":"Hepatic nuclear receptor activation leading to altered amphibian metamorphosis","targetName":"protein","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":295,"keyEventName":"Induction, Upregulation of glucuronyltransferase activity"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":1158,"keyEventName":"Increased, Hepatic thyroid hormone uptake/transport"},{"keyEventId":401,"keyEventName":"Increase, Biliary excretion TH glucuronide"},{"keyEventId":1157,"keyEventName":"Activation, Hepatic nuclear receptor(s)"}],"reference":"https://aopwiki.org/aops/194"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"translocator protein","targetId":"ENSG00000100300","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"translocator protein","targetId":"ENSG00000100300","adverseOutcome":"impaired, Fertility","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"translocator protein","targetId":"ENSG00000100300","adverseOutcome":"Malformation, Male reproductive tract","adverseOutcomeId":348,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":162,"aopName":"Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse","targetName":"UDP-glucuronosyltransferase","adverseOutcome":"Increased Apoptosis, Adenomas/carcinomas (follicular cell)","adverseOutcomeId":1026,"keyEvents":[{"keyEventId":1021,"keyEventName":"Increased, T4/T3 catabolism"},{"keyEventId":1020,"keyEventName":"Increased, induction of UDPGT's in liver"},{"keyEventId":1026,"keyEventName":"Increased Apoptosis, Adenomas/carcinomas (follicular cell)"},{"keyEventId":1025,"keyEventName":"Increased, Hyperplasia (follicular cells)"},{"keyEventId":1022,"keyEventName":"Decreased, serum T4/T3"},{"keyEventId":1024,"keyEventName":"Increased, Hypertrophy and proliferation (follicular cell)"},{"keyEventId":1023,"keyEventName":"Increased, Thyroid-stimulating hormone (TSH)"}],"reference":"https://aopwiki.org/aops/162"}
{"aopId":315,"aopName":"Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response","targetName":"tyrosine-protein kinase JAK3","targetId":"ENSG00000105639","adverseOutcome":"Impairment of T-cell dependent antibody response","adverseOutcomeId":1719,"keyEvents":[{"keyEventId":1717,"keyEventName":"Suppression of STAT5 binding to cytokine gene promoters"},{"keyEventId":1716,"keyEventName":"Blockade of STAT5 phosphorylation"},{"keyEventId":1718,"keyEventName":"Suppression of IL-4 production"},{"keyEventId":1719,"keyEventName":"Impairment of T-cell dependent antibody response"},{"keyEventId":1715,"keyEventName":"Inhibition of JAK3"}],"status":"Under Development","reference":"https://aopwiki.org/aops/315"}
{"aopId":95,"aopName":"Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival","targetName":"potassium voltage-gated channel subfamily H member 2 (human)","adverseOutcome":"Reduced, survival","adverseOutcomeId":592,"keyEvents":[{"keyEventId":585,"keyEventName":"Decreased, Sodium conductance 1"},{"keyEventId":586,"keyEventName":"Reduced, swimming speed"},{"keyEventId":592,"keyEventName":"Reduced, survival"},{"keyEventId":587,"keyEventName":"Reduced, feeding 1"},{"keyEventId":593,"keyEventName":"Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel "},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/95"}
{"aopId":104,"aopName":"Altered ion channel activity leading impaired heart function","targetName":"potassium voltage-gated channel subfamily H member 2 (human)","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":699,"keyEventName":"Increased, cardiac arrthymia"},{"keyEventId":697,"keyEventName":"impaired, ion channels"},{"keyEventId":698,"keyEventName":"Altered, Action Potential"}],"reference":"https://aopwiki.org/aops/104"}
{"aopId":278,"aopName":"IKK complex inhibition leading to liver injury","targetName":"transcription factor NF-kappa-B subunit","adverseOutcome":"Liver Injury","adverseOutcomeId":1549,"keyEvents":[{"keyEventId":1574,"keyEventName":"Inhibition, IKK complex"},{"keyEventId":1579,"keyEventName":"Increase, proinflammatory mediators (TNFalpha)"},{"keyEventId":1548,"keyEventName":"Necrotic Tissue"},{"keyEventId":1575,"keyEventName":"Activation, Caspase 8 pathway"},{"keyEventId":1549,"keyEventName":"Liver Injury"},{"keyEventId":1576,"keyEventName":"Activation, Tissue resident cells (Kuppfer cells)"},{"keyEventId":55,"keyEventName":"Cell injury/death"},{"keyEventId":202,"keyEventName":"Inhibition, Nuclear factor kappa B (NF-kB)"}],"reference":"https://aopwiki.org/aops/278"}
{"aopId":278,"aopName":"IKK complex inhibition leading to liver injury","targetName":"transcription factor NF-kappa-B subunit","adverseOutcome":"Necrotic Tissue","adverseOutcomeId":1548,"keyEvents":[{"keyEventId":1574,"keyEventName":"Inhibition, IKK complex"},{"keyEventId":1579,"keyEventName":"Increase, proinflammatory mediators (TNFalpha)"},{"keyEventId":1548,"keyEventName":"Necrotic Tissue"},{"keyEventId":1575,"keyEventName":"Activation, Caspase 8 pathway"},{"keyEventId":1549,"keyEventName":"Liver Injury"},{"keyEventId":1576,"keyEventName":"Activation, Tissue resident cells (Kuppfer cells)"},{"keyEventId":55,"keyEventName":"Cell injury/death"},{"keyEventId":202,"keyEventName":"Inhibition, Nuclear factor kappa B (NF-kB)"}],"reference":"https://aopwiki.org/aops/278"}
{"aopId":277,"aopName":"Impaired IL-1R1 signaling leading to increased susceptibility to infection","targetName":"transcription factor NF-kappa-B subunit","adverseOutcome":"Increase, Increased susceptibility to infection","adverseOutcomeId":986,"keyEvents":[{"keyEventId":986,"keyEventName":"Increase, Increased susceptibility to infection"},{"keyEventId":1702,"keyEventName":"Suppression of  T cell activation"},{"keyEventId":1700,"keyEventName":"Impaired IL-1R1 signaling"},{"keyEventId":202,"keyEventName":"Inhibition, Nuclear factor kappa B (NF-kB)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/277"}
{"aopId":14,"aopName":"Glucocorticoid Receptor Activation Leading to Increased Disease Susceptibility","targetName":"transcription factor NF-kappa-B subunit","adverseOutcome":"Increased, Disease susceptibility","adverseOutcomeId":323,"keyEvents":[{"keyEventId":152,"keyEventName":"Suppression, Inflammatory cytokines"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":168,"keyEventName":"Decreased, Lymphocytes"},{"keyEventId":145,"keyEventName":"Induction, IKB inhibitory protein"},{"keyEventId":323,"keyEventName":"Increased, Disease susceptibility"},{"keyEventId":403,"keyEventName":"Suppression, Immune system"},{"keyEventId":202,"keyEventName":"Inhibition, Nuclear factor kappa B (NF-kB)"}],"reference":"https://aopwiki.org/aops/14"}
{"aopId":7,"aopName":"Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcomeId":406,"keyEvents":[{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":408,"keyEventName":"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"},{"keyEventId":405,"keyEventName":"irregularities, ovarian cycle"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/7"}
{"aopId":7,"aopName":"Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"impaired, Fertility","adverseOutcomeId":406,"keyEvents":[{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":408,"keyEventName":"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"},{"keyEventId":405,"keyEventName":"irregularities, ovarian cycle"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/7"}
{"aopId":7,"aopName":"Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"irregularities, ovarian cycle","adverseOutcomeId":405,"keyEvents":[{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":408,"keyEventName":"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"},{"keyEventId":405,"keyEventName":"irregularities, ovarian cycle"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/7"}
{"aopId":25,"aopName":"Aromatase inhibition leading to reproductive dysfunction","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":36,"keyEventName":"Inhibition, Aromatase"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/25"}
{"aopId":271,"aopName":"Inhibition of thyroid peroxidase leading to impaired fertility in fish","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcomeId":78,"keyEvents":[{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":408,"keyEventName":"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"status":"Under Development","reference":"https://aopwiki.org/aops/271"}
{"aopId":271,"aopName":"Inhibition of thyroid peroxidase leading to impaired fertility in fish","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":408,"keyEventName":"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"status":"Under Development","reference":"https://aopwiki.org/aops/271"}
{"aopId":346,"aopName":"Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":36,"keyEventName":"Inhibition, Aromatase"},{"keyEventId":1789,"keyEventName":"Reduction, 17beta-estradiol synthesis by the undifferentiated gonad "},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1790,"keyEventName":"Increased, Differentiation to Testis "},{"keyEventId":1791,"keyEventName":"Increased, Male Biased Sex Ratio"}],"reference":"https://aopwiki.org/aops/346"}
{"aopId":153,"aopName":"Aromatase Inhibition leading to Ovulation Inhibition and Decreased Fertility in Female Rats","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"Decreased fertility, Reduced number of oocytes ovulated ","adverseOutcomeId":972,"keyEvents":[{"keyEventId":967,"keyEventName":"Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus"},{"keyEventId":972,"keyEventName":"Decreased fertility, Reduced number of oocytes ovulated "},{"keyEventId":964,"keyEventName":"Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol"},{"keyEventId":965,"keyEventName":"reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic production of estradiol in granulosa cells"},{"keyEventId":966,"keyEventName":"Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulosa cells leading to decreased estradiol in circulation"},{"keyEventId":971,"keyEventName":"Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation "},{"keyEventId":969,"keyEventName":"Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons "},{"keyEventId":970,"keyEventName":"Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs"},{"keyEventId":968,"keyEventName":"Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces kisspeptinergic neuron response "}],"reference":"https://aopwiki.org/aops/153"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"aromatase","targetId":"ENSG00000137869","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":209,"aopName":"Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP ","targetName":"sterol regulatory element-binding protein 2 proteolytic cleavage product","adverseOutcome":"Hepatotoxicity","adverseOutcomeId":1291,"keyEvents":[{"keyEventId":1284,"keyEventName":"Up Regulation, SREBF2"},{"keyEventId":1288,"keyEventName":"Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"},{"keyEventId":1285,"keyEventName":"Up Regulation, Unsaturated fatty acid"},{"keyEventId":1291,"keyEventName":"Hepatotoxicity"},{"keyEventId":1287,"keyEventName":"Glutathione synthesis"},{"keyEventId":1286,"keyEventName":"Down Regulation, GSS and GSTs gene"},{"keyEventId":1289,"keyEventName":"Perturbation of cholesterol"},{"keyEventId":1290,"keyEventName":"Glutathione homeostasis"}],"reference":"https://aopwiki.org/aops/209"}
{"aopId":167,"aopName":"Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse.","targetName":"homeobox protein SIX1","targetId":"ENSG00000126778","adverseOutcome":"Increased, adenosquamous carcinomas of endometrium","adverseOutcomeId":1070,"keyEvents":[{"keyEventId":1070,"keyEventName":"Increased, adenosquamous carcinomas of endometrium"},{"keyEventId":1067,"keyEventName":"Proliferation/Clonal Expansion, aberrant basal cells"},{"keyEventId":1069,"keyEventName":"Increased, Hyperplasia (glandular epithelial cells of endometrium)"},{"keyEventId":1065,"keyEventName":"Activation, estrogen receptor alpha"},{"keyEventId":1064,"keyEventName":"prepubertal increase, Estrogen receptor (ER) activity"},{"keyEventId":1068,"keyEventName":"squamous metaplasia, aberrant basal cells"},{"keyEventId":1066,"keyEventName":"Promotion, SIX-1 postive basal-type progenitor cells"}],"reference":"https://aopwiki.org/aops/167"}
{"aopId":8,"aopName":"Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals","targetName":"beta-1,3-glucuronyltransferase","adverseOutcome":"Loss, Cochlear function","adverseOutcomeId":319,"keyEvents":[{"keyEventId":295,"keyEventName":"Induction, Upregulation of glucuronyltransferase activity"},{"keyEventId":758,"keyEventName":"Hippocampal Physiology, Altered"},{"keyEventId":756,"keyEventName":"Hippocampal gene expression, Altered "},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":401,"keyEventName":"Increase, Biliary excretion TH glucuronide"},{"keyEventId":239,"keyEventName":"Activation, Pregnane-X receptor, NR1l2"},{"keyEventId":319,"keyEventName":"Loss, Cochlear function"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "},{"keyEventId":757,"keyEventName":"Hippocampal anatomy, Altered "}],"status":"Under Development","reference":"https://aopwiki.org/aops/8"}
{"aopId":194,"aopName":"Hepatic nuclear receptor activation leading to altered amphibian metamorphosis","targetName":"beta-1,3-glucuronyltransferase","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":295,"keyEventName":"Induction, Upregulation of glucuronyltransferase activity"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":1158,"keyEventName":"Increased, Hepatic thyroid hormone uptake/transport"},{"keyEventId":401,"keyEventName":"Increase, Biliary excretion TH glucuronide"},{"keyEventId":1157,"keyEventName":"Activation, Hepatic nuclear receptor(s)"}],"reference":"https://aopwiki.org/aops/194"}
{"aopId":187,"aopName":"Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage","targetName":"prothrombin","targetId":"ENSG00000180210","adverseOutcome":"Impaired recruitment , Population trajectory","adverseOutcomeId":1136,"keyEvents":[{"keyEventId":1135,"keyEventName":"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"},{"keyEventId":1122,"keyEventName":"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "},{"keyEventId":1169,"keyEventName":"Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin"},{"keyEventId":1130,"keyEventName":"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"},{"keyEventId":1133,"keyEventName":"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"},{"keyEventId":1131,"keyEventName":"Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "},{"keyEventId":1134,"keyEventName":"Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone"},{"keyEventId":1132,"keyEventName":"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"},{"keyEventId":1136,"keyEventName":"Impaired recruitment , Population trajectory"},{"keyEventId":1138,"keyEventName":"Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP"},{"keyEventId":1151,"keyEventName":"Osteoporosis and vascular calcification, Bone deterioration"}],"status":"Under Development","reference":"https://aopwiki.org/aops/187"}
{"aopId":34,"aopName":"LXR activation leading to hepatic steatosis","targetName":"acyl-CoA desaturase","targetId":"ENSG00000099194","adverseOutcome":"N/A, Liver Steatosis","adverseOutcomeId":345,"keyEvents":[{"keyEventId":89,"keyEventName":"Synthesis, De Novo FA"},{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":264,"keyEventName":"Activation, SREBP-1c"},{"keyEventId":116,"keyEventName":"Activation, FAS"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":115,"keyEventName":"Increase, FA Influx"},{"keyEventId":345,"keyEventName":"N/A, Liver Steatosis"},{"keyEventId":258,"keyEventName":"Activation, SCD-1"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":167,"keyEventName":"Activation, LXR"}],"reference":"https://aopwiki.org/aops/34"}
{"aopId":57,"aopName":"AhR activation leading to hepatic steatosis","targetName":"acyl-CoA desaturase","targetId":"ENSG00000099194","adverseOutcome":"Accumulation, Liver lipid","adverseOutcomeId":455,"keyEvents":[{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":467,"keyEventName":"Increased, LDL uptake"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":466,"keyEventName":"Up Regulation, LDLR (low density lipoprotein receptor)"},{"keyEventId":80,"keyEventName":"Up Regulation, CYP1A1"},{"keyEventId":455,"keyEventName":"Accumulation, Liver lipid"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":450,"keyEventName":"Suppression, VLDL secretion"},{"keyEventId":216,"keyEventName":"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/57"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"acyl-CoA desaturase","targetId":"ENSG00000099194","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"acyl-CoA desaturase","targetId":"ENSG00000099194","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"acyl-CoA desaturase","targetId":"ENSG00000099194","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"acyl-CoA desaturase","targetId":"ENSG00000099194","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":98,"aopName":"5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to decreased shelter seeking and increased predation","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcomeId":588,"keyEvents":[{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":627,"keyEventName":"Decreased, anxiety"},{"keyEventId":629,"keyEventName":"Decreased, sheltering"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/98"}
{"aopId":98,"aopName":"5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to decreased shelter seeking and increased predation","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcome":"Increased, predation","adverseOutcomeId":588,"keyEvents":[{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":627,"keyEventName":"Decreased, anxiety"},{"keyEventId":629,"keyEventName":"Decreased, sheltering"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/98"}
{"aopId":203,"aopName":"5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcomeId":1141,"keyEvents":[{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":1141,"keyEventName":"Decreased, Reproductive Success"},{"keyEventId":621,"keyEventName":"Increase, cilia movement"},{"keyEventId":1142,"keyEventName":"Increased, valve movement"},{"keyEventId":1256,"keyEventName":"increased mantel display"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":1257,"keyEventName":"Induced parturition"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/203"}
{"aopId":203,"aopName":"5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcome":"Decreased, Reproductive Success","adverseOutcomeId":1141,"keyEvents":[{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":1141,"keyEventName":"Decreased, Reproductive Success"},{"keyEventId":621,"keyEventName":"Increase, cilia movement"},{"keyEventId":1142,"keyEventName":"Increased, valve movement"},{"keyEventId":1256,"keyEventName":"increased mantel display"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":1257,"keyEventName":"Induced parturition"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/203"}
{"aopId":203,"aopName":"5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcome":"Decline, Population","adverseOutcomeId":361,"keyEvents":[{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":1141,"keyEventName":"Decreased, Reproductive Success"},{"keyEventId":621,"keyEventName":"Increase, cilia movement"},{"keyEventId":1142,"keyEventName":"Increased, valve movement"},{"keyEventId":1256,"keyEventName":"increased mantel display"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":1257,"keyEventName":"Induced parturition"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/203"}
{"aopId":195,"aopName":"5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcome":"Increased, Population","adverseOutcomeId":1164,"keyEvents":[{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":621,"keyEventName":"Increase, cilia movement"},{"keyEventId":1164,"keyEventName":"Increased, Population"},{"keyEventId":1142,"keyEventName":"Increased, valve movement"},{"keyEventId":1161,"keyEventName":"Increased, oocyte maturation"},{"keyEventId":1163,"keyEventName":"Increased, Reproductive Success"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":1255,"keyEventName":"induced spawning"}],"reference":"https://aopwiki.org/aops/195"}
{"aopId":97,"aopName":"5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcome":"Decline, Population","adverseOutcomeId":361,"keyEvents":[{"keyEventId":623,"keyEventName":"Increase, predation"},{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":622,"keyEventName":"Increased, locomotion"},{"keyEventId":1142,"keyEventName":"Increased, valve movement"},{"keyEventId":625,"keyEventName":"Increased, muscular waves in foot"},{"keyEventId":1143,"keyEventName":"Depletion, energy reserves"},{"keyEventId":624,"keyEventName":"Increased, foot detachment"},{"keyEventId":1139,"keyEventName":"Increased, water retention in foot"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/97"}
{"aopId":97,"aopName":"5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcome":"Increase, predation","adverseOutcomeId":623,"keyEvents":[{"keyEventId":623,"keyEventName":"Increase, predation"},{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":622,"keyEventName":"Increased, locomotion"},{"keyEventId":1142,"keyEventName":"Increased, valve movement"},{"keyEventId":625,"keyEventName":"Increased, muscular waves in foot"},{"keyEventId":1143,"keyEventName":"Depletion, energy reserves"},{"keyEventId":624,"keyEventName":"Increased, foot detachment"},{"keyEventId":1139,"keyEventName":"Increased, water retention in foot"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/97"}
{"aopId":204,"aopName":"5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcome":"Increased, Population","adverseOutcomeId":1164,"keyEvents":[{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":621,"keyEventName":"Increase, cilia movement"},{"keyEventId":1164,"keyEventName":"Increased, Population"},{"keyEventId":1142,"keyEventName":"Increased, valve movement"},{"keyEventId":1256,"keyEventName":"increased mantel display"},{"keyEventId":1163,"keyEventName":"Increased, Reproductive Success"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":1257,"keyEventName":"Induced parturition"}],"reference":"https://aopwiki.org/aops/204"}
{"aopId":204,"aopName":"5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcomeId":1163,"keyEvents":[{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":621,"keyEventName":"Increase, cilia movement"},{"keyEventId":1164,"keyEventName":"Increased, Population"},{"keyEventId":1142,"keyEventName":"Increased, valve movement"},{"keyEventId":1256,"keyEventName":"increased mantel display"},{"keyEventId":1163,"keyEventName":"Increased, Reproductive Success"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":1257,"keyEventName":"Induced parturition"}],"reference":"https://aopwiki.org/aops/204"}
{"aopId":204,"aopName":"5-hydroxytryptamine transporter inhibition leading to increased reproductive success and population increase","targetName":"sodium-dependent serotonin transporter","targetId":"ENSG00000108576","adverseOutcome":"Increased, Reproductive Success","adverseOutcomeId":1163,"keyEvents":[{"keyEventId":626,"keyEventName":"Increased, serotonin (5-HT) "},{"keyEventId":621,"keyEventName":"Increase, cilia movement"},{"keyEventId":1164,"keyEventName":"Increased, Population"},{"keyEventId":1142,"keyEventName":"Increased, valve movement"},{"keyEventId":1256,"keyEventName":"increased mantel display"},{"keyEventId":1163,"keyEventName":"Increased, Reproductive Success"},{"keyEventId":619,"keyEventName":"Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT)"},{"keyEventId":1257,"keyEventName":"Induced parturition"}],"reference":"https://aopwiki.org/aops/204"}
{"aopId":10,"aopName":"Binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain","targetName":"gamma-aminobutyric acid receptor subunit alpha-5","targetId":"ENSG00000186297","adverseOutcome":"Occurrence, Epileptic seizure","adverseOutcomeId":613,"keyEvents":[{"keyEventId":669,"keyEventName":"Reduction, Neuronal synaptic inhibition"},{"keyEventId":616,"keyEventName":"Occurrence, A paroxysmal depolarizing shift"},{"keyEventId":682,"keyEventName":"Generation, Amplified excitatory postsynaptic potential (EPSP)"},{"keyEventId":667,"keyEventName":"Binding at picrotoxin site, iGABAR chloride channel"},{"keyEventId":613,"keyEventName":"Occurrence, Epileptic seizure"},{"keyEventId":64,"keyEventName":"Reduction, Ionotropic GABA receptor chloride channel conductance"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/10"}
{"aopId":57,"aopName":"AhR activation leading to hepatic steatosis","targetName":"phosphoenolpyruvate carboxykinase, cytosolic [GTP]","targetId":"ENSG00000124253","adverseOutcome":"Accumulation, Liver lipid","adverseOutcomeId":455,"keyEvents":[{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":467,"keyEventName":"Increased, LDL uptake"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":466,"keyEventName":"Up Regulation, LDLR (low density lipoprotein receptor)"},{"keyEventId":80,"keyEventName":"Up Regulation, CYP1A1"},{"keyEventId":455,"keyEventName":"Accumulation, Liver lipid"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":450,"keyEventName":"Suppression, VLDL secretion"},{"keyEventId":216,"keyEventName":"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/57"}
{"aopId":153,"aopName":"Aromatase Inhibition leading to Ovulation Inhibition and Decreased Fertility in Female Rats","targetName":"metastasis-suppressor KiSS-1 (rat)","adverseOutcome":"Decreased fertility, Reduced number of oocytes ovulated ","adverseOutcomeId":972,"keyEvents":[{"keyEventId":967,"keyEventName":"Decreased positive estrogenic feedback on hypothalamus, Reduced estradiol in circulation decreases estrogen concentration at hypothalamus"},{"keyEventId":972,"keyEventName":"Decreased fertility, Reduced number of oocytes ovulated "},{"keyEventId":964,"keyEventName":"Inhibition of Aromatase Enzyme, Chemical exposure during critical window of estrous cycle between diestrus 2 and proestrus inhibits aromatase conversion of testosterone to estradiol"},{"keyEventId":965,"keyEventName":"reduction in ovarian granulosa cells synthesis of estradiol, Reduced steroidogenic production of estradiol in granulosa cells"},{"keyEventId":966,"keyEventName":"Reduced Estradiol in Circulation, Reduced steroidogenic production of estradiol in granulosa cells leading to decreased estradiol in circulation"},{"keyEventId":971,"keyEventName":"Ovulation of oocytes Reduced, Delayed, or Blocked, Decrease or delay in LH surge required for ovulation "},{"keyEventId":969,"keyEventName":"Decreased GnRH Release, Decreased Kisspeptin stimulation of GnRH neurons "},{"keyEventId":970,"keyEventName":"Decreased LH release from Anterior Pituitary, Decreased GnRH stimulation of Anterior Pituitary Gonadotrophs"},{"keyEventId":968,"keyEventName":"Decreased Kisspeptin release from neurons in AVPV, Decreased hypothalamic estrogen reduces kisspeptinergic neuron response "}],"reference":"https://aopwiki.org/aops/153"}
{"aopId":210,"aopName":"Activation of c-Jun N-terminal kinase (JNK) and Forkhead box O (FOXO) and reduction of WNT pathways leading to reproductive failure: Integrated multi-OMICS approach for AOP building","targetName":"forkhead box protein O (Caenorhabditis elegans)","adverseOutcome":"Reproductive failure","adverseOutcomeId":1277,"keyEvents":[{"keyEventId":1277,"keyEventName":"Reproductive failure"},{"keyEventId":209,"keyEventName":"Peptide Oxidation"},{"keyEventId":1295,"keyEventName":"Defect of Embryogenesis"},{"keyEventId":1292,"keyEventName":"Activation, JNK"},{"keyEventId":1294,"keyEventName":"Inhibition, Wnt pathway"},{"keyEventId":1293,"keyEventName":"Activation, FOXO"}],"reference":"https://aopwiki.org/aops/210"}
{"aopId":31,"aopName":"Oxidation of iron in hemoglobin leading to hematotoxicity","targetName":"hemoglobin subunit alpha (human)","adverseOutcome":"N/A, Cyanosis occurs","adverseOutcomeId":321,"keyEvents":[{"keyEventId":321,"keyEventName":"N/A, Cyanosis occurs"},{"keyEventId":246,"keyEventName":"Increase, RBC congestion in liver"},{"keyEventId":213,"keyEventName":"N/A, Parent compound is converted to the reactive metabolite and forms free radicals leading to oxidation of heme iron(II) in hemoglobin to iron(III)"},{"keyEventId":173,"keyEventName":"N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number"},{"keyEventId":118,"keyEventName":"Formation, Formation of hemoglobin adducts"},{"keyEventId":161,"keyEventName":"Increase, Liver and splenic hemosiderosis"},{"keyEventId":131,"keyEventName":"Down Regulation, Gulcose-6-phosphate dehydrogenase"},{"keyEventId":250,"keyEventName":"Damaging, Red blood cells; hemolysis"},{"keyEventId":21,"keyEventName":"Altered regulation, Alpha hemoglobin"},{"keyEventId":211,"keyEventName":"Propagation, Oxidative stress"}],"status":"Under Development","reference":"https://aopwiki.org/aops/31"}
{"aopId":170,"aopName":"Anti-dopaminergic activity leading to mammary adenomas and carcinomas in the SD rat","targetName":"prolactin","targetId":"ENSG00000172179","adverseOutcome":"Increased, Adenomas/carcinomas (mammary)","adverseOutcomeId":1079,"keyEvents":[{"keyEventId":1085,"keyEventName":"Increased, hyperplasia (mammary gland)"},{"keyEventId":1083,"keyEventName":"Decreased, Dopaminergic activity"},{"keyEventId":1079,"keyEventName":"Increased, Adenomas/carcinomas (mammary)"},{"keyEventId":1084,"keyEventName":"Increased, prolactin secretion"},{"keyEventId":1080,"keyEventName":"Increased, latency period"}],"reference":"https://aopwiki.org/aops/170"}
{"aopId":168,"aopName":"GnRH pulse disruption leading to mammary adenomas and carcinomas in the SD rat.","targetName":"prolactin","targetId":"ENSG00000172179","adverseOutcome":"Increased, Adenomas/carcinomas (mammary)","adverseOutcomeId":1079,"keyEvents":[{"keyEventId":1075,"keyEventName":"prolonged, estrus"},{"keyEventId":1072,"keyEventName":"Decreased, LH Surge from anterior pituitary"},{"keyEventId":1077,"keyEventName":"Increased, prolactin exposure"},{"keyEventId":1071,"keyEventName":"Decreased, GnRH pulsatility/release in hypothalamus"},{"keyEventId":1074,"keyEventName":"interruption, Ovulation"},{"keyEventId":1078,"keyEventName":"Hyperplasia, Mammary gland"},{"keyEventId":1079,"keyEventName":"Increased, Adenomas/carcinomas (mammary)"},{"keyEventId":1080,"keyEventName":"Increased, latency period"},{"keyEventId":1076,"keyEventName":"Increased, circulating estrogen levels"}],"reference":"https://aopwiki.org/aops/168"}
{"aopId":34,"aopName":"LXR activation leading to hepatic steatosis","targetName":"peroxisome proliferator-activated receptor gamma","targetId":"ENSG00000132170","adverseOutcome":"N/A, Liver Steatosis","adverseOutcomeId":345,"keyEvents":[{"keyEventId":89,"keyEventName":"Synthesis, De Novo FA"},{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":264,"keyEventName":"Activation, SREBP-1c"},{"keyEventId":116,"keyEventName":"Activation, FAS"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":115,"keyEventName":"Increase, FA Influx"},{"keyEventId":345,"keyEventName":"N/A, Liver Steatosis"},{"keyEventId":258,"keyEventName":"Activation, SCD-1"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":167,"keyEventName":"Activation, LXR"}],"reference":"https://aopwiki.org/aops/34"}
{"aopId":72,"aopName":"Epigenetic modification of PPARG leading to adipogenesis","targetName":"peroxisome proliferator-activated receptor gamma","targetId":"ENSG00000132170","adverseOutcome":"obesity","adverseOutcomeId":1447,"keyEvents":[{"keyEventId":1447,"keyEventName":"obesity"},{"keyEventId":1448,"keyEventName":"activation of CCAAT/enhancer-binding protein alpha"},{"keyEventId":1451,"keyEventName":"decreased reward"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":1452,"keyEventName":"decreased DNA methylation of tyrosine hydroxylase"},{"keyEventId":1449,"keyEventName":"increased adipogenesis"},{"keyEventId":1450,"keyEventName":"decreased dopamine"},{"keyEventId":1453,"keyEventName":"decreased methylation of dopamine transporter promoter"},{"keyEventId":1454,"keyEventName":"chronic high fat diet"},{"keyEventId":1028,"keyEventName":"Activation of specific nuclear receptors, PPAR-gamma activation"}],"reference":"https://aopwiki.org/aops/72"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"peroxisome proliferator-activated receptor gamma","targetId":"ENSG00000132170","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"peroxisome proliferator-activated receptor gamma","targetId":"ENSG00000132170","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":36,"aopName":"Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis","targetName":"peroxisome proliferator-activated receptor gamma","targetId":"ENSG00000132170","adverseOutcomeId":459,"keyEvents":[{"keyEventId":233,"keyEventName":"Decreased, PPAR-gamma activation"},{"keyEventId":232,"keyEventName":"Decreased, PPAR-beta activation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":8,"keyEventName":"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"},{"keyEventId":140,"keyEventName":"Decreased, HSD17B10 expression"},{"keyEventId":231,"keyEventName":"Decreased, PPAR-alpha activation"}],"reference":"https://aopwiki.org/aops/36"}
{"aopId":36,"aopName":"Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis","targetName":"peroxisome proliferator-activated receptor gamma","targetId":"ENSG00000132170","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":233,"keyEventName":"Decreased, PPAR-gamma activation"},{"keyEventId":232,"keyEventName":"Decreased, PPAR-beta activation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":8,"keyEventName":"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"},{"keyEventId":140,"keyEventName":"Decreased, HSD17B10 expression"},{"keyEventId":231,"keyEventName":"Decreased, PPAR-alpha activation"}],"reference":"https://aopwiki.org/aops/36"}
{"aopId":164,"aopName":"Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse","targetName":"beta-2 adrenergic receptor","targetId":"ENSG00000169252","adverseOutcome":"Promotion, mesovarian leiomyomas","adverseOutcomeId":1044,"keyEvents":[{"keyEventId":1038,"keyEventName":"Activation, beta-2 adrenergic receptor"},{"keyEventId":1043,"keyEventName":"Hypertrophy/hyperplasia, smooth muscle"},{"keyEventId":1042,"keyEventName":"Proliferation/Clonal Expansion, smooth muscle"},{"keyEventId":1039,"keyEventName":"Increased activity, beta-2 adrenergic receptor"},{"keyEventId":1044,"keyEventName":"Promotion, mesovarian leiomyomas"},{"keyEventId":1040,"keyEventName":"relaxation, smooth muscle"}],"reference":"https://aopwiki.org/aops/164"}
{"aopId":34,"aopName":"LXR activation leading to hepatic steatosis","targetName":"sterol regulatory element-binding protein 1","targetId":"ENSG00000072310","adverseOutcome":"N/A, Liver Steatosis","adverseOutcomeId":345,"keyEvents":[{"keyEventId":89,"keyEventName":"Synthesis, De Novo FA"},{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":264,"keyEventName":"Activation, SREBP-1c"},{"keyEventId":116,"keyEventName":"Activation, FAS"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":115,"keyEventName":"Increase, FA Influx"},{"keyEventId":345,"keyEventName":"N/A, Liver Steatosis"},{"keyEventId":258,"keyEventName":"Activation, SCD-1"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":167,"keyEventName":"Activation, LXR"}],"reference":"https://aopwiki.org/aops/34"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"sterol regulatory element-binding protein 1","targetId":"ENSG00000072310","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"sterol regulatory element-binding protein 1","targetId":"ENSG00000072310","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"sterol regulatory element-binding protein 1","targetId":"ENSG00000072310","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"sterol regulatory element-binding protein 1","targetId":"ENSG00000072310","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":62,"aopName":"AKT2 activation leading to hepatic steatosis","targetName":"sterol regulatory element-binding protein 1","targetId":"ENSG00000072310","adverseOutcomeId":459,"keyEvents":[{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":486,"keyEventName":"systemic inflammation leading to hepatic steatosis"},{"keyEventId":484,"keyEventName":"Activation, AKT2"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/62"}
{"aopId":62,"aopName":"AKT2 activation leading to hepatic steatosis","targetName":"sterol regulatory element-binding protein 1","targetId":"ENSG00000072310","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":486,"keyEventName":"systemic inflammation leading to hepatic steatosis"},{"keyEventId":484,"keyEventName":"Activation, AKT2"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/62"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"hydroxymethylglutaryl-CoA synthase, mitochondrial","targetId":"ENSG00000134240","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"hydroxymethylglutaryl-CoA synthase, mitochondrial","targetId":"ENSG00000134240","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":166,"aopName":"PPARalpha activation leading to pancreatic acinar tumors in the rat and mouse","targetName":"cholecystokinin","targetId":"ENSG00000187094","adverseOutcome":"Increased, Pancreatic acinar tumors","adverseOutcomeId":1063,"keyEvents":[{"keyEventId":1057,"keyEventName":"Increased, PPAR-alpha activation"},{"keyEventId":1063,"keyEventName":"Increased, Pancreatic acinar tumors"},{"keyEventId":1058,"keyEventName":"Decreased, bile flow"},{"keyEventId":1061,"keyEventName":"prolonged, elevation of serun CCK"},{"keyEventId":1060,"keyEventName":"Alteration, lipid metabolism"},{"keyEventId":1062,"keyEventName":"Increased, Cellular proliferation / hyperplasia of acinar cells"},{"keyEventId":1059,"keyEventName":"Increased, cholestasis"}],"reference":"https://aopwiki.org/aops/166"}
{"aopId":34,"aopName":"LXR activation leading to hepatic steatosis","targetName":"carbohydrate-responsive element-binding protein","targetId":"ENSG00000009950","adverseOutcome":"N/A, Liver Steatosis","adverseOutcomeId":345,"keyEvents":[{"keyEventId":89,"keyEventName":"Synthesis, De Novo FA"},{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":264,"keyEventName":"Activation, SREBP-1c"},{"keyEventId":116,"keyEventName":"Activation, FAS"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":115,"keyEventName":"Increase, FA Influx"},{"keyEventId":345,"keyEventName":"N/A, Liver Steatosis"},{"keyEventId":258,"keyEventName":"Activation, SCD-1"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":167,"keyEventName":"Activation, LXR"}],"reference":"https://aopwiki.org/aops/34"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"carbohydrate-responsive element-binding protein","targetId":"ENSG00000009950","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"carbohydrate-responsive element-binding protein","targetId":"ENSG00000009950","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":192,"aopName":"Pendrin inhibition leading to altered amphibian metamorphosis","targetName":"pendrin","targetId":"ENSG00000091137","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":426,"keyEventName":"Decreased, Thyroxine (T4) in serum"},{"keyEventId":1155,"keyEventName":"Inhibition, Pendrin"}],"reference":"https://aopwiki.org/aops/192"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"17-beta-hydroxysteroid dehydrogenase 14","targetId":"ENSG00000087076","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"17-beta-hydroxysteroid dehydrogenase 14","targetId":"ENSG00000087076","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":10,"aopName":"Binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain","targetName":"gamma-aminobutyric acid receptor subunit alpha-1","targetId":"ENSG00000022355","adverseOutcome":"Occurrence, Epileptic seizure","adverseOutcomeId":613,"keyEvents":[{"keyEventId":669,"keyEventName":"Reduction, Neuronal synaptic inhibition"},{"keyEventId":616,"keyEventName":"Occurrence, A paroxysmal depolarizing shift"},{"keyEventId":682,"keyEventName":"Generation, Amplified excitatory postsynaptic potential (EPSP)"},{"keyEventId":667,"keyEventName":"Binding at picrotoxin site, iGABAR chloride channel"},{"keyEventId":613,"keyEventName":"Occurrence, Epileptic seizure"},{"keyEventId":64,"keyEventName":"Reduction, Ionotropic GABA receptor chloride channel conductance"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/10"}
{"aopId":209,"aopName":"Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP ","targetName":"3-hydroxyacyl-CoA dehydrogenase type-2","targetId":"ENSG00000072506","adverseOutcome":"Hepatotoxicity","adverseOutcomeId":1291,"keyEvents":[{"keyEventId":1284,"keyEventName":"Up Regulation, SREBF2"},{"keyEventId":1288,"keyEventName":"Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"},{"keyEventId":1285,"keyEventName":"Up Regulation, Unsaturated fatty acid"},{"keyEventId":1291,"keyEventName":"Hepatotoxicity"},{"keyEventId":1287,"keyEventName":"Glutathione synthesis"},{"keyEventId":1286,"keyEventName":"Down Regulation, GSS and GSTs gene"},{"keyEventId":1289,"keyEventName":"Perturbation of cholesterol"},{"keyEventId":1290,"keyEventName":"Glutathione homeostasis"}],"reference":"https://aopwiki.org/aops/209"}
{"aopId":36,"aopName":"Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis","targetName":"3-hydroxyacyl-CoA dehydrogenase type-2","targetId":"ENSG00000072506","adverseOutcomeId":459,"keyEvents":[{"keyEventId":233,"keyEventName":"Decreased, PPAR-gamma activation"},{"keyEventId":232,"keyEventName":"Decreased, PPAR-beta activation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":8,"keyEventName":"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"},{"keyEventId":140,"keyEventName":"Decreased, HSD17B10 expression"},{"keyEventId":231,"keyEventName":"Decreased, PPAR-alpha activation"}],"reference":"https://aopwiki.org/aops/36"}
{"aopId":36,"aopName":"Peroxisomal Fatty Acid Beta-Oxidation Inhibition Leading to Steatosis","targetName":"3-hydroxyacyl-CoA dehydrogenase type-2","targetId":"ENSG00000072506","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":233,"keyEventName":"Decreased, PPAR-gamma activation"},{"keyEventId":232,"keyEventName":"Decreased, PPAR-beta activation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":8,"keyEventName":"Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity"},{"keyEventId":140,"keyEventName":"Decreased, HSD17B10 expression"},{"keyEventId":231,"keyEventName":"Decreased, PPAR-alpha activation"}],"reference":"https://aopwiki.org/aops/36"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"acetyl-CoA carboxylase 1","targetId":"ENSG00000278540","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"acetyl-CoA carboxylase 1","targetId":"ENSG00000278540","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":187,"aopName":"Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage","targetName":"coagulation factor X (mouse)","adverseOutcome":"Impaired recruitment , Population trajectory","adverseOutcomeId":1136,"keyEvents":[{"keyEventId":1135,"keyEventName":"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"},{"keyEventId":1122,"keyEventName":"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "},{"keyEventId":1169,"keyEventName":"Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin"},{"keyEventId":1130,"keyEventName":"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"},{"keyEventId":1133,"keyEventName":"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"},{"keyEventId":1131,"keyEventName":"Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "},{"keyEventId":1134,"keyEventName":"Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone"},{"keyEventId":1132,"keyEventName":"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"},{"keyEventId":1136,"keyEventName":"Impaired recruitment , Population trajectory"},{"keyEventId":1138,"keyEventName":"Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP"},{"keyEventId":1151,"keyEventName":"Osteoporosis and vascular calcification, Bone deterioration"}],"status":"Under Development","reference":"https://aopwiki.org/aops/187"}
{"aopId":105,"aopName":"Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat)","targetName":"major urinary protein (rat)","adverseOutcome":"Increase, Adenomas/carcinomas (renal tubular)","adverseOutcomeId":713,"keyEvents":[{"keyEventId":767,"keyEventName":"Increase, Hyperplasia (renal tubular cells)"},{"keyEventId":714,"keyEventName":"Increased, Binding of chemicals to 2u (serum)"},{"keyEventId":713,"keyEventName":"Increase, Adenomas/carcinomas (renal tubular)"},{"keyEventId":709,"keyEventName":"Increase, Cytotoxicity (renal tubular cell)"},{"keyEventId":708,"keyEventName":"Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)"},{"keyEventId":710,"keyEventName":"Increase, Regenerative cell proliferation (tubular epithelial cells)"}],"reference":"https://aopwiki.org/aops/105"}
{"aopId":150,"aopName":"Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcomeId":947,"keyEvents":[{"keyEventId":947,"keyEventName":"Increase, Early Life Stage Mortality"},{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":317,"keyEventName":"Altered, Cardiovascular development/function"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/150"}
{"aopId":150,"aopName":"Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcome":"Increase, Early Life Stage Mortality","adverseOutcomeId":947,"keyEvents":[{"keyEventId":947,"keyEventName":"Increase, Early Life Stage Mortality"},{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":317,"keyEventName":"Altered, Cardiovascular development/function"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/150"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":123,"aopName":"Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":802,"keyEventName":"Increased, HIF-1 alpha transcription"},{"keyEventId":801,"keyEventName":"modulation, Unknown"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"reference":"https://aopwiki.org/aops/123"}
{"aopId":220,"aopName":"Cyp2E1 Activation Leading to Liver Cancer","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcome":"Liver Cancer","adverseOutcomeId":1395,"keyEvents":[{"keyEventId":1395,"keyEventName":"Liver Cancer"},{"keyEventId":1394,"keyEventName":"Induction, persistent proliferation/sustained proliferation"},{"keyEventId":1391,"keyEventName":"Activation of Cyp2E1"},{"keyEventId":1392,"keyEventName":"Oxidative Stress "},{"keyEventId":1393,"keyEventName":"Hepatocytotoxicity"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/220"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":122,"aopName":"Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":799,"keyEventName":"Increased, HIF-1 heterodimer"},{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":800,"keyEventName":"Decreased, Aromatase (Cyp19a1) mRNA"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":798,"keyEventName":"Inhibition, Prolyl hydroxylases"}],"reference":"https://aopwiki.org/aops/122"}
{"aopId":151,"aopName":"AhR activation leading to preeclampsia","targetName":"hypoxia-inducible factor 1-alpha","targetId":"ENSG00000100644","adverseOutcome":"increase, Preeclampsia","adverseOutcomeId":1893,"keyEvents":[{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":1892,"keyEventName":"increase, placental insufficiency"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":1893,"keyEventName":"increase, Preeclampsia"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":1891,"keyEventName":"abnormal, placental labyrinth vasculature morphology"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"Under Development","reference":"https://aopwiki.org/aops/151"}
{"aopId":103,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint","targetName":"MAD2 like protein (fruit fly)","adverseOutcome":"Reduced, Reproductive Success","adverseOutcomeId":675,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":696,"keyEventName":"Increased, Chromosome misseggregation"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":695,"keyEventName":"Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"}],"reference":"https://aopwiki.org/aops/103"}
{"aopId":103,"aopName":"Cyclooxygenase inhibition leading to reproductive dysfunction via interference with spindle assembly checkpoint","targetName":"MAD2 like protein (fruit fly)","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":691,"keyEventName":"Reduced, Maturation inducing steroid, plasma"},{"keyEventId":696,"keyEventName":"Increased, Chromosome misseggregation"},{"keyEventId":79,"keyEventName":"Inhibition, Cyclooxygenase activity"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":692,"keyEventName":"Reduced, Maturation inducing steroid receptor signalling, oocyte"},{"keyEventId":689,"keyEventName":"Reduced, Gonadotropin releasing hormone, hypothalamus"},{"keyEventId":675,"keyEventName":"Reduced, Reproductive Success"},{"keyEventId":695,"keyEventName":"Upregulated, Spindle assembly checkpoint protein Mad2-oocyte"},{"keyEventId":690,"keyEventName":"Reduced, Luteinizing hormone (LH), plasma "},{"keyEventId":687,"keyEventName":"Reduced, Prostaglandin E2 concentration, hypothalamus"}],"reference":"https://aopwiki.org/aops/103"}
{"aopId":119,"aopName":"Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse)","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Increase, Adenomas/carcinomas (follicular cell)","adverseOutcomeId":741,"keyEvents":[{"keyEventId":741,"keyEventName":"Increase, Adenomas/carcinomas (follicular cell)"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":739,"keyEventName":"Increase, Hypertrophy and proliferation (follicular cell)"},{"keyEventId":771,"keyEventName":"Decrease, Serum thyroid hormone (T4/T3)"},{"keyEventId":740,"keyEventName":"Increase, Hyperplasia (follicular cells)"},{"keyEventId":753,"keyEventName":"Increase, Thyroid-stimulating hormone (TSH)"},{"keyEventId":788,"keyEventName":"Decrease, Incorporation of active iodide into iodotyrosines"}],"reference":"https://aopwiki.org/aops/119"}
{"aopId":363,"aopName":"Thyroperoxidase inhibition leading to increased mortality via altered retinal layer structure","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":1877,"keyEventName":"Altered, retinal layer structure"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1643,"keyEventName":"Altered, Visual function"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"}],"reference":"https://aopwiki.org/aops/363"}
{"aopId":363,"aopName":"Thyroperoxidase inhibition leading to increased mortality via altered retinal layer structure","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":1877,"keyEventName":"Altered, retinal layer structure"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1643,"keyEventName":"Altered, Visual function"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"}],"reference":"https://aopwiki.org/aops/363"}
{"aopId":365,"aopName":"Thyroperoxidase inhibition leading to increased mortality via altered photoreceptor patterning","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":1640,"keyEventName":"Altered, Photoreceptor patterning"},{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1643,"keyEventName":"Altered, Visual function"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"}],"reference":"https://aopwiki.org/aops/365"}
{"aopId":365,"aopName":"Thyroperoxidase inhibition leading to increased mortality via altered photoreceptor patterning","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":1640,"keyEventName":"Altered, Photoreceptor patterning"},{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1643,"keyEventName":"Altered, Visual function"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"}],"reference":"https://aopwiki.org/aops/365"}
{"aopId":271,"aopName":"Inhibition of thyroid peroxidase leading to impaired fertility in fish","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcomeId":78,"keyEvents":[{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":408,"keyEventName":"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"status":"Under Development","reference":"https://aopwiki.org/aops/271"}
{"aopId":271,"aopName":"Inhibition of thyroid peroxidase leading to impaired fertility in fish","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":408,"keyEventName":"reduction in ovarian granulosa cells, Aromatase (Cyp19a1)"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"}],"status":"Under Development","reference":"https://aopwiki.org/aops/271"}
{"aopId":364,"aopName":"Thyroperoxidase inhibition leading to increased mortality via decreased eye size","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1878,"keyEventName":"Decreased, Eye size"},{"keyEventId":1643,"keyEventName":"Altered, Visual function"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"}],"reference":"https://aopwiki.org/aops/364"}
{"aopId":364,"aopName":"Thyroperoxidase inhibition leading to increased mortality via decreased eye size","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1878,"keyEventName":"Decreased, Eye size"},{"keyEventId":1643,"keyEventName":"Altered, Visual function"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"}],"reference":"https://aopwiki.org/aops/364"}
{"aopId":175,"aopName":"Thyroperoxidase inhibition leading to altered amphibian metamorphosis","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"}],"reference":"https://aopwiki.org/aops/175"}
{"aopId":42,"aopName":"Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Cognitive Function, Decreased ","adverseOutcomeId":402,"keyEvents":[{"keyEventId":758,"keyEventName":"Hippocampal Physiology, Altered"},{"keyEventId":756,"keyEventName":"Hippocampal gene expression, Altered "},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":402,"keyEventName":"Cognitive Function, Decreased "},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "},{"keyEventId":757,"keyEventName":"Hippocampal anatomy, Altered "}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/42"}
{"aopId":159,"aopName":"Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1007,"keyEventName":"Reduced, Anterior swim bladder inflation"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/159"}
{"aopId":159,"aopName":"Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation","targetName":"thyroid peroxidase","targetId":"ENSG00000115705","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1007,"keyEventName":"Reduced, Anterior swim bladder inflation"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":1005,"keyEventName":"Reduced, Swimming performance"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":1003,"keyEventName":"Decreased, Triiodothyronine (T3) in serum"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/159"}
{"aopId":191,"aopName":"Type III iodotyrosine deiodinase (DIO3) inhibition leading to altered amphibian metamorphosis","targetName":"type III iodothyronine deiodinase","adverseOutcome":"Altered, Amphibian metamorphosis","adverseOutcomeId":1101,"keyEvents":[{"keyEventId":1829,"keyEventName":"Altered, Thyroid hormone-dependent gene expression"},{"keyEventId":1154,"keyEventName":"Increased, Triiodothyronine (T3) in tissues"},{"keyEventId":1153,"keyEventName":"Inhibition, Deiodinase 3"},{"keyEventId":1101,"keyEventName":"Altered, Amphibian metamorphosis"}],"reference":"https://aopwiki.org/aops/191"}
{"aopId":399,"aopName":"Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)","targetName":"tyrosine-protein kinase fyna (zebrafish)","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":1885,"keyEventName":"Inhibition of Plxna2"},{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1886,"keyEventName":"Increase, Overexpression of rasl11b"},{"keyEventId":1878,"keyEventName":"Decreased, Eye size"},{"keyEventId":1643,"keyEventName":"Altered, Visual function"},{"keyEventId":1821,"keyEventName":"Decrease, Cell proliferation"},{"keyEventId":1884,"keyEventName":"Inhibition of Fyna"}],"reference":"https://aopwiki.org/aops/399"}
{"aopId":399,"aopName":"Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos)","targetName":"tyrosine-protein kinase fyna (zebrafish)","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":1885,"keyEventName":"Inhibition of Plxna2"},{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1886,"keyEventName":"Increase, Overexpression of rasl11b"},{"keyEventId":1878,"keyEventName":"Decreased, Eye size"},{"keyEventId":1643,"keyEventName":"Altered, Visual function"},{"keyEventId":1821,"keyEventName":"Decrease, Cell proliferation"},{"keyEventId":1884,"keyEventName":"Inhibition of Fyna"}],"reference":"https://aopwiki.org/aops/399"}
{"aopId":19,"aopName":"Androgen receptor antagonism leading to adverse effects in the male foetus (mammals)","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"N/A, Impairment of reproductive capacity","adverseOutcomeId":337,"keyEvents":[{"keyEventId":27,"keyEventName":"N/A, Androgen receptor, Antagonism"},{"keyEventId":310,"keyEventName":"Alteration, Wnt pathway"},{"keyEventId":240,"keyEventName":"Feminisation or incomplete development, Primary and accessory male sex organs"},{"keyEventId":286,"keyEventName":"Altered, Transcription of genes by AR"},{"keyEventId":337,"keyEventName":"N/A, Impairment of reproductive capacity"}],"reference":"https://aopwiki.org/aops/19"}
{"aopId":376,"aopName":"Androgen receptor agonism leading to male-biased sex ratio","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1790,"keyEventName":"Increased, Differentiation to Testis "},{"keyEventId":1791,"keyEventName":"Increased, Male Biased Sex Ratio"},{"keyEventId":25,"keyEventName":"Agonism, Androgen receptor"}],"reference":"https://aopwiki.org/aops/376"}
{"aopId":187,"aopName":"Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"Impaired recruitment , Population trajectory","adverseOutcomeId":1136,"keyEvents":[{"keyEventId":1135,"keyEventName":"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"},{"keyEventId":1122,"keyEventName":"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "},{"keyEventId":1169,"keyEventName":"Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin"},{"keyEventId":1130,"keyEventName":"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"},{"keyEventId":1133,"keyEventName":"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"},{"keyEventId":1131,"keyEventName":"Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "},{"keyEventId":1134,"keyEventName":"Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone"},{"keyEventId":1132,"keyEventName":"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"},{"keyEventId":1136,"keyEventName":"Impaired recruitment , Population trajectory"},{"keyEventId":1138,"keyEventName":"Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP"},{"keyEventId":1151,"keyEventName":"Osteoporosis and vascular calcification, Bone deterioration"}],"status":"Under Development","reference":"https://aopwiki.org/aops/187"}
{"aopId":307,"aopName":"Decreased testosterone synthesis leading to short anogenital distance (AGD) in male (mammalian) offspring","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"decrease, male anogenital distance","adverseOutcomeId":1688,"keyEvents":[{"keyEventId":1688,"keyEventName":"decrease, male anogenital distance"},{"keyEventId":1613,"keyEventName":"Decrease, dihydrotestosterone (DHT) level"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":286,"keyEventName":"Altered, Transcription of genes by AR"},{"keyEventId":1614,"keyEventName":"Decrease, androgen receptors (AR) activation"},{"keyEventId":1690,"keyEventName":"reduction, testosterone levels "}],"status":"Under Development","reference":"https://aopwiki.org/aops/307"}
{"aopId":111,"aopName":"Decrease in androgen receptor activity leading to Leydig cell tumors (in rat)","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"Increase, Leydig cell tumors","adverseOutcomeId":745,"keyEvents":[{"keyEventId":743,"keyEventName":"Decreased, Testosterone binding to androgen receptor (hypothalamus)"},{"keyEventId":754,"keyEventName":"Increased, Luteinizing hormone (LH) "},{"keyEventId":742,"keyEventName":"Decreased, Androgen receptor activity"},{"keyEventId":744,"keyEventName":"Increase, Hyperplasia (Leydig cells)"},{"keyEventId":745,"keyEventName":"Increase, Leydig cell tumors"}],"reference":"https://aopwiki.org/aops/111"}
{"aopId":345,"aopName":"Androgen receptor (AR) antagonism leading to decreased fertility in females","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"Decreased fertility, Reduced number of oocytes ovulated ","adverseOutcomeId":972,"keyEvents":[{"keyEventId":26,"keyEventName":"Antagonism, Androgen receptor"},{"keyEventId":1800,"keyEventName":"Granulosa cell proliferation of gonadotropin-independent follicles, Reduced"},{"keyEventId":972,"keyEventName":"Decreased fertility, Reduced number of oocytes ovulated "},{"keyEventId":286,"keyEventName":"Altered, Transcription of genes by AR"}],"reference":"https://aopwiki.org/aops/345"}
{"aopId":344,"aopName":"Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"increase, retained nipples in males","adverseOutcomeId":1786,"keyEvents":[{"keyEventId":26,"keyEventName":"Antagonism, Androgen receptor"},{"keyEventId":1786,"keyEventName":"increase, retained nipples in males"},{"keyEventId":286,"keyEventName":"Altered, Transcription of genes by AR"},{"keyEventId":1614,"keyEventName":"Decrease, androgen receptors (AR) activation"}],"reference":"https://aopwiki.org/aops/344"}
{"aopId":305,"aopName":"5α-reductase inhibition leading to short anogenital distance (AGD) in male (mammalian) offspring","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"decrease, male anogenital distance","adverseOutcomeId":1688,"keyEvents":[{"keyEventId":1688,"keyEventName":"decrease, male anogenital distance"},{"keyEventId":1613,"keyEventName":"Decrease, dihydrotestosterone (DHT) level"},{"keyEventId":286,"keyEventName":"Altered, Transcription of genes by AR"},{"keyEventId":1617,"keyEventName":"5α-reductase, inhibition"},{"keyEventId":1614,"keyEventName":"Decrease, androgen receptors (AR) activation"}],"status":"Under Development","reference":"https://aopwiki.org/aops/305"}
{"aopId":23,"aopName":"Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish)","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":129,"keyEventName":"Reduction, Gonadotropins, circulating concentrations"},{"keyEventId":25,"keyEventName":"Agonism, Androgen receptor"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":274,"keyEventName":"Reduction, Testosterone synthesis by ovarian theca cells"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/23"}
{"aopId":117,"aopName":"Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat)","targetName":"androgen receptor","targetId":"ENSG00000169083","adverseOutcome":"Increase, hepatocellular adenomas and carcinomas","adverseOutcomeId":719,"keyEvents":[{"keyEventId":774,"keyEventName":"Increase, Preneoplastic foci (hepatocytes)"},{"keyEventId":719,"keyEventName":"Increase, hepatocellular adenomas and carcinomas"},{"keyEventId":716,"keyEventName":"Increase, cell proliferation (hepatocytes)"},{"keyEventId":785,"keyEventName":"Activation, Androgen receptor"}],"status":"Under Development","reference":"https://aopwiki.org/aops/117"}
{"aopId":57,"aopName":"AhR activation leading to hepatic steatosis","targetName":"aryl hydrocarbon receptor","targetId":"ENSG00000106546","adverseOutcome":"Accumulation, Liver lipid","adverseOutcomeId":455,"keyEvents":[{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":467,"keyEventName":"Increased, LDL uptake"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":466,"keyEventName":"Up Regulation, LDLR (low density lipoprotein receptor)"},{"keyEventId":80,"keyEventName":"Up Regulation, CYP1A1"},{"keyEventId":455,"keyEventName":"Accumulation, Liver lipid"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":450,"keyEventName":"Suppression, VLDL secretion"},{"keyEventId":216,"keyEventName":"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/57"}
{"aopId":150,"aopName":"Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF","targetName":"aryl hydrocarbon receptor","targetId":"ENSG00000106546","adverseOutcomeId":947,"keyEvents":[{"keyEventId":947,"keyEventName":"Increase, Early Life Stage Mortality"},{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":317,"keyEventName":"Altered, Cardiovascular development/function"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/150"}
{"aopId":150,"aopName":"Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF","targetName":"aryl hydrocarbon receptor","targetId":"ENSG00000106546","adverseOutcome":"Increase, Early Life Stage Mortality","adverseOutcomeId":947,"keyEvents":[{"keyEventId":947,"keyEventName":"Increase, Early Life Stage Mortality"},{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":317,"keyEventName":"Altered, Cardiovascular development/function"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/150"}
{"aopId":41,"aopName":"Sustained AhR Activation leading to Rodent Liver Tumours","targetName":"aryl hydrocarbon receptor","targetId":"ENSG00000106546","adverseOutcome":"Formation, Hepatocellular and Bile duct tumors","adverseOutcomeId":856,"keyEvents":[{"keyEventId":165,"keyEventName":"Activation, Long term AHR receptor driven direct and indirect gene expression changes"},{"keyEventId":856,"keyEventName":"Formation, Hepatocellular and Bile duct tumors"},{"keyEventId":854,"keyEventName":"Alterations, Cellular proliferation / hyperplasia"},{"keyEventId":853,"keyEventName":"Changes/Inhibition, Cellular Homeostasis and Apoptosis"},{"keyEventId":139,"keyEventName":"N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/41"}
{"aopId":131,"aopName":"Aryl hydrocarbon receptor activation leading to uroporphyria","targetName":"aryl hydrocarbon receptor","targetId":"ENSG00000106546","adverseOutcome":"Uroporphyria","adverseOutcomeId":369,"keyEvents":[{"keyEventId":18,"keyEventName":"Activation, AhR"},{"keyEventId":846,"keyEventName":"Accumulation, Highly carboxylated porphyrins"},{"keyEventId":369,"keyEventName":"Uroporphyria"},{"keyEventId":845,"keyEventName":"Inhibition, UROD"},{"keyEventId":844,"keyEventName":"Oxidation, Uroporphyrinogen"},{"keyEventId":850,"keyEventName":"Induction, CYP1A2/CYP1A5"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/131"}
{"aopId":310,"aopName":"Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR","targetName":"aryl hydrocarbon receptor","targetId":"ENSG00000106546","adverseOutcomeId":78,"keyEvents":[{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1698,"keyEventName":"Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":1697,"keyEventName":"Increase, DNA methyltransferase expression"},{"keyEventId":1699,"keyEventName":"Decrease, expression of gonadotropin releasing hormone receptor"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/310"}
{"aopId":310,"aopName":"Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR","targetName":"aryl hydrocarbon receptor","targetId":"ENSG00000106546","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1698,"keyEventName":"Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":1697,"keyEventName":"Increase, DNA methyltransferase expression"},{"keyEventId":1699,"keyEventName":"Decrease, expression of gonadotropin releasing hormone receptor"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/310"}
{"aopId":310,"aopName":"Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR","targetName":"aryl hydrocarbon receptor","targetId":"ENSG00000106546","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1698,"keyEventName":"Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":1697,"keyEventName":"Increase, DNA methyltransferase expression"},{"keyEventId":1699,"keyEventName":"Decrease, expression of gonadotropin releasing hormone receptor"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/310"}
{"aopId":151,"aopName":"AhR activation leading to preeclampsia","targetName":"aryl hydrocarbon receptor","targetId":"ENSG00000106546","adverseOutcome":"increase, Preeclampsia","adverseOutcomeId":1893,"keyEvents":[{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":1892,"keyEventName":"increase, placental insufficiency"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":1893,"keyEventName":"increase, Preeclampsia"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":1891,"keyEventName":"abnormal, placental labyrinth vasculature morphology"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"Under Development","reference":"https://aopwiki.org/aops/151"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"nuclear receptor subfamily 1 group I member 3","targetId":"ENSG00000143257","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"nuclear receptor subfamily 1 group I member 3","targetId":"ENSG00000143257","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":107,"aopName":"Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat","targetName":"nuclear receptor subfamily 1 group I member 3","targetId":"ENSG00000143257","adverseOutcome":"Increase, hepatocellular adenomas and carcinomas","adverseOutcomeId":719,"keyEvents":[{"keyEventId":774,"keyEventName":"Increase, Preneoplastic foci (hepatocytes)"},{"keyEventId":719,"keyEventName":"Increase, hepatocellular adenomas and carcinomas"},{"keyEventId":715,"keyEventName":"Activation, Constitutive androstane receptor"},{"keyEventId":716,"keyEventName":"Increase, cell proliferation (hepatocytes)"},{"keyEventId":1214,"keyEventName":"Altered gene expression specific to CAR activation, Hepatocytes"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/107"}
{"aopId":8,"aopName":"Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals","targetName":"nuclear receptor subfamily 1 group I member 3","targetId":"ENSG00000143257","adverseOutcome":"Loss, Cochlear function","adverseOutcomeId":319,"keyEvents":[{"keyEventId":295,"keyEventName":"Induction, Upregulation of glucuronyltransferase activity"},{"keyEventId":758,"keyEventName":"Hippocampal Physiology, Altered"},{"keyEventId":756,"keyEventName":"Hippocampal gene expression, Altered "},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":401,"keyEventName":"Increase, Biliary excretion TH glucuronide"},{"keyEventId":239,"keyEventName":"Activation, Pregnane-X receptor, NR1l2"},{"keyEventId":319,"keyEventName":"Loss, Cochlear function"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "},{"keyEventId":757,"keyEventName":"Hippocampal anatomy, Altered "}],"status":"Under Development","reference":"https://aopwiki.org/aops/8"}
{"aopId":14,"aopName":"Glucocorticoid Receptor Activation Leading to Increased Disease Susceptibility","targetName":"NF-kappa-B inhibitor","adverseOutcome":"Increased, Disease susceptibility","adverseOutcomeId":323,"keyEvents":[{"keyEventId":152,"keyEventName":"Suppression, Inflammatory cytokines"},{"keyEventId":122,"keyEventName":"Activation, Glucocorticoid Receptor"},{"keyEventId":168,"keyEventName":"Decreased, Lymphocytes"},{"keyEventId":145,"keyEventName":"Induction, IKB inhibitory protein"},{"keyEventId":323,"keyEventName":"Increased, Disease susceptibility"},{"keyEventId":403,"keyEventName":"Suppression, Immune system"},{"keyEventId":202,"keyEventName":"Inhibition, Nuclear factor kappa B (NF-kB)"}],"reference":"https://aopwiki.org/aops/14"}
{"aopId":131,"aopName":"Aryl hydrocarbon receptor activation leading to uroporphyria","targetName":"cytochrome P450 1A5 (chicken)","adverseOutcome":"Uroporphyria","adverseOutcomeId":369,"keyEvents":[{"keyEventId":18,"keyEventName":"Activation, AhR"},{"keyEventId":846,"keyEventName":"Accumulation, Highly carboxylated porphyrins"},{"keyEventId":369,"keyEventName":"Uroporphyria"},{"keyEventId":845,"keyEventName":"Inhibition, UROD"},{"keyEventId":844,"keyEventName":"Oxidation, Uroporphyrinogen"},{"keyEventId":850,"keyEventName":"Induction, CYP1A2/CYP1A5"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/131"}
{"aopId":124,"aopName":"HMG-CoA reductase inhibition leading to decreased fertility","targetName":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","targetId":"ENSG00000113161","adverseOutcome":"Decrease, Fertility","adverseOutcomeId":330,"keyEvents":[{"keyEventId":808,"keyEventName":"Decreased, Testosterone"},{"keyEventId":330,"keyEventName":"Decrease, Fertility"},{"keyEventId":805,"keyEventName":"Decreased, mevalonate"},{"keyEventId":807,"keyEventName":"Decreased, cholesterol"},{"keyEventId":809,"keyEventName":"malformed, Male reproductive tract"},{"keyEventId":804,"keyEventName":"Inhibition, HMG-CoA reductase"}],"reference":"https://aopwiki.org/aops/124"}
{"aopId":281,"aopName":"Acetylcholinesterase Inhibition Leading to Neurodegeneration","targetName":"muscarinic acetylcholine receptor","adverseOutcomeId":352,"keyEvents":[{"keyEventId":352,"keyEventName":"N/A, Neurodegeneration"},{"keyEventId":388,"keyEventName":"Overactivation, NMDARs"},{"keyEventId":1623,"keyEventName":"Occurrence, Focal Seizure"},{"keyEventId":1788,"keyEventName":"Status epilepticus"},{"keyEventId":1602,"keyEventName":"Activation, Muscarinic Acetylcholine Receptors"},{"keyEventId":389,"keyEventName":"Increased, Intracellular Calcium overload"},{"keyEventId":10,"keyEventName":"Acetylcholine accumulation in synapses"},{"keyEventId":12,"keyEventName":"Acetylcholinesterase (AchE) Inhibition"},{"keyEventId":55,"keyEventName":"Cell injury/death"}],"reference":"https://aopwiki.org/aops/281"}
{"aopId":281,"aopName":"Acetylcholinesterase Inhibition Leading to Neurodegeneration","targetName":"muscarinic acetylcholine receptor","adverseOutcome":"N/A, Neurodegeneration","adverseOutcomeId":352,"keyEvents":[{"keyEventId":352,"keyEventName":"N/A, Neurodegeneration"},{"keyEventId":388,"keyEventName":"Overactivation, NMDARs"},{"keyEventId":1623,"keyEventName":"Occurrence, Focal Seizure"},{"keyEventId":1788,"keyEventName":"Status epilepticus"},{"keyEventId":1602,"keyEventName":"Activation, Muscarinic Acetylcholine Receptors"},{"keyEventId":389,"keyEventName":"Increased, Intracellular Calcium overload"},{"keyEventId":10,"keyEventName":"Acetylcholine accumulation in synapses"},{"keyEventId":12,"keyEventName":"Acetylcholinesterase (AchE) Inhibition"},{"keyEventId":55,"keyEventName":"Cell injury/death"}],"reference":"https://aopwiki.org/aops/281"}
{"aopId":154,"aopName":"Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response","targetName":"interleukin-4","targetId":"ENSG00000113520","adverseOutcome":"Impairment, T-cell dependent antibody response","adverseOutcomeId":984,"keyEvents":[{"keyEventId":979,"keyEventName":"Interference, nuclear localization of NFAT"},{"keyEventId":1202,"keyEventName":"Suppression, IL-2 and IL-4 production"},{"keyEventId":980,"keyEventName":"Inhibition, Calcineurin Activity"},{"keyEventId":984,"keyEventName":"Impairment, T-cell dependent antibody response"},{"keyEventId":981,"keyEventName":"Reduction, NFAT/AP-1 complex formation"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/154"}
{"aopId":315,"aopName":"Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response","targetName":"interleukin-4","targetId":"ENSG00000113520","adverseOutcome":"Impairment of T-cell dependent antibody response","adverseOutcomeId":1719,"keyEvents":[{"keyEventId":1717,"keyEventName":"Suppression of STAT5 binding to cytokine gene promoters"},{"keyEventId":1716,"keyEventName":"Blockade of STAT5 phosphorylation"},{"keyEventId":1718,"keyEventName":"Suppression of IL-4 production"},{"keyEventId":1719,"keyEventName":"Impairment of T-cell dependent antibody response"},{"keyEventId":1715,"keyEventName":"Inhibition of JAK3"}],"status":"Under Development","reference":"https://aopwiki.org/aops/315"}
{"aopId":43,"aopName":"Disruption of VEGFR Signaling Leading to Developmental Defects","targetName":"vascular endothelial growth factor receptor 1","targetId":"ENSG00000102755","adverseOutcome":"Increased, Developmental Defects","adverseOutcomeId":1001,"keyEvents":[{"keyEventId":298,"keyEventName":"Insufficiency, Vascular"},{"keyEventId":1001,"keyEventName":"Increased, Developmental Defects"},{"keyEventId":305,"keyEventName":"Inhibition, VegfR2"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":28,"keyEventName":"Reduction, Angiogenesis"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/43"}
{"aopId":119,"aopName":"Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse)","targetName":"iodotyrosine deiodinase 1 (mouse)","adverseOutcome":"Increase, Adenomas/carcinomas (follicular cell)","adverseOutcomeId":741,"keyEvents":[{"keyEventId":741,"keyEventName":"Increase, Adenomas/carcinomas (follicular cell)"},{"keyEventId":279,"keyEventName":"Thyroperoxidase, Inhibition"},{"keyEventId":739,"keyEventName":"Increase, Hypertrophy and proliferation (follicular cell)"},{"keyEventId":771,"keyEventName":"Decrease, Serum thyroid hormone (T4/T3)"},{"keyEventId":740,"keyEventName":"Increase, Hyperplasia (follicular cells)"},{"keyEventId":753,"keyEventName":"Increase, Thyroid-stimulating hormone (TSH)"},{"keyEventId":788,"keyEventName":"Decrease, Incorporation of active iodide into iodotyrosines"}],"reference":"https://aopwiki.org/aops/119"}
{"aopId":94,"aopName":"Sodium channel inhibition leading to congenital malformations","targetName":"sodium channel protein type 1 subunit alpha","targetId":"ENSG00000144285","adverseOutcome":"Increased, amputations","adverseOutcomeId":591,"keyEvents":[{"keyEventId":584,"keyEventName":"Inhibition, sodium channel"},{"keyEventId":590,"keyEventName":"N/A, hypoxia"},{"keyEventId":585,"keyEventName":"Decreased, Sodium conductance 1"},{"keyEventId":444,"keyEventName":"Increased, Atrioventricular block and bradycardia"},{"keyEventId":591,"keyEventName":"Increased, amputations"},{"keyEventId":445,"keyEventName":"Respiratory distress/arrest"}],"reference":"https://aopwiki.org/aops/94"}
{"aopId":96,"aopName":"Axonal sodium channel modulation leading to acute mortality","targetName":"sodium channel protein type 1 subunit alpha","targetId":"ENSG00000144285","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":602,"keyEventName":"Increased, Ataxia, paralysis, or hyperactivity"},{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":601,"keyEventName":"Overactivation, muscle contraction"},{"keyEventId":600,"keyEventName":"Overactivation, Neuronotransmitter release"},{"keyEventId":598,"keyEventName":"modulation, sodium channel"},{"keyEventId":599,"keyEventName":"prolonged, Depolarization of neuronal membrane"}],"reference":"https://aopwiki.org/aops/96"}
{"aopId":93,"aopName":"sodium channel inhibition leading to increased predation","targetName":"sodium channel protein type 1 subunit alpha","targetId":"ENSG00000144285","adverseOutcomeId":588,"keyEvents":[{"keyEventId":584,"keyEventName":"Inhibition, sodium channel"},{"keyEventId":585,"keyEventName":"Decreased, Sodium conductance 1"},{"keyEventId":586,"keyEventName":"Reduced, swimming speed"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/93"}
{"aopId":93,"aopName":"sodium channel inhibition leading to increased predation","targetName":"sodium channel protein type 1 subunit alpha","targetId":"ENSG00000144285","adverseOutcome":"Increased, predation","adverseOutcomeId":588,"keyEvents":[{"keyEventId":584,"keyEventName":"Inhibition, sodium channel"},{"keyEventId":585,"keyEventName":"Decreased, Sodium conductance 1"},{"keyEventId":586,"keyEventName":"Reduced, swimming speed"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/93"}
{"aopId":91,"aopName":"Sodium channel inhibition leading to reduced survival","targetName":"sodium channel protein type 1 subunit alpha","targetId":"ENSG00000144285","adverseOutcomeId":587,"keyEvents":[{"keyEventId":584,"keyEventName":"Inhibition, sodium channel"},{"keyEventId":586,"keyEventName":"Reduced, swimming speed"},{"keyEventId":585,"keyEventName":"Decreased, Sodium conductance 1"},{"keyEventId":592,"keyEventName":"Reduced, survival"},{"keyEventId":587,"keyEventName":"Reduced, feeding 1"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/91"}
{"aopId":91,"aopName":"Sodium channel inhibition leading to reduced survival","targetName":"sodium channel protein type 1 subunit alpha","targetId":"ENSG00000144285","adverseOutcome":"Reduced, feeding 1","adverseOutcomeId":587,"keyEvents":[{"keyEventId":584,"keyEventName":"Inhibition, sodium channel"},{"keyEventId":586,"keyEventName":"Reduced, swimming speed"},{"keyEventId":585,"keyEventName":"Decreased, Sodium conductance 1"},{"keyEventId":592,"keyEventName":"Reduced, survival"},{"keyEventId":587,"keyEventName":"Reduced, feeding 1"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/91"}
{"aopId":91,"aopName":"Sodium channel inhibition leading to reduced survival","targetName":"sodium channel protein type 1 subunit alpha","targetId":"ENSG00000144285","adverseOutcomeId":588,"keyEvents":[{"keyEventId":584,"keyEventName":"Inhibition, sodium channel"},{"keyEventId":586,"keyEventName":"Reduced, swimming speed"},{"keyEventId":585,"keyEventName":"Decreased, Sodium conductance 1"},{"keyEventId":592,"keyEventName":"Reduced, survival"},{"keyEventId":587,"keyEventName":"Reduced, feeding 1"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/91"}
{"aopId":91,"aopName":"Sodium channel inhibition leading to reduced survival","targetName":"sodium channel protein type 1 subunit alpha","targetId":"ENSG00000144285","adverseOutcome":"Increased, predation","adverseOutcomeId":588,"keyEvents":[{"keyEventId":584,"keyEventName":"Inhibition, sodium channel"},{"keyEventId":586,"keyEventName":"Reduced, swimming speed"},{"keyEventId":585,"keyEventName":"Decreased, Sodium conductance 1"},{"keyEventId":592,"keyEventName":"Reduced, survival"},{"keyEventId":587,"keyEventName":"Reduced, feeding 1"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/91"}
{"aopId":91,"aopName":"Sodium channel inhibition leading to reduced survival","targetName":"sodium channel protein type 1 subunit alpha","targetId":"ENSG00000144285","adverseOutcome":"Reduced, survival","adverseOutcomeId":592,"keyEvents":[{"keyEventId":584,"keyEventName":"Inhibition, sodium channel"},{"keyEventId":586,"keyEventName":"Reduced, swimming speed"},{"keyEventId":585,"keyEventName":"Decreased, Sodium conductance 1"},{"keyEventId":592,"keyEventName":"Reduced, survival"},{"keyEventId":587,"keyEventName":"Reduced, feeding 1"},{"keyEventId":588,"keyEventName":"Increased, predation"}],"reference":"https://aopwiki.org/aops/91"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"STAR","targetId":"ENSG00000147465","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"STAR","targetId":"ENSG00000070019","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"STAR","targetId":"ENSG00000147465","adverseOutcome":"impaired, Fertility","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"STAR","targetId":"ENSG00000070019","adverseOutcome":"impaired, Fertility","adverseOutcomeId":406,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"STAR","targetId":"ENSG00000147465","adverseOutcome":"Malformation, Male reproductive tract","adverseOutcomeId":348,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":18,"aopName":"PPARα activation in utero leading to impaired fertility in males","targetName":"STAR","targetId":"ENSG00000070019","adverseOutcome":"Malformation, Male reproductive tract","adverseOutcomeId":348,"keyEvents":[{"keyEventId":446,"keyEventName":"Reduction, testosterone level"},{"keyEventId":447,"keyEventName":"Reduction, Cholesterol transport in mitochondria"},{"keyEventId":289,"keyEventName":"Decrease, Translocator protein (TSPO)"},{"keyEventId":413,"keyEventName":"Reduction, Testosterone synthesis in Leydig cells"},{"keyEventId":406,"keyEventName":"impaired, Fertility"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":348,"keyEventName":"Malformation, Male reproductive tract"},{"keyEventId":266,"keyEventName":"Decrease, Steroidogenic acute regulatory protein (STAR)"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/18"}
{"aopId":126,"aopName":"Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation","targetName":"alpha-2A adrenergic receptor","targetId":"ENSG00000150594","adverseOutcome":"Decreased, Decreased fecundity ","adverseOutcomeId":527,"keyEvents":[{"keyEventId":532,"keyEventName":"Delayed, Ovulation"},{"keyEventId":848,"keyEventName":"Decreased, Binding of NE to NE receptors on GnRH neurons"},{"keyEventId":533,"keyEventName":"Decreased, Cortical granule release/distribution upon fertilization"},{"keyEventId":849,"keyEventName":"Inhibition, Antgonism of NE receptor"},{"keyEventId":527,"keyEventName":"Decreased, Decreased fecundity "},{"keyEventId":534,"keyEventName":"Altered, Formation of cortical envelope"},{"keyEventId":536,"keyEventName":"Altered, Chromosome number (polyploid) zygote"},{"keyEventId":530,"keyEventName":"Decreased, GnRH pulsatility/release"},{"keyEventId":529,"keyEventName":"Decreased, GnRH cfos activity"},{"keyEventId":531,"keyEventName":"Decreased, LH Surge"},{"keyEventId":535,"keyEventName":"Abnormal, Sperm penetration (polyspermy)"}],"reference":"https://aopwiki.org/aops/126"}
{"aopId":34,"aopName":"LXR activation leading to hepatic steatosis","targetName":"oxysterols receptor LXR-beta","targetId":"ENSG00000131408","adverseOutcome":"N/A, Liver Steatosis","adverseOutcomeId":345,"keyEvents":[{"keyEventId":89,"keyEventName":"Synthesis, De Novo FA"},{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":264,"keyEventName":"Activation, SREBP-1c"},{"keyEventId":116,"keyEventName":"Activation, FAS"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":115,"keyEventName":"Increase, FA Influx"},{"keyEventId":345,"keyEventName":"N/A, Liver Steatosis"},{"keyEventId":258,"keyEventName":"Activation, SCD-1"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":167,"keyEventName":"Activation, LXR"}],"reference":"https://aopwiki.org/aops/34"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"oxysterols receptor LXR-beta","targetId":"ENSG00000131408","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"oxysterols receptor LXR-beta","targetId":"ENSG00000131408","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":43,"aopName":"Disruption of VEGFR Signaling Leading to Developmental Defects","targetName":"vascular endothelial growth factor receptor 2","targetId":"ENSG00000128052","adverseOutcome":"Increased, Developmental Defects","adverseOutcomeId":1001,"keyEvents":[{"keyEventId":298,"keyEventName":"Insufficiency, Vascular"},{"keyEventId":1001,"keyEventName":"Increased, Developmental Defects"},{"keyEventId":305,"keyEventName":"Inhibition, VegfR2"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":28,"keyEventName":"Reduction, Angiogenesis"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/43"}
{"aopId":6,"aopName":"Antagonist binding to PPARα leading to body-weight loss","targetName":"nuclear receptor corepressor 1","targetId":"ENSG00000141027","adverseOutcome":"Decreased, Body Weight","adverseOutcomeId":864,"keyEvents":[{"keyEventId":858,"keyEventName":"Decreased, PPARalpha transactivation of gene expression"},{"keyEventId":861,"keyEventName":"Decreased, Ketogenesis (production of ketone bodies)"},{"keyEventId":1000,"keyEventName":"stabilization, PPAR alpha co-repressor"},{"keyEventId":864,"keyEventName":"Decreased, Body Weight"},{"keyEventId":863,"keyEventName":"Increased, Catabolism of Muscle Protein"},{"keyEventId":1528,"keyEventName":"Fatty Acid Beta Oxidation, Decreased"},{"keyEventId":862,"keyEventName":"Not Increased, Circulating Ketone Bodies"},{"keyEventId":998,"keyEventName":"Binding of antagonist, PPAR alpha"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/6"}
{"aopId":187,"aopName":"Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage","targetName":"coagulation factor IX (mouse)","adverseOutcome":"Impaired recruitment , Population trajectory","adverseOutcomeId":1136,"keyEvents":[{"keyEventId":1135,"keyEventName":"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"},{"keyEventId":1122,"keyEventName":"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "},{"keyEventId":1169,"keyEventName":"Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin"},{"keyEventId":1130,"keyEventName":"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"},{"keyEventId":1133,"keyEventName":"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"},{"keyEventId":1131,"keyEventName":"Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "},{"keyEventId":1134,"keyEventName":"Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone"},{"keyEventId":1132,"keyEventName":"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"},{"keyEventId":1136,"keyEventName":"Impaired recruitment , Population trajectory"},{"keyEventId":1138,"keyEventName":"Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP"},{"keyEventId":1151,"keyEventName":"Osteoporosis and vascular calcification, Bone deterioration"}],"status":"Under Development","reference":"https://aopwiki.org/aops/187"}
{"aopId":34,"aopName":"LXR activation leading to hepatic steatosis","targetName":"platelet glycoprotein 4","targetId":"ENSG00000135218","adverseOutcome":"N/A, Liver Steatosis","adverseOutcomeId":345,"keyEvents":[{"keyEventId":89,"keyEventName":"Synthesis, De Novo FA"},{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":264,"keyEventName":"Activation, SREBP-1c"},{"keyEventId":116,"keyEventName":"Activation, FAS"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":115,"keyEventName":"Increase, FA Influx"},{"keyEventId":345,"keyEventName":"N/A, Liver Steatosis"},{"keyEventId":258,"keyEventName":"Activation, SCD-1"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":176,"keyEventName":"Damaging, Mitochondria"},{"keyEventId":167,"keyEventName":"Activation, LXR"}],"reference":"https://aopwiki.org/aops/34"}
{"aopId":57,"aopName":"AhR activation leading to hepatic steatosis","targetName":"platelet glycoprotein 4","targetId":"ENSG00000135218","adverseOutcome":"Accumulation, Liver lipid","adverseOutcomeId":455,"keyEvents":[{"keyEventId":291,"keyEventName":"Accumulation, Triglyceride"},{"keyEventId":467,"keyEventName":"Increased, LDL uptake"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":466,"keyEventName":"Up Regulation, LDLR (low density lipoprotein receptor)"},{"keyEventId":80,"keyEventName":"Up Regulation, CYP1A1"},{"keyEventId":455,"keyEventName":"Accumulation, Liver lipid"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":450,"keyEventName":"Suppression, VLDL secretion"},{"keyEventId":216,"keyEventName":"Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/57"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"platelet glycoprotein 4","targetId":"ENSG00000135218","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":58,"aopName":"NR1I3 (CAR) suppression leading to hepatic steatosis","targetName":"platelet glycoprotein 4","targetId":"ENSG00000135218","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":456,"keyEventName":"Suppression, Constitutive androstane receptor, NR1l3"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":228,"keyEventName":"peroxisome proliferator activated receptor promoter demethylation"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":470,"keyEventName":"Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)"},{"keyEventId":167,"keyEventName":"Activation, LXR"},{"keyEventId":468,"keyEventName":"Inhibition, PPAR alpha"},{"keyEventId":463,"keyEventName":"Up Regulation, FAS"},{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":66,"keyEventName":"Activation, ChREBP"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":457,"keyEventName":"Activation, SREBF1"}],"reference":"https://aopwiki.org/aops/58"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"platelet glycoprotein 4","targetId":"ENSG00000135218","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"platelet glycoprotein 4","targetId":"ENSG00000135218","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":220,"aopName":"Cyp2E1 Activation Leading to Liver Cancer","targetName":"von Hippel-Lindau disease tumor suppressor","targetId":"ENSG00000134086","adverseOutcome":"Liver Cancer","adverseOutcomeId":1395,"keyEvents":[{"keyEventId":1395,"keyEventName":"Liver Cancer"},{"keyEventId":1394,"keyEventName":"Induction, persistent proliferation/sustained proliferation"},{"keyEventId":1391,"keyEventName":"Activation of Cyp2E1"},{"keyEventId":1392,"keyEventName":"Oxidative Stress "},{"keyEventId":1393,"keyEventName":"Hepatocytotoxicity"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/220"}
{"aopId":126,"aopName":"Alpha-noradrenergic antagonism leads to reduced fecundity via delayed ovulation","targetName":"proto-oncogene c-Fos (mouse)","adverseOutcome":"Decreased, Decreased fecundity ","adverseOutcomeId":527,"keyEvents":[{"keyEventId":532,"keyEventName":"Delayed, Ovulation"},{"keyEventId":848,"keyEventName":"Decreased, Binding of NE to NE receptors on GnRH neurons"},{"keyEventId":533,"keyEventName":"Decreased, Cortical granule release/distribution upon fertilization"},{"keyEventId":849,"keyEventName":"Inhibition, Antgonism of NE receptor"},{"keyEventId":527,"keyEventName":"Decreased, Decreased fecundity "},{"keyEventId":534,"keyEventName":"Altered, Formation of cortical envelope"},{"keyEventId":536,"keyEventName":"Altered, Chromosome number (polyploid) zygote"},{"keyEventId":530,"keyEventName":"Decreased, GnRH pulsatility/release"},{"keyEventId":529,"keyEventName":"Decreased, GnRH cfos activity"},{"keyEventId":531,"keyEventName":"Decreased, LH Surge"},{"keyEventId":535,"keyEventName":"Abnormal, Sperm penetration (polyspermy)"}],"reference":"https://aopwiki.org/aops/126"}
{"aopId":73,"aopName":"Xenobiotic Inhibition of Dopamine-beta-Hydroxylase and subsequent reduced fecundity","targetName":"proto-oncogene c-Fos (mouse)","adverseOutcome":"Decreased, Decreased fecundity ","adverseOutcomeId":527,"keyEvents":[{"keyEventId":526,"keyEventName":"Inhibition, Inhibition of Dopamine-beta-hydroxylase"},{"keyEventId":532,"keyEventName":"Delayed, Ovulation"},{"keyEventId":533,"keyEventName":"Decreased, Cortical granule release/distribution upon fertilization"},{"keyEventId":527,"keyEventName":"Decreased, Decreased fecundity "},{"keyEventId":528,"keyEventName":"Decreased, Synthesis of NE"},{"keyEventId":534,"keyEventName":"Altered, Formation of cortical envelope"},{"keyEventId":536,"keyEventName":"Altered, Chromosome number (polyploid) zygote"},{"keyEventId":530,"keyEventName":"Decreased, GnRH pulsatility/release"},{"keyEventId":529,"keyEventName":"Decreased, GnRH cfos activity"},{"keyEventId":531,"keyEventName":"Decreased, LH Surge"},{"keyEventId":535,"keyEventName":"Abnormal, Sperm penetration (polyspermy)"}],"reference":"https://aopwiki.org/aops/73"}
{"aopId":208,"aopName":"Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) and Transforming growth factor (TGF)-beta pathways activation leading to reproductive failure","targetName":"signal transducer and transcription activator STAT","adverseOutcome":"Reproductive failure","adverseOutcomeId":1277,"keyEvents":[{"keyEventId":1277,"keyEventName":"Reproductive failure"},{"keyEventId":1283,"keyEventName":"Activation, TGF-beta pathway"},{"keyEventId":1282,"keyEventName":"Activation, JAK/STAT pathway"}],"reference":"https://aopwiki.org/aops/208"}
{"aopId":315,"aopName":"Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response","targetName":"signal transducer and transcription activator STAT","adverseOutcome":"Impairment of T-cell dependent antibody response","adverseOutcomeId":1719,"keyEvents":[{"keyEventId":1717,"keyEventName":"Suppression of STAT5 binding to cytokine gene promoters"},{"keyEventId":1716,"keyEventName":"Blockade of STAT5 phosphorylation"},{"keyEventId":1718,"keyEventName":"Suppression of IL-4 production"},{"keyEventId":1719,"keyEventName":"Impairment of T-cell dependent antibody response"},{"keyEventId":1715,"keyEventName":"Inhibition of JAK3"}],"status":"Under Development","reference":"https://aopwiki.org/aops/315"}
{"aopId":130,"aopName":"Phospholipase A inhibitors lead to hepatotoxicity","targetName":"phospholipase A1 member A (human)","adverseOutcome":"Formation, Liver fibrosis","adverseOutcomeId":840,"keyEvents":[{"keyEventId":828,"keyEventName":"Inhibition, Phospholipase A"},{"keyEventId":840,"keyEventName":"Formation, Liver fibrosis"},{"keyEventId":836,"keyEventName":"Occurrence, Cytoplasmic vacuolization (Bile duct cell)"},{"keyEventId":831,"keyEventName":"Disturbance, Lysosomal function"},{"keyEventId":839,"keyEventName":"Formation, Mallory body"},{"keyEventId":838,"keyEventName":"Induction, Microvesicular fat"},{"keyEventId":829,"keyEventName":"Damage, Lipid bilayer"},{"keyEventId":833,"keyEventName":"Occurrence, Cytoplasmic vacuolization (hepatocyte)"},{"keyEventId":832,"keyEventName":"Injury, Mitochondria"},{"keyEventId":837,"keyEventName":"Occurrence, Cytoplasmic vacuolization (kupffer cell)"},{"keyEventId":835,"keyEventName":"Occurrence, Ballooning degeneration (hepatocyte)"}],"status":"Under Development","reference":"https://aopwiki.org/aops/130"}
{"aopId":212,"aopName":"Histone deacetylase inhibition leading to testicular atrophy","targetName":"cell cycle-related cyclin","adverseOutcome":"Testicular atrophy","adverseOutcomeId":1506,"keyEvents":[{"keyEventId":1262,"keyEventName":"Apoptosis"},{"keyEventId":1505,"keyEventName":"Cell cycle, disrupted"},{"keyEventId":1502,"keyEventName":"Histone deacetylase inhibition"},{"keyEventId":1515,"keyEventName":"Spermatocyte depletion"},{"keyEventId":1503,"keyEventName":"Histone acetylation, increase"},{"keyEventId":1506,"keyEventName":"Testicular atrophy"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/212"}
{"aopId":209,"aopName":"Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP ","targetName":"glutathione S-transferase","adverseOutcome":"Hepatotoxicity","adverseOutcomeId":1291,"keyEvents":[{"keyEventId":1284,"keyEventName":"Up Regulation, SREBF2"},{"keyEventId":1288,"keyEventName":"Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene"},{"keyEventId":1285,"keyEventName":"Up Regulation, Unsaturated fatty acid"},{"keyEventId":1291,"keyEventName":"Hepatotoxicity"},{"keyEventId":1287,"keyEventName":"Glutathione synthesis"},{"keyEventId":1286,"keyEventName":"Down Regulation, GSS and GSTs gene"},{"keyEventId":1289,"keyEventName":"Perturbation of cholesterol"},{"keyEventId":1290,"keyEventName":"Glutathione homeostasis"}],"reference":"https://aopwiki.org/aops/209"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"nuclear factor erythroid 2-related factor 2","targetId":"ENSG00000116044","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"nuclear factor erythroid 2-related factor 2","targetId":"ENSG00000116044","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":187,"aopName":"Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage","targetName":"coagulation factor VII (mouse)","adverseOutcome":"Impaired recruitment , Population trajectory","adverseOutcomeId":1136,"keyEvents":[{"keyEventId":1135,"keyEventName":"Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction"},{"keyEventId":1122,"keyEventName":"Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis  "},{"keyEventId":1169,"keyEventName":"Anticoagulant rodenticide interferes with carboxylation of Gla proteins in bone, Impairment of post-translational modification (carboxylation) of osteocalcin"},{"keyEventId":1130,"keyEventName":"Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)"},{"keyEventId":1133,"keyEventName":"Hemostasis, Depletion from blood of fully functional carboxylated clotting factors"},{"keyEventId":1131,"keyEventName":"Failure in gamma-glutamyl carboxylation of  clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) "},{"keyEventId":1134,"keyEventName":"Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone"},{"keyEventId":1132,"keyEventName":"Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal"},{"keyEventId":1136,"keyEventName":"Impaired recruitment , Population trajectory"},{"keyEventId":1138,"keyEventName":"Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP"},{"keyEventId":1151,"keyEventName":"Osteoporosis and vascular calcification, Bone deterioration"}],"status":"Under Development","reference":"https://aopwiki.org/aops/187"}
{"aopId":298,"aopName":"Chronic reactive oxygen species leading to human treatment-resistant gastric cancer","targetName":"protein-serine O-palmitoleoyltransferase porcupine","targetId":"ENSG00000102312","adverseOutcome":"Treatment-resistant gastric cancer","adverseOutcomeId":1651,"keyEvents":[{"keyEventId":1755,"keyEventName":"Proliferation / beta-catenin activation"},{"keyEventId":1650,"keyEventName":"Epithelial-mesenchymal transition"},{"keyEventId":1754,"keyEventName":"Sustained tissue damage / macrophage activation / porcupine-induced Wnt secretion"},{"keyEventId":1651,"keyEventName":"Treatment-resistant gastric cancer"},{"keyEventId":1753,"keyEventName":"Chronic reactive oxygen species"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/298"}
{"aopId":150,"aopName":"Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF","targetName":"aryl hydrocarbon receptor nuclear translocator","targetId":"ENSG00000143437","adverseOutcomeId":947,"keyEvents":[{"keyEventId":947,"keyEventName":"Increase, Early Life Stage Mortality"},{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":317,"keyEventName":"Altered, Cardiovascular development/function"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/150"}
{"aopId":150,"aopName":"Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF","targetName":"aryl hydrocarbon receptor nuclear translocator","targetId":"ENSG00000143437","adverseOutcome":"Increase, Early Life Stage Mortality","adverseOutcomeId":947,"keyEvents":[{"keyEventId":947,"keyEventName":"Increase, Early Life Stage Mortality"},{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":317,"keyEventName":"Altered, Cardiovascular development/function"},{"keyEventId":110,"keyEventName":"Impairment, Endothelial network"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/150"}
{"aopId":310,"aopName":"Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR","targetName":"aryl hydrocarbon receptor nuclear translocator","targetId":"ENSG00000143437","adverseOutcomeId":78,"keyEvents":[{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1698,"keyEventName":"Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":1697,"keyEventName":"Increase, DNA methyltransferase expression"},{"keyEventId":1699,"keyEventName":"Decrease, expression of gonadotropin releasing hormone receptor"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/310"}
{"aopId":310,"aopName":"Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR","targetName":"aryl hydrocarbon receptor nuclear translocator","targetId":"ENSG00000143437","adverseOutcome":"Reduction, Cumulative fecundity and spawning","adverseOutcomeId":78,"keyEvents":[{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1698,"keyEventName":"Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":1697,"keyEventName":"Increase, DNA methyltransferase expression"},{"keyEventId":1699,"keyEventName":"Decrease, expression of gonadotropin releasing hormone receptor"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/310"}
{"aopId":310,"aopName":"Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR","targetName":"aryl hydrocarbon receptor nuclear translocator","targetId":"ENSG00000143437","adverseOutcome":"Decrease, Population trajectory","adverseOutcomeId":360,"keyEvents":[{"keyEventId":309,"keyEventName":"Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development"},{"keyEventId":285,"keyEventName":"Reduction, Vitellogenin synthesis in liver"},{"keyEventId":360,"keyEventName":"Decrease, Population trajectory"},{"keyEventId":1698,"keyEventName":"Increase, hypermethylation of the promotor region of gonadotropin releasing hormone receptor"},{"keyEventId":219,"keyEventName":"Reduction, Plasma 17beta-estradiol concentrations"},{"keyEventId":221,"keyEventName":"Reduction, Plasma vitellogenin concentrations"},{"keyEventId":1697,"keyEventName":"Increase, DNA methyltransferase expression"},{"keyEventId":1699,"keyEventName":"Decrease, expression of gonadotropin releasing hormone receptor"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":78,"keyEventName":"Reduction, Cumulative fecundity and spawning"},{"keyEventId":3,"keyEventName":"Reduction, 17beta-estradiol synthesis by ovarian granulosa cells"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"reference":"https://aopwiki.org/aops/310"}
{"aopId":151,"aopName":"AhR activation leading to preeclampsia","targetName":"aryl hydrocarbon receptor nuclear translocator","targetId":"ENSG00000143437","adverseOutcome":"increase, Preeclampsia","adverseOutcomeId":1893,"keyEvents":[{"keyEventId":945,"keyEventName":"reduced dimerization, ARNT/HIF1-alpha"},{"keyEventId":1892,"keyEventName":"increase, placental insufficiency"},{"keyEventId":944,"keyEventName":"dimerization, AHR/ARNT"},{"keyEventId":1893,"keyEventName":"increase, Preeclampsia"},{"keyEventId":948,"keyEventName":"reduced production, VEGF"},{"keyEventId":1891,"keyEventName":"abnormal, placental labyrinth vasculature morphology"},{"keyEventId":18,"keyEventName":"Activation, AhR"}],"status":"Under Development","reference":"https://aopwiki.org/aops/151"}
{"aopId":54,"aopName":"Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment ","targetName":"brain-derived neurotrophic factor","targetId":"ENSG00000176697","adverseOutcomeId":341,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":851,"keyEventName":"Decrease of GABAergic interneurons"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":424,"keyEventName":"Inhibition, Na+/I- symporter (NIS)"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":386,"keyEventName":"Decrease of neuronal network function"},{"keyEventId":425,"keyEventName":"Decrease of Thyroidal iodide"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "},{"keyEventId":385,"keyEventName":"Decrease of synaptogenesis"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/54"}
{"aopId":54,"aopName":"Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment ","targetName":"brain-derived neurotrophic factor","targetId":"ENSG00000176697","adverseOutcome":"Impairment, Learning and memory","adverseOutcomeId":341,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":851,"keyEventName":"Decrease of GABAergic interneurons"},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":424,"keyEventName":"Inhibition, Na+/I- symporter (NIS)"},{"keyEventId":277,"keyEventName":"Thyroid hormone synthesis, Decreased"},{"keyEventId":386,"keyEventName":"Decrease of neuronal network function"},{"keyEventId":425,"keyEventName":"Decrease of Thyroidal iodide"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "},{"keyEventId":385,"keyEventName":"Decrease of synaptogenesis"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/54"}
{"aopId":12,"aopName":"Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging","targetName":"brain-derived neurotrophic factor","targetId":"ENSG00000176697","adverseOutcomeId":352,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":52,"keyEventName":"Decreased, Calcium influx"},{"keyEventId":352,"keyEventName":"N/A, Neurodegeneration"},{"keyEventId":188,"keyEventName":"Neuroinflammation"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":201,"keyEventName":"Binding of antagonist, NMDA receptors"},{"keyEventId":195,"keyEventName":"Inhibition, NMDARs"},{"keyEventId":55,"keyEventName":"Cell injury/death"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/12"}
{"aopId":12,"aopName":"Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging","targetName":"brain-derived neurotrophic factor","targetId":"ENSG00000176697","adverseOutcome":"N/A, Neurodegeneration","adverseOutcomeId":352,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":52,"keyEventName":"Decreased, Calcium influx"},{"keyEventId":352,"keyEventName":"N/A, Neurodegeneration"},{"keyEventId":188,"keyEventName":"Neuroinflammation"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":201,"keyEventName":"Binding of antagonist, NMDA receptors"},{"keyEventId":195,"keyEventName":"Inhibition, NMDARs"},{"keyEventId":55,"keyEventName":"Cell injury/death"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/12"}
{"aopId":12,"aopName":"Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging","targetName":"brain-derived neurotrophic factor","targetId":"ENSG00000176697","adverseOutcomeId":341,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":52,"keyEventName":"Decreased, Calcium influx"},{"keyEventId":352,"keyEventName":"N/A, Neurodegeneration"},{"keyEventId":188,"keyEventName":"Neuroinflammation"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":201,"keyEventName":"Binding of antagonist, NMDA receptors"},{"keyEventId":195,"keyEventName":"Inhibition, NMDARs"},{"keyEventId":55,"keyEventName":"Cell injury/death"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/12"}
{"aopId":12,"aopName":"Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging","targetName":"brain-derived neurotrophic factor","targetId":"ENSG00000176697","adverseOutcome":"Impairment, Learning and memory","adverseOutcomeId":341,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":52,"keyEventName":"Decreased, Calcium influx"},{"keyEventId":352,"keyEventName":"N/A, Neurodegeneration"},{"keyEventId":188,"keyEventName":"Neuroinflammation"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":201,"keyEventName":"Binding of antagonist, NMDA receptors"},{"keyEventId":195,"keyEventName":"Inhibition, NMDARs"},{"keyEventId":55,"keyEventName":"Cell injury/death"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/12"}
{"aopId":13,"aopName":"Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities","targetName":"brain-derived neurotrophic factor","targetId":"ENSG00000176697","adverseOutcomeId":341,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":52,"keyEventName":"Decreased, Calcium influx"},{"keyEventId":383,"keyEventName":"Reduced, Presynaptic release of glutamate"},{"keyEventId":382,"keyEventName":"Aberrant, Dendritic morphology"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":201,"keyEventName":"Binding of antagonist, NMDA receptors"},{"keyEventId":195,"keyEventName":"Inhibition, NMDARs"},{"keyEventId":386,"keyEventName":"Decrease of neuronal network function"},{"keyEventId":55,"keyEventName":"Cell injury/death"},{"keyEventId":385,"keyEventName":"Decrease of synaptogenesis"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/13"}
{"aopId":13,"aopName":"Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities","targetName":"brain-derived neurotrophic factor","targetId":"ENSG00000176697","adverseOutcome":"Impairment, Learning and memory","adverseOutcomeId":341,"keyEvents":[{"keyEventId":381,"keyEventName":"Reduced levels of BDNF"},{"keyEventId":52,"keyEventName":"Decreased, Calcium influx"},{"keyEventId":383,"keyEventName":"Reduced, Presynaptic release of glutamate"},{"keyEventId":382,"keyEventName":"Aberrant, Dendritic morphology"},{"keyEventId":341,"keyEventName":"Impairment, Learning and memory"},{"keyEventId":201,"keyEventName":"Binding of antagonist, NMDA receptors"},{"keyEventId":195,"keyEventName":"Inhibition, NMDARs"},{"keyEventId":386,"keyEventName":"Decrease of neuronal network function"},{"keyEventId":55,"keyEventName":"Cell injury/death"},{"keyEventId":385,"keyEventName":"Decrease of synaptogenesis"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/13"}
{"aopId":131,"aopName":"Aryl hydrocarbon receptor activation leading to uroporphyria","targetName":"cytochrome P450 1A2","targetId":"ENSG00000140505","adverseOutcome":"Uroporphyria","adverseOutcomeId":369,"keyEvents":[{"keyEventId":18,"keyEventName":"Activation, AhR"},{"keyEventId":846,"keyEventName":"Accumulation, Highly carboxylated porphyrins"},{"keyEventId":369,"keyEventName":"Uroporphyria"},{"keyEventId":845,"keyEventName":"Inhibition, UROD"},{"keyEventId":844,"keyEventName":"Oxidation, Uroporphyrinogen"},{"keyEventId":850,"keyEventName":"Induction, CYP1A2/CYP1A5"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/131"}
{"aopId":33,"aopName":"Kidney toxicity induced by activation of 5HT2C","targetName":"5-hydroxytryptamine receptor 2C","targetId":"ENSG00000147246","adverseOutcome":"Increased, Kidney Failure","adverseOutcomeId":759,"keyEvents":[{"keyEventId":294,"keyEventName":"N/A, Unknown"},{"keyEventId":759,"keyEventName":"Increased, Kidney Failure"},{"keyEventId":9,"keyEventName":"Activation, 5HT2c"}],"reference":"https://aopwiki.org/aops/33"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"microsomal triglyceride transfer protein large subunit MTTP","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":61,"aopName":"NFE2L2/FXR activation leading to hepatic steatosis","targetName":"microsomal triglyceride transfer protein large subunit MTTP","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":879,"keyEventName":"Activation, MTTP"},{"keyEventId":451,"keyEventName":"Inhibition, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":227,"keyEventName":"Activation, PPARα"},{"keyEventId":483,"keyEventName":"Activation, LXR alpha"},{"keyEventId":878,"keyEventName":"Inhibition, SREBP1c"},{"keyEventId":478,"keyEventName":"Activation, NRF2"},{"keyEventId":881,"keyEventName":"Increased, Triglyceride"},{"keyEventId":458,"keyEventName":"Increased, De Novo FA synthesis"},{"keyEventId":479,"keyEventName":"Activation, NR1H4"},{"keyEventId":880,"keyEventName":"Increased, ApoB100"},{"keyEventId":480,"keyEventName":"Activation, SHP"},{"keyEventId":482,"keyEventName":"Decreased, DHB4/HSD17B4"}],"reference":"https://aopwiki.org/aops/61"}
{"aopId":8,"aopName":"Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals","targetName":"nuclear receptor subfamily 1 group I member 2","targetId":"ENSG00000144852","adverseOutcome":"Loss, Cochlear function","adverseOutcomeId":319,"keyEvents":[{"keyEventId":295,"keyEventName":"Induction, Upregulation of glucuronyltransferase activity"},{"keyEventId":758,"keyEventName":"Hippocampal Physiology, Altered"},{"keyEventId":756,"keyEventName":"Hippocampal gene expression, Altered "},{"keyEventId":281,"keyEventName":" Thyroxine (T4) in serum, Decreased"},{"keyEventId":401,"keyEventName":"Increase, Biliary excretion TH glucuronide"},{"keyEventId":239,"keyEventName":"Activation, Pregnane-X receptor, NR1l2"},{"keyEventId":319,"keyEventName":"Loss, Cochlear function"},{"keyEventId":280,"keyEventName":"Thyroxine (T4) in neuronal tissue, Decreased "},{"keyEventId":757,"keyEventName":"Hippocampal anatomy, Altered "}],"status":"Under Development","reference":"https://aopwiki.org/aops/8"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"nuclear receptor subfamily 1 group I member 2","targetId":"ENSG00000144852","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":60,"aopName":"NR1I2 (Pregnane X Receptor, PXR)  activation leading to hepatic steatosis","targetName":"nuclear receptor subfamily 1 group I member 2","targetId":"ENSG00000144852","adverseOutcome":"Increased, Liver Steatosis","adverseOutcomeId":459,"keyEvents":[{"keyEventId":454,"keyEventName":"Increased, Triglyceride formation"},{"keyEventId":327,"keyEventName":"Accumulation, Fatty acid"},{"keyEventId":462,"keyEventName":"Up Regulation, SCD-1"},{"keyEventId":54,"keyEventName":"Up Regulation, CD36"},{"keyEventId":179,"keyEventName":"Decreased, Mitochondrial fatty acid beta-oxidation"},{"keyEventId":472,"keyEventName":"Down Regulation, CPT1A"},{"keyEventId":459,"keyEventName":"Increased, Liver Steatosis"},{"keyEventId":465,"keyEventName":"Increased, FA Influx"},{"keyEventId":474,"keyEventName":"Down Regulation, HMGCS2"},{"keyEventId":245,"keyEventName":"Activation, PXR/SXR"},{"keyEventId":471,"keyEventName":"Inhibition, FoxA2"},{"keyEventId":477,"keyEventName":"Decreased, Ketogenesis"}],"reference":"https://aopwiki.org/aops/60"}
{"aopId":106,"aopName":"Chemical binding to tubulin in oocytes leading to aneuploid offspring","targetName":"tubulin","adverseOutcome":"Increase, Aneuploid offspring","adverseOutcomeId":728,"keyEvents":[{"keyEventId":718,"keyEventName":"Binding, Tubulin"},{"keyEventId":723,"keyEventName":"Altered, Chromosome number"},{"keyEventId":728,"keyEventName":"Increase, Aneuploid offspring"},{"keyEventId":752,"keyEventName":"Altered, Meiotic chromosome dynamics"},{"keyEventId":720,"keyEventName":"Disruption, Microtubule dynamics"},{"keyEventId":721,"keyEventName":"Disorganization, Meiotic Spindle"}],"status":"EAGMST Under Review","reference":"https://aopwiki.org/aops/106"}
{"aopId":6,"aopName":"Antagonist binding to PPARα leading to body-weight loss","targetName":"nuclear receptor corepressor 2","targetId":"ENSG00000196498","adverseOutcome":"Decreased, Body Weight","adverseOutcomeId":864,"keyEvents":[{"keyEventId":858,"keyEventName":"Decreased, PPARalpha transactivation of gene expression"},{"keyEventId":861,"keyEventName":"Decreased, Ketogenesis (production of ketone bodies)"},{"keyEventId":1000,"keyEventName":"stabilization, PPAR alpha co-repressor"},{"keyEventId":864,"keyEventName":"Decreased, Body Weight"},{"keyEventId":863,"keyEventName":"Increased, Catabolism of Muscle Protein"},{"keyEventId":1528,"keyEventName":"Fatty Acid Beta Oxidation, Decreased"},{"keyEventId":862,"keyEventName":"Not Increased, Circulating Ketone Bodies"},{"keyEventId":998,"keyEventName":"Binding of antagonist, PPAR alpha"}],"status":"TFHA/WNT Endorsed","reference":"https://aopwiki.org/aops/6"}
{"aopId":138,"aopName":"Organic anion transporter (OAT1) inhibition leading to renal failure and mortality","targetName":"solute carrier family 22 member 6","targetId":"ENSG00000197901","adverseOutcome":"Decline, Population","adverseOutcomeId":361,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1106,"keyEventName":"Occurrence, cardiac arrhythmia"},{"keyEventId":1097,"keyEventName":"Occurrence, renal proximal tubular necrosis"},{"keyEventId":877,"keyEventName":"Inhibition, organic anion transporter 1 (OAT1)"},{"keyEventId":1096,"keyEventName":"Increased, blood uric acid concentration"},{"keyEventId":1088,"keyEventName":"Increased, Oxidative Stress"},{"keyEventId":1098,"keyEventName":"Increased, blood potassium concentration"},{"keyEventId":1102,"keyEventName":"Occurrence, tophi (urate) deposition"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/138"}
{"aopId":138,"aopName":"Organic anion transporter (OAT1) inhibition leading to renal failure and mortality","targetName":"solute carrier family 22 member 6","targetId":"ENSG00000197901","adverseOutcome":"Increased Mortality","adverseOutcomeId":351,"keyEvents":[{"keyEventId":351,"keyEventName":"Increased Mortality"},{"keyEventId":1106,"keyEventName":"Occurrence, cardiac arrhythmia"},{"keyEventId":1097,"keyEventName":"Occurrence, renal proximal tubular necrosis"},{"keyEventId":877,"keyEventName":"Inhibition, organic anion transporter 1 (OAT1)"},{"keyEventId":1096,"keyEventName":"Increased, blood uric acid concentration"},{"keyEventId":1088,"keyEventName":"Increased, Oxidative Stress"},{"keyEventId":1098,"keyEventName":"Increased, blood potassium concentration"},{"keyEventId":1102,"keyEventName":"Occurrence, tophi (urate) deposition"},{"keyEventId":361,"keyEventName":"Decline, Population"}],"reference":"https://aopwiki.org/aops/138"}
